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THE BETA-CATENIN/MUC1.CT INTERACTION IN PANCREATIC CANCER
Edwin J. Wiest, Ph.D.
University of Nebraska, 2018
Supervisor: Michael A. Hollingsworth, Ph.D.
MUC1 is overexpressed in over 90% of pancreatic cancer cases, and its
interaction with beta-catenin promotes progression of the disease. Various in vitro and
in vivo methods show that beta-catenin and MUC1 interact by way of the cytoplasmic tail
of MUC1 (MUC1.CT). This interaction occurs in the membrane of pancreatic cancer
cells but is found to a smaller extent in the nucleus as well. Biophysical methods
suggest that MUC1 interacts with beta-catenin through a sequence of amino acids in the
tail of MUC1 that sit very near the transmembrane domain of MUC1. In pancreatic
ductal adenocarcinoma cells, it appears that EGF stimulation causes tyrosine residue
phosphorylation of the cytoplasmic tail of MUC1 and a simultaneous reduction in the
beta-catenin/MUC1.CT interaction in the membrane of the cells. The evidence
presented here indicates that phosphorylation of the tail of MUC1 tends to decrease its
interaction with beta-catenin.
While studying the beta-catenin/MUC1.CT interaction, it was inadvertently
discovered that a Met receptor inhibitor, SU11274, fluoresces when excited by laser light
of 488 nm. The inhibitor moves rapidly into cells and accumulates in discrete regions of
the cell. Evidence suggests that SU11274 associates with the endoplasmic reticulum.
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CHAPTER 1. INTRODUCTION
Pancreatic Cancer
The Pancreas
The pancreas is a mixed organ that produces enzymes as well as hormones.
The endocrine cells are found in groups called the islets of Langerhans. These cells
produce hormones such as insulin and glucagon. The acinar cells of the exocrine
pancreas produce enzymes that aid in the digestion of food. Pancreatic ducts transport
these enzymes to the duodenum [1].
Pancreatic Ductal Adenocarcinoma
Pancreatic cancer is associated with a dismal prognosis, which has been the
case for decades. Pancreatic ductal adenocarcinoma (PDAC) is the most common form
of pancreatic cancer, and it is the fourth leading cause of cancer death in developed
countries [2]. The disease often goes undiagnosed for many years due to a lack of
definite symptoms and specific tumor markers. By taking command of the local nervous
system and vasculature the disease is able to metastasize rapidly. Pancreatic cancer is
characterized by a complex and compact tumor microenvironment and is resistant to
conventional treatments [2]. Barring improved treatment, the disease is predicted to be
the second leading cause of cancer-related death by 2030 [3].
Pancreatic Cancer Microenvironment
The activating mutation in over 90% of pancreatic cancer cases is KRAS, and
inactivation of tumor suppressors TP53, CDKN2A, and SMAD4 occur in 50-80% of
cases [2]. In the context of heightened expression of oncogenic KRAS and loss of
CDKN2A, signaling molecules such as transforming growth factor-alpha (TGFα), insulinlike growth factor 1 (IGF1), fibroblast growth factor (FGF), hepatocyte growth factor
(HGF), and their respective receptors—epidermal growth factor receptor (EGFR),
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receptor tyrosine-protein kinase erb-B2 (ERBB2), HER3, IGF1 receptor, FGF receptors,
and hepatocyte growth factor receptor (MET)—trigger pancreatic cancer cell
proliferation, migration, and invasion [4]. The overactive state of MET and EGFR is
exacerbated by the formation of MET/EGFR heterodimers [4, 5]. In addition, aberrant
transforming growth factor-beta (TGFβ) signaling leads to mitogen-activated protein
kinase phosphorylation, proto-oncogene tyrosine-protein kinase Src (SRC) and AKT
phosphorylation, and upregulation of the Wnt ligand WNT7B through a SMAD4dependent mechanism [6].
Pancreatic Cancer and Mucins
Disease progression of pancreatic cancer involves increased expression, altered
glycosylation, and aberrant localization of mucins [7]. Pancreatic lesions are
characterized by a many-fold increase in MUC1 as well as de novo expression of MUC4,
MUC5AC, MUC5B, MUC13, MUC15, MUC16 and MUC17 [7]. The loss of cell polarity
that accompanies tumor formation involves a loss in asymmetric distribution of mucins,
allowing (once apical) mucins to come in close proximity with (formerly basolaterally
restricted) receptor tyrosine-protein kinases (RTKs) such as EGFR, ERBB2, ERBB3,
and FGFR [7]. These RTKs regulate signaling cascades that give rise to the cancer
phenotype: survival, growth, proliferation, and metastasis.
Pancreatic Cancer and Wnt Signaling
A body of evidence suggests that pancreatic ductal adenocarcinoma arises, at
least in some cases, from ductal cells of the pancreas [8-10]. Wnt signaling is believed
to encourage pancreatic cancer development [11, 12], and may even be required for
pancreatic carcinogenesis in some cases [13]. It is known that Wnt target LGR5 is
produced by a population of cells in the pancreas [14], that isolated pancreatic duct cells
can self-renew [15], that following pancreatic damage, duct cells contribute to endocrine
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and acinar cell regeneration [16], and that the stem cell marker Sox9 is expressed in
duct cells (and not acinar or endocrine cells) that serve as progenitor cells for the
exocrine pancreas during organ maintenance [17]. Given these facts, it is easy to
imagine how dysregulated Wnt signaling may give rise to or aid in the progression of
pancreatic ductal adenocarcinoma.
Wnt Signaling
Since the description of the first recognized member of the Wnt signaling family
in 1982 the field has grown steadily. Wnt signaling is now understood to play a key role
in growth and development as well as stem cell biology [14]. Wnt signaling involves a
Wnt ligand (of which there are 19 known [18]) binding to a receptor complex comprised
of the 7-transmembrane frizzled (FZD) protein and the low-density lipoprotein receptorrelated protein 5/6 (LRP5/6) [14]. When a Wnt ligand binds to the FZD/LRP complex,
the intracellular carrier of the Wnt signal, beta-catenin, accumulates in the cytoplasm
and eventually moves into the nucleus where it forms a complex with DNA bound T-cell
factor (TCF) or LEF (lymphoid enhancer-binding protein) to direct transcriptional
programs involved in cell proliferation and differentiation [14, 19].
Beta-Catenin
The key driver of Wnt signaling within cells is beta-catenin, whose stability is
tightly regulated by the beta-catenin destruction complex, which is composed of betacatenin itself; two serine/threonine kinases, glycogen synthase kinase 3β (GSK-3β), and
casein kinase 1 (CK1); a scaffolding protein, Axin; adenomatous polyposis coli (APC);
and the E3-ubiquitin ligase, β-TrCP [20]. When FZD/LRP receptors are not bound to a
Wnt ligand, CK1 and GSK-3β phosphorylate beta-catenin at serine residues on the Nterminus of beta-catenin. CK1 first phosphorylates serine residue 45, and then GSK-3β
phosphorylates threonine residue 41, serine residue 37, and serine residue 33 [21]. This
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phosphorylation pattern is a signal for the F-box-containing protein E3 ubiquitin ligase βTrCP to ubiquitinate beta-catenin, which is then sent to the proteasome for degradation
[14].
Beta-Catenin in Cell-Cell Adhesion
Cell-cell adhesion makes the production and maintenance of multicellular tissues
possible. Adherens junctions and tight junctions enable epithelial cells to connect with
one another to produce epithelial sheets. Epithelial-cadherin (E-cadherin), the
transmembrane protein at the core of the adherens junction [22], is linked to the
cytoskeleton by way of catenin molecules, including alpha-catenin and beta-catenin [23].
Because of its interaction with E-cadherin, beta-catenin is not only involved in
intracellular signaling and gene transcription but also local control of the actin
cytoskeleton [22]. The importance of proper maintenance of cell-cell adhesion is
highlighted by the fact that loss of cell-cell adhesion is correlated with increased
proliferation, and tumor invasiveness [22].
Beta-Catenin Structure
Beta-catenin has an N-terminal region of about 150 amino acids, an armadillo
repeat domain (the “arm domain”), and a C-terminal tail that interacts with the general
transcription apparatus. The arm domain contains 12 sets of three a helices (armadillo
repeats), except repeat 7, which contains only two. Structural studies have shown that
beta-catenin binding partners involved in adhesion (the classical cadherin cytoplasmic
domain) and in Wnt signaling [T-cell factor transcription factors, ICAT, APC, and Axin]
interact with the arm domain in a similar way [23]. Cell culture studies have shown that
interactions between members of the adherens junction are regulated by
phosphorylation. The tails of classical cadherins have a serine-rich region that is
phosphorylated. Phosphorylation of this site within cadherins by GSK-3β and casein
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kinase II (CKII) strengthens its affinity for beta-catenin by about 800-fold [24-26].
Mutation of these serine residues to alanine residues caused a reduction in cell-cell
adhesion in NIH 3T3 cells [26]. Recently it was shown that three residues within this
serine-rich region are required for high-affinity beta-catenin binding and are essential for
proper cadherin–catenin complex formation and E-cadherin surface stability and function
[27]. Src phosphorylation of beta-catenin Tyr654 reduces its affinity for cadherin [28],
while CKII phosphorylation of beta-catenin increases its affinity for α-catenin [29].
Extracellular regions of cadherins on opposing cells bind to one another, and their
cytoplasmic regions bind to the proteins p120 catenin and beta-catenin. Beta-catenin
binds to α-catenin, which in turn binds to actin, but the association between these
proteins is dynamic [30].
The N-terminal tail of beta-catenin has no intrinsic three-dimensional structure
[31]. The arm domain mediates binding to TCF/LEF proteins, the beta-catenin
destruction complex components Axin and APC, and the cytoplasmic domain of classical
cadherins [31]. TCFs, APC, and cadherins share an amino acid sequence motif
(DXqqXjX2-7E) where X is any amino acid, q is an aliphatic hydrophobic residue, and j
is an aromatic residue. This motif binds to the beta-catenin superhelical groove that
spans arm repeats 5-10 [24, 32].
Wnt Signaling in Stem Cell Biology
Wnt signaling is required for most stem cell types. In fact, Wnt proteins can be
used to maintain embryonic stem cells in the pluripotent state [33], and Wnt signaling
blockade cause elimination of hair follicles [34]. Also, two stem-cell specific Wnt target
genes include Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) and
Axin2, which are involved in the maintenance of adult stem cells of the intestine,
stomach, pancreas, liver, kidney, ovary, inner ear, taste buds, and mammary gland [14].
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Wnt Signaling in Cancer
Because Wnt signals are involved in epithelial stem cell maintenance, it would be
anticipated that mutations in Wnt pathway proteins are often found in carcinomas [14]
Aberrant Wnt signaling is well documented in colorectal cancer [35]. Loss of APC is the
most common cause of colorectal cancer [12]. Wnt signaling abnormalities are also well
studied in leukemia, melanoma, and breast cancer [12]. While it is well established that
PDAC is mainly driven by oncogenic Ras signaling, the role of Wnt signaling in PDAC is
not fully characterized [12]. Wnt mutations are not common in PDAC, but abnormal
levels and nuclear localization of beta-catenin was observed in about 65% of PDAC
(n=31) in one study [36].
Noncanonical Wnt Signaling
In addition to Wnt signaling through beta-catenin, Wnt ligands can also activate
noncanonical Wnt signaling, which include the planar cell polarity (PCP) pathway and
the Wnt/calcium pathway [37]. Noncanonical Wnt signaling, which is independent of
beta-catenin, regulates cellular polarity and cell motility. Crosstalk occurs between the
canonical and noncanonical Wnt signaling pathways. For example, in the PCP pathway
Wnt activates RhoA and Rac leading to activation of JNK and AP1. AP1 is a
heterodimeric transcription factor composed of any two of the following: cJun, JunB,
JunD, cFos, Fra1, Fra2, ATF2, and CREB, and two of these (cJun and Fra1) are target
genes of the canonical Wnt pathway [38]. Noncanonical Wnt signaling is implicated in
many diseases including cancer. Studies in gastric cancer, melanoma, and glioblastoma
indicate that malignant cells hijack noncanonical Wnt signaling to activate migration and
metastasis [39-42].
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MUCINS
Mucins Defined
Mucins are high molecular weight heavily glycosylated proteins. Mucins may be
produced by secretory or polarized epithelial cells that line the luminal surfaces of
respiratory, gastrointestinal, and reproductive tracts [43]. Mucins are also produced by
hematopoietic tissues [44]. Mucins serve to protect and lubricate these surfaces. MUC1
also acts to influence adhesive properties of the cell by modifying gene expression upon
structural and microenvironmental changes at the cell surface [45].
Mucins are classified as either membrane-bound or secretory mucins. Secretory
mucins lack a transmembrane domain and are secreted into the extracellular space.
These include MUC2, MUC5AC, MUC5B, MUC6, MUC7, MUC8, and MUC19.
Membrane-bound mucins are type I membrane proteins with single transmembrane
domains and C-terminal cytoplasmic tails. These include MUC1, MUC3A, MUC3B,
MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, and MUC20. Membrane-bound
mucins may be released from cells through proteolytic cleavage. MUC1 secretory forms
are likely splice variants lacking a transmembrane domain [46].
Membrane-Bound Mucins
Due to their presence at the luminal surface, transmembrane mucins also serve
as sensors of the external environment. Outside-in signaling occurs upon ligand binding
to the extracellular domain of the membrane-bound mucin or as a result of altered
conformation caused by changes in pH, ionic composition, or other physical interactions
at the luminal surface. Such signals are transmitted to the interior of the cell by way of
post-translational modification of the cytoplasmic tail (e.g., phosphorylation,
ubiquitination, proteolytic cleavage) [47].
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MUC1
MUC1, a cell surface mucin, is 120 to 300 kDa. The actual molecular mass
varies in proportion to the polymorphic variable number of tandem repeats (VNTR)
domain. This mass can increase two-fold when MUC1 is fully glycosylated. MUC1 is
actually composed of two subunits, a larger extracellular subunit that is heavily
glycosylated, and a smaller fragment known as the MUC1 C-terminal subunit. The
larger subunit is comprised of an N-terminal signal sequence and VNTR domain, which
contains 20-100 repeats of the sequence GSTAPPAHGVTSAPDTRPAP [31]. The
smaller subunit is comprised of an extracellular stem of 58 residues, a 28 amino-acid
transmembrane domain, and a 72 amino acid cytoplasmic tail. The three domains of the
smaller subunit have a combined mass of 14 kDa, which is increased to about 25 or 30
kDa after glycosylation and phosphorylation. The CQC motif of the cytoplasmic tail has
also been implicated as a self-association motif, enabling MUC1.CT to form dimers [48].
Also, the CQCRRK motif forms a turn, conferring some secondary structure to the
otherwise simple random-coil structure of the cytoplasmic tail of MUC1 [49].
MUC1.CT Signaling
Concerning signaling, of the membrane-bound mucins MUC1 has been studied
the most. MUC1.CT contains 72 residues, 23 of which may be phosphorylated (seven
tyrosine residues, six threonine residues, and nine serine residues). Phosphorylation
alters the binding affinity of MUC1.CT with various proteins, including transcription
factors and kinases [47]. The interactions of MUC1.CT with kinases, transcription
factors, and other proteins is summarized in Figure 1.

ZA
(ta P-70
wi rget , PD
th
s
be MU GFR
ta- C1
c a .C
ten T t
i n) o n
uc
le u
s
PD
nu GFR
c le
us (targ
PK
wi ets
th
C𝝳
be MUC
GS
taca 1.CT
MU K-3
ER
ten
β
C1
(de
(ta BB1
in) to
.
C
r
,
c
T i re
wi get c-S
nte as
inc th be s MU rc, L
rac es b
rea ta- C1 yn
tio eta
c
,
.
se
n)
-ca
s H aten CT to Lck,
ten
i
n
F
sp
n
,
G
in/
uc
90
F
R
l
eu
int
-3
s
era
cti
on
)

9

Kinases that phosphorylate MUC1.CT

CQCRRKNYGQLDIFPARDTYHPMSEYPTYHTHGRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPAVAATSANL

AP-2

Nuclear import
Dimerization

beta-catenin
Hsp90 (targets MUC1.CT
to mitochondria)
Grb-2
TLR5
SOS1 (Ras
signaling)

Nuclear localization
Endocytosis

Endocytosis

Transcription factors and other MUC1.CT interacting partners
p53

ERBB2

ER-⍺ (protects MUC1.CT from proteasomal degradation
and causes recruitment of p160)

ERBB3

c-Jun (displaced by MUC1 at target genes,
causing a rise in c-Jun levels)

ERBB4

p120 catenin

ICAM-1 (calcium
signaling)

Ɣ-catenin (targets MUC1.CT to nucleolus)
APC
Hsp70 (targets MUC1.CT to mitochondria)

Figure 1. MUC1.CT interacting partners

IKKs (triggers IκB
degradation,
NF-κB activity)
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MUC1.CT and Heat Shock Proteins
MUC1 interacts with two heat shock proteins: Hsp70, and Hsp90 [50]. The
association of MUC1.CT with Hsp70 and Hsp90 is involved in translocation of MUC1.CT
to mitochondria [50]. MUC1.CT also interacts with the SH2 domain of Grb-2, purportedly
when the tyrosine residue of the YTNP sequence of MUC1.CT is phosphorylated. SOS1
then binds the MUC1.CT/Grb-2 complex (by way of the SH3 domain of Grb-2), which
enables signaling through Ras [51].
MUC1.CT and AP-2, Grb2
Studies in which the ectodomain of MUC1 was replaced with the ectodomain of
Tac (to avoid the confounding issue of extracellular domain glycosylation) indicate that
the tyrosine residues of the two MUC1.CT motifs YHPM and YTNP are required for
efficient endocytosis of the MUC1 chimera. Mutation of the tyrosine residue of the
YHPM motif essentially blocked coimmunoprecipitation of the chimera with AP-2,
indicating that YHPM is recognized as a YXXϕ motif by the μ2 subunit of AP-2. Mutation
of the tyrosine residue of the YHPM motif blocked coimmunoprecipitation of the chimera
with Grb2, which suggests a role for Grb2 in the endocytosis of MUC1 [52].
MUC1.CT and ErbB Kinase Family Members
Full-length MUC1 interacts with the four members of the ErbB family of RTKs
[53, 54]. Whether or not EGF is present, MUC1 coimmunoprecipitates and colocalizes
with ERBB1 in tumor cells. In addition, ligand bound ERBB1 phosphorylates MUC1.CT
at the tyrosine residue of the YEKV motif [55]. This phosphorylation results in an
increased affinity for the SH2 domain of c-Src, and beta-catenin and increases nuclear
localization of MUC1.CT. Phosphorylation of the same residue is important for the
interaction of MUC1.CT with Hsp90, which is necessary for the movement of MUC1.CT
to the outer membrane of mitochondria [50].
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It appears that MUC1 affects extracellular signal-regulated kinase (ERK)
signaling independently of ErbB kinases. Stimulation of a CD8/MUC1.CT chimera
caused tyrosine residue phosphorylation of MUC1.CT and activation of ERK1/2 [56].
SiRNA knockdown of MUC1 in two breast cancer cell lines caused a decrease in the
transcription of MEK1 and led to a decrease in total and phosphorylated levels of
MEK1/2 [57]. In addition, reduction of MUC1 in Jurkat lymphoma cells resulted in
decreased T cell activation, including ERK1/2 phosphorylation and cell proliferation [58].
MUC1.CT Phosphorylation by FGFR and PDGFR
Activation of fibroblast growth factor receptor 3 (FGFR-3) causes MUC1.CT
phosphorylation of the tyrosine residue within the YEKV motif with divergent results:
MUC1.CT association with beta-catenin and nuclear targeting and Hsp90 association
and targeting to the outer membrane of mitochondria [59]. In addition, platelet-derived
growth factor receptor (PDGFR) activation causes MUC1.CT phosphorylation of the
tyrosine residues within the YHPM and YVPP motifs with concomitant nuclear
localization of MUC1.CT and beta-catenin [60].
MUC1.CT Signaling through ICAM-1, MAP Kinase Pathways
Studies indicate that intercellular adhesion molecule 1 (ICAM-1) serves as a
ligand for MUC1 [61-63]. The binding of ICAM-1 to MUC1 activates calcium signaling
that is independent of the mitogen-activated protein (MAP) kinase pathway [61]. Studies
with signaling pathway inhibitors indicate that this calcium response involves Src,
phosphatidylinositol 3-kinase (PI3K), and phospholipase C enzymes. The MUC1/ICAM1 interaction increases migration of MUC1-expressing cells in vitro, which suggests that
this interaction regulates cellular adhesion and motility [64]. The binding of
Pseudomonas aeruginosa spurs phosphorylation of MUC1.CT resulting in the activation
of the MAP kinase pathway [65].
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MUC1.CT and Src Family Non-RTKs
Of the nine Src family non-RTKs, c-Src, Lyn, and Lck have been shown to bind
and phosphorylate MUC1.CT at the tyrosine residue of the YEKV motif [58, 66-69]. The
c-Src SH2 domain physically interacts with the YEKV motif. This interaction blocks the
binding of GSK-3β to MUC1.CT. GSK-3β is also able to phosphorylate MUC1.CT. This
leads to reduced interaction between MUC1.CT and beta-catenin. Therefore, c-Src
phosphorylation of MUC1.CT at the tyrosine residue of the YEKV motif enhances the
MUC1.CT/beta-catenin interaction and prevents the interaction of MUC1.CT with GSK3β [67]. Other kinases known to phosphorylate MUC1.CT include the δ isoform of
protein kinase C (PKCδ) and the ζ chain-associated protein kinase of 70 kDa (ZAP-70)
[45, 70].
MUC1.CT and TLR5
A recent study shows that an interaction between MUC1.CT and toll-like receptor
5 (TLR5) interaction in A549 lung adenocarcinoma cells increases upon stimulation with
TGF-α. This is apparently due to activation of EGFR and concomitant tyrosine residue
phosphorylation of MUC1.CT [71]. In addition, stimulation of normal human bronchial
epithelial cells with TNF-α increased MUC1 and EGFR protein levels, and stimulation of
these cells with Pseudomonas aeruginosa caused an increase in MUC1.CT tyrosine
residue phosphorylation and increased both the MUC1.CT/TLR5 and MUC1.CT/EGFR
interactions [72]
MUC1.CT and γ-Catenin
The ERBB3 ligand heregulin is known to enhance interaction of MUC1.CT with γcatenin. The MUC1.CT-γ-catenin complex is then targeted to the nucleolus. In fact,
MUC1.CT can be coimmunoprecipitated with ERBB2, and stimulation with heregulin
enhances this interaction [47].
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MUC1.CT and Transcription Factors
MUC1.CT has been shown to interact with beta-catenin, p120 catenin, p53, and
ER-α in the nucleus. Interaction between MUC1.CT and the inhibitor of κB (IκB) kinases
(IKKs) have been reported as well [73]. Such interactions have been shown to influence
transcription. For example, MUC1.CT has been shown to associate with transcription
factors at the promoter of the connective tissue growth factor (CTGF) causing a change
in CTGF expression [74]. It may be that MUC1.CT also enters the nucleus apart from
any transcription factor. The CQC and the positively charged RRK MUC1.CT motifs are
involved in its nuclear import and localization, respectively [53, 75].
Interaction of MUC1.CT with ER-α and members of the NF-κB signaling pathway
is of immense biological consequence. It appears that MUC1.CT interaction with ER-α
protects it from proteasomal degradation, and actually promotes the recruitment of p160
coactivator. Strikingly, the MUC1.CT/ER-α interaction is not ER ligand-dependent [76].
Concerning NF-κB, it appears that MUC1.CT activates IKKs, which trigger IκB
degradation, enabling the transcriptional activity of NF-κB [73]. In addition, it has been
shown that MUC1 displaces c-Jun from promoters of c-Jun target genes. This alteration
in the AP-1 transcriptome relies on MUC1-mediated increase in steady state levels of cJun [77].
MUC1 in cancer
MUC1 overexpression occurs in many types of cancers including breast, ovarian,
lung, colon, and pancreatic carcinomas [78], and MUC1 expression usually increases
with progression of disease. In the case of breast cancer, MUC1 expression or levels of
certain MUC1-associated glycans correlates with poor survival [79]. In the pancreas, in
precursor lesions (pancreatic intraepithelial neoplasias or PanINs), MUC1 expression is
low, but increases greatly in invasive carcinoma [80].
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MUC1 and Apoptosis
MUC1 may aid in resistance to apoptosis and anti-tumor drug killing [81]. MUC1
can stimulate Akt and antiapoptotic protein Bcl-X to block genotoxin-induced apoptosis
[82]. Additionally, chemotherapy-induced cell killing is attenuated in the presence of
MUC1 while cell killing is increased upon loss of MUC1 expression [81-83]. MUC1
decreases the level of intracellular reactive oxygen species (ROS) and activates
FOXO3a in response to oxidative stress [84, 85]. However, MUC1 expression can also
induce Fas-mediated apoptosis [86], highlighting the complex nature of MUC1’s
involvement in cell death.
MUC1 Glycosylation in Cancer
MUC1 expression on tumor cells differs from that of normal cells in terms of
localization and glycosylation. MUC1 is normally found at the apical membrane of
epithelial cells, but in tumor cells MUC1 expression is greatly increased, and MUC1 is
found over the entire plasma membrane and in the cytoplasm [78]. Loss of apical MUC1
is associated with poor prognosis in lung cancer [87]. MUC1 is aberrantly glycosylated
in tumors as well: the carbohydrate chains are typically truncated and include sugar
moieties that are not normally present on MUC1 [88].
MUC1.CT and Adhesion Properties of Cancer Cells
The steric hindrance of the MUC1 extracellular domain provides an antiadhesive
property to protect epithelial cells from pathogens, but this same feature allows tumor
cells to evade immune cells [78, 89]. Also, MUC1 on tumor cells is associated with
increased metastasis [90, 91]. This may result from interactions of MUC1 with adhesion
molecules such as ICAM-1, which may assist these tumor cells in invading into the
endothelium and attaching to cells in the metastatic niche [64].
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MUC1.CT and Cell Migration
MUC1.CT colocalizes with beta-catenin and fascin and vinculin at sites of focal
adhesion in the process of collagen matrix cell invasion [91]. Fascin supports cell
protrusions in migrating cells. This suggests a role for MUC1.CT in cell migration.
MUC1.CT and Wnt Signaling
MUC1.CT interacts directly with three members of the Wnt signaling pathway:
beta-catenin, APC, and GSK-3b [92-94]. MUC1.CT contains a motif, known as the
serine-rich motif (SXXXXXSSL, where X is any amino acid) which interacts with betacatenin. It has been reported that beta-catenin interacts with MUC1.CT through this
motif [94, 95]. The affinity of interaction between beta-catenin and MUC1.CT depends
on phosphorylation of MUC1.CT at specific residues, and this interaction increases
levels of beta-catenin in the nucleus [60, 67]. MUC1.CT has also been shown to interact
with p120 catenin [96].
It is important to note that not all researchers agree that MUC1 positively
regulates beta-catenin activity. One group reported that in a nonmalignant cell line
MUC1 decreased Wnt signal transduction through direct interaction with beta-catenin
[97], and another group showed that in a breast cancer cell line and a pancreatic cancer
cell line that MUC1 levels are inversely related to beta-catenin levels [98].
MUC1/Wnt Pathway and Cancer
Interactions of MUC1.CT with different components of the Wnt signaling cascade
are related to cancer progression. Phosphorylation of the threonine residue within the
TDRSPYEKV motif of MUC1.CT also increases its interaction with beta-catenin, while
phosphorylation of the serine residue within this motif inhibits the same interaction [99].
The interaction between MUC1.CT and beta-catenin may sequester beta-catenin from
its association with E-cadherin at the adherens junction. This would, in turn, stimulate
anchorage-independent growth in vitro and might facilitate the metastasis of tumor cells
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in vivo [100, 101]. In fact, loss of MUC1 leads to a decrease in beta-catenin as a result
of increased GSK3-β-mediated phosphorylation and degradation of beta-catenin [95].
In addition, it has been shown that MUC1.CT interacts with APC in breast cancer
[92]. This interaction is enhanced by EGF stimulation. In fact, MUC1 knockout in the
mouse mammary tumor virus (MMTV)-Wnt-1 transgenic background resulted in a delay
in mammary tumorigenesis [91].
MUC1.CT peptides with wild-type GSK-3β and beta-catenin binding motifs
increased the invasive potential of the MDA-MB-468 breast cancer cell line. This
appears to be irrespective of the phosphorylation status of the MUC1.CT peptides.
MUC1.CT peptides which lacked either the GSK-3β or beta-catenin binding motif no
longer enhanced invasion [91]. This suggests a role for these interactions in invasion.
Also, MUC1 is associated with increased beta-catenin levels in both the cytoplasm and
nucleus of breast carcinoma cells. This is due to MUC1.CT blocking GSK-3β from
phosphorylating beta-catenin [102]. It may be that MUC1.CT sequesters beta-catenin,
keeping it from interaction with cadherins and the adherens junction. In some cell types,
MUC1.CT promotes transcriptional activation of the beta-catenin-TCF-binding sites such
as cyclin D1 [95].
Epidermal Growth Factor Receptor Signaling
EGFR Family
Discovered in 1959, Epidermal growth factor receptor (EGFR, also known as
ERBB1/HER1) is the prototypical EGFR family member, which also includes
ERBB2/HER2/Neu, ERBB3/HER3, and ERBB4/HER4 [103]. Though ERBB2 contains
no ligand-binding domain, seven ligands are known to bind to the other three family
members, including epidermal growth factor (EGF), transforming growth factor-α
(TGFα), heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC),
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amphiregulin (AR), epiregulin (EPI), and epigen [104]. The classical EGFR ligand, EGF,
is a 53 amino acid protein. The normal concentration of EGF in human fluids ranges
from as much as 500 ng/mL in bile and milk to 1-2 ng/mL in plasma, serum, and saliva
[103]. Upon ligand binding, these family members form homo- and heterodimers with
each other, leading to transautophosphorylation (though ERBB3 contains no kinase
domain). This results in the recruitment of signaling proteins and then rapid endosomal
internalization of the receptors. Finally, the receptors are either recycled or destroyed in
lysosomes [104].
EGFR Structure
EGFR is an 1186 amino acid transmembrane protein comprised of an
extracellular ligand binding/dimerization arm domain, a transmembrane domain, and an
intracellular tyrosine kinase/C-terminal tail domain. The kinase domain of the
intracellular portion of EGFR contains an adenosine tri-phosphate (ATP) binding site.
When a ligand docks on a member of the EGFR family, EGFR family receptors form
dimers, which use the bound ATP to phosphorylate one another
(transautophosphorylation), which leads to receptor activation. The kinase domain also
contains lysine residues that are necessary for ubiquitination of the receptors for proper
sorting or degradation of the receptors. The C-terminal tail is the site of many tyrosine
residues, which may be phosphorylated to serve as sites for recruiting proteins involved
in signal transduction [103].
EGFR Signaling
EGFR activates ERK/mitogen activated protein kinase (MAPK),
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (AKT), protooncogene tyrosine-protein kinase Src (SRC), phospholipase C gamma 1 (PLCγ1)/protein kinase C (PKC), c-Jun N-terminal kinase (JNK), and Janus kinase
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(JAK)/signal transducer and activator of transcription (STAT) signaling pathways [103].
Following transphosphorylation of EGFR, the protein binds the Src homology 2 (SH2)
domain of growth factor receptor binding protein 2 (GRB2). EGFR activation also leads
to recruitment of Src homology and collagen (SHC). GRB2 then binds SOS1 (son of
sevenless 1), which leads to activation of the RAS/rapidly accelerated fibrosarcoma
(RAF)/mitogen-activated protein kinase kinase (MEK)/ERK signaling cascade, resulting
in cell proliferation, differentiation, and survival [105, 106]. Evidence suggests that fulllength EGFR is able to translocate into the nucleus. It has been hypothesized that
EGFR may complex with importin-β by way of a nuclear localization signal, making
interaction with nucleoporins of the nuclear pore complex and uptake into the nucleus
possible [107].
EGFR and Cancer
This family of receptors plays a significant role in promoting cell proliferation,
angiogenesis, cell migration, adhesion, metastasis, and the inhibition of apoptosis [103].
Because of the ability of ErbB family members to confer such oncogenic properties to
cells, constitutive activation or overexpression of these receptors is often found in
cancers, including carcinomas, sarcomas, non-small cell lung cancer, and malignant
gliomas [103]. Mutation of EGFR can lead to constitutive activation, the majority of
which stabilize ligand-independent dimerization with other ErbB family members [108,
109]. Other mutations allow endocytosis escape. One such mutation, EGFRvIII, occurs
in a considerable portion of glioblastomas [110]. A point mutation, L858R, is a common
EGFR tyrosine kinase domain mutation in non-small-cell lung cancer [111, 112]. This
mutation leads to as much as fifty-fold increase in kinase activity in vitro [113]. Another
kinase domain mutation, T790M, results in increased EGFR activity and confers
resistance to tyrosine kinase inhibitors [114].
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EGFR has been reported to be overexpressed in 30 to 95% of PDAC cases,
depending on the study [115]. Once activated, EGFR induces cyclin D1, which
complexes with CDK4/6 to initiate cell cycle progression [103]. This effect of activated
EGFR is pivotal to its oncogenic capability, and aberrant levels of EGFR have been
correlated with higher expression of cyclin D1 in non-small-cell lung cancer and breast
cancer [116, 117].
EGFR Inhibition as Cancer Therapy
The two major therapies which target EGFR include humanized monoclonal
antibodies against the extracellular domain of EGFR and tyrosine kinase inhibitors
(TKIs). The antibodies block ligand binding and may also promote endocytosis and
destruction of the receptor [118]. TKIs, such as Erlotinib, Gefitinib, and Lapatinib, are
ATP mimetics that inhibit transautophosphorylation by competitively and reversibly
binding to the ATP pocket of the tyrosine kinase domain [119]. Erlotinib, in combination
with gemcitabine, is used as a first-line pancreatic cancer therapy [120].
EGFR and Wnt Signaling
Experimental evidence in keratinocytes indicates that EGFR phosphorylation of
beta-catenin at tyrosine residue 654 decreases beta-catenin/E-cadherin binding, with
loss of beta-catenin at the membrane and increased levels in the nucleus [121]. In an
oral cancer study, again beta-catenin/E-cadherin interaction was found to decrease with
EGF stimulation, and nuclear beta-catenin levels increased with concomitant increase in
cyclin D1 levels [122]. This is in line with a triple-negative breast cancer study in which
low membrane beta-catenin in the presence of EGFR correlated with unfavorable
disease-free survival, but not in the absence of EGFR. In addition, the authors reported
that decreased beta-catenin membrane staining correlated with increased nuclear betacatenin staining [123].
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The Interplay of EGFR, MUC1, and Wnt Signaling
Beta-catenin is stabilized by MUC1.CT [124], and nuclear beta-catenin levels rise
with MUC1 overexpression [67, 124]. EGF is abundant in the microenvironment of
pancreatic cancer, and active EGFR is highly expressed by pancreatic cancer cells [2,
4]. In addition, MUC1 has been reported to increase EGFR levels [7, 125]. Aberrant
Wnt signaling [36, 126, 127] and EGFR activity [128-130] are well documented in
pancreatic cancer. EGFR has been reported to directly phosphorylate the tyrosine
residue of the YEKV motif of MUC1.CT, and this phosphorylation apparently increases
the interaction between MUC1.CT and beta-catenin [55]. For these reasons, this
dissertation is devoted primarily to understanding the interaction between beta-catenin
and MUC1.CT in the context of EGF stimulation in the hope of demystifying this element
of pancreatic cancer.
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CHAPTER 2. MATERIALS AND METHODS
Reagents
Primary Antibodies
The beta-catenin antibody 15B8 [131] (53483, Santa Cruz) was a monoclonal
antibody produced in mouse. This antibody recognizes the C-terminus of beta-catenin.
The MUC1.CT antibody CT2 (80952, Abcam) was a monoclonal antibody produced in
Armenian hamster. Mouse IgG isotype control antibody was 02-6100, Thermo Fisher
Scientific. The Armenian hamster IgG isotype control antibody was 18479, Abcam.
Actin antibody (A5441, Sigma-Aldrich) was used as a loading control for
cytoplasm/membrane fractions. HDAC2 antibody was used (5113, Cell Signaling) as a
loading control for nuclear fractions. An EGFR antibody (373746, Santa Cruz) was used
as a membrane marker. An anti-phosphotyrosine antibody (7020, Santa Cruz) was used
to determine MUC1.CT tyrosine residue phosphorylation.
Confocal microscopy primary antibodies for cell staining included beta-catenin
antibody 15B8 (53483, Santa Cruz) and MUC1.CT antibody CT2 (80952, Abcam). For
PDAC tissue staining MUC1.CT antibody CT2 and the rabbit monoclonal beta-catenin
antibody D10A8 (8480, Cell Signaling) were employed.
For the SU11274 organelle localization study cell compartments were stained
with the following antibodies: endoplasmic reticulum, anti-calreticulin Alexa Fluor 647
(1:100 v/v, 196159, Abcam); lysosomes, anti-Lamp1 (1:1,000 µg/µL, 24170, Abcam);
early endosomes, anti-EEA1 Alexa Fluor 647 (1:50 v/v, 196186, Abcam); Golgi
apparatus, anti-giantin (1:300 v/v, 80864, Abcam); late endosomes, anti-Rab9 (1:250
µg/µL, 179815, Abcam); recycling endosomes, anti-Rab11 (1:100 v/v, 700184, Thermo
Fisher Scientific). Anti-rabbit Alexa Fluor 647 (1:3,000 µg/µL, A-21245, Thermo Fisher

22
Scientific) was applied to the cells in the case that the primary antibody was not
conjugated to Alexa Fluor 647.
Secondary Antibodies
The mouse secondary antibody used in western blotting was IRDye® 680RD
anti-mouse (926-68072, LI-COR). The goat-anti Armenian hamster antibody was Affini
Pure IgG (127-005-160, Jackson Immuno Research) to which IRDye 800CW NHS ester
(929-70020) was conjugated per LI-COR protocol.
Confocal microscopy secondaries for fixed-cell experiments included goat-antiArmenian hamster Alexa Fluor 488 (173003, Abcam), goat-anti mouse Alexa Fluor 568
(A11031, Life Technologies), and goat anti-rabbit Alexa Fluor 647 (A21245, Life
Technologies). Goat anti-Armenian hamster Alexa Fluor 488 (173003, Abcam) and goat
anti-rabbit Alexa Fluor 647 (A21245, Life Technologies) were used for staining PDAC
tissue samples.
Growth Factors
Connective tissue growth factor (CTGF) (PHG0286, Invitrogen) was applied to
cells at 100 ng/mL. Platelet-derived growth factor (PDGF) (PHG0045, Invitrogen) was
applied to cells at 10 ng/mL. Hepatocyte growth factor (HGF) (H9661, Sigma Aldrich)
was applied to cells at 10 ng/mL. Epidermal growth factor (EGF) (PHG0311, Thermo
Fisher Scientific) was applied to cells at 10 ng/mL. EGF activity was confirmed by
increased ERK phosphorylation (Thr 202/Tyr 204) in the cytoplasm/membrane and
nuclear fractions of S2-013.MUC1F cells (data not shown).
Buffers
Unless indicated otherwise, cells were lysed in 250 mM sucrose, 20 mM HEPES,
10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT at pH 7.4. Halt
phosphatase/protease inhibitors (78440, Thermo Fisher Scientific) or Pierce
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phosphatase and protease inhibitor (88667, Thermo Fisher Scientific) and 1 mM DTT
were added to the lysis buffer immediately before use. The nuclear lysis buffer was 250
mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1
mM DTT, 10% glycerol, 0.1% SDS, pH 7.4.
The elution buffer for two-dimensional gel electrophoresis consisted of 7M urea
(4.2g in 10 mL solution), 2M thiourea (1.5g in 10 mL solution), 3% CHAPS (0.3g in 10
mL solution), and 1% Triton-X 100 (1 mL 10% Triton-X 100 in 10 mL solution).
MUC1.CT Peptides
MUC1.CT peptides used in ITC experiments were purchased from Biomatik and
Genscript. Peptides used in OpenSPR experiments were purchased from Biomatik,
CSBio, Genscript, and RS Synthesis. Red font p followed by a red font S or Y indicates
a phosphorylated serine or tyrosine residue. Red font E indicates a serine residue to
glutamate residue phosphomimetic mutation. The Biomatik peptide was
GRpYVPPSSTDRSPpYEKVSAGNGGSSLSYTNPA (HPLC purity above 98%, identity
confirmed by mass spectrometry). The CSBio peptides included the following:
NYGQLDIFPARDTYHPMSEYPTYHTHGRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPA
VAATSAN and CQCRRKNYGQLDIFPARDTYHPMSEYPTYH (both with HPLC purity
above 98% and identity confirmed by mass spectrometry). The Genscript peptides
included the following: VSAGNGGSSLSYTNPA, GRYVPPSSTDRSPYEKV,
GRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPA, and
GRYVPPSSTDRSPYEKVSAGNGGEELEYTNPA (all with HPLC purity above 95% and
identity confirmed by mass spectrometry and amino acid analysis). The RS synthesis
peptides included the following: PYEKVSAGNGGSSLSYTNPA,
PYEKVpSAGNGGSSLSYTNPA, PYEKVSAGNGGpSSLSYTNPA,
PYEKVSAGNGGSpSLSYTNPA, PYEKVSAGNGGSSLpSYTNPA,
KSVGSPNESTAYSGLNAGYP (scrambled peptide),
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CQCRRKNYGQLDIFPARDTpYHPMSEYPTYH, and
GRYVPPpSpSpTDRSPYEKVSAGNGGSSLSYTN (all with HPLC purity above 95%, TFA
to chloride ion counter exchanged, and identity confirmed by mass spectrometry).
Recombinant Protein Constructs
M57 pPET28a-TEV-full-length human beta-catenin (Randall Moon, plasmid
#17198, Addgene) was expressed in BL21 (DE3) E. coli [132] (kanamycin selection).
When the bacteria reached an optical density (600 nm) of about 1.0, they were induced
for 2 to 3 hours with 0.5 mM IPTG at 37°C (with 175 rpm rotation). For isothermal
titration calorimetry (ITC) experiments, the protein was purified over a 5mL nickel
column. Buffer A was 50 mM Tris, 150 mM NaCl, 10 mM imidazole, pH 8.0, and buffer
B was 50 mM Tris, 150 mM NaCl, 600 mM imidazole, pH 8.0. A linear gradient
(increasing percentage of imidazole) was used for elution of the protein. In ITC
experiments the protein was purified further by size exclusion chromatography in 150
mM NaCl, 30 mM Tris, 2 mM beta-mercaptoethanol, pH 8.0. The same construct was
used for OpenSPR experiments. In OpenSPR experiments the protein was purified with
PBS, pH 8.0, using a linear gradient of imidazole to elute the protein from the column.
The protein was dialyzed three times in PBS, pH 8.0 for at least two hours per dialysis
step.
The Ecyto [24] construct was a gift from the lab of Dr. William Weis, Stanford
School of Medicine. The protein was expressed in BL21 (DE3) E. coli (Ampicillin
selection) to an optical density (600 nm) of about 1.0. The bacteria were induced for 4
hours with 0.5 mM IPTG at 37°C (with rotation at 175 rpm). The protein was purified
with a GSTrap (28401748, GE Healthcare). The binding buffer was PBS, 2 mM DTT, pH
8.0. The elution buffer was PBS, pH 8.0, 2 mM DTT, 10 mM reduced glutathione. The
protein was dialyzed three times in PBS, pH 8.0 for at least two hours per dialysis step.
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His-tag MUC1.CT (pET-19b vector) was produced by Ryan Hanson in the
Hollingsworth lab. Translated, it was of the sequence
MGHHHHHHHHHHSSGHIDDDKHMLECQCRRKNYGQLDIFPARDTYHPMSEYPTYHT
HGRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPAVAATSANL (MUC1.CT in italics).
The protein was expressed in BL21 (DE3) cells at 37°C, which were induced at an
optical density (600 nm) of 0.5 to 1.0 for 4h at 37°C with 0.5 mM IPTG. The protein was
purified with a cobalt affinity column. The binding buffer was 10 mM imidazole in PBS at
pH 8.0. The protein was eluted in PBS, 1M imidazole, pH 8.0 (stepwise elution with 5
column volumes 30%, 3 column volumes 40%, 3 column volumes 50%, and 5 column
volumes 100% elution buffer). The protein was concentrated, and the imidazole
essentially removed by three rounds of buffer exchange with PBS, pH 8.0.
Cell Line and Culture Conditions
S2-013.MUC1F [133] is a pancreatic cancer cell line derived from a liver
metastasis that was genetically engineered to express FLAG-tagged MUC1. CFPAC-1
is a pancreatic ductal adenocarcinoma cell line obtained from a patient with cystic
fibrosis [134]. The cells were cultured in DMEM containing 5% FBS. Cells were
incubated at 37°C and 5% CO2. Cells were typically grown to 80% confluency prior to
lysis for western blot or immunoprecipitation experiments and prior to imaging for
confocal microscopy experiments.
Constructs Used in Cells
To study localization and trafficking of MUC1.CT and beta-catenin, cells labeled
with fluorescent MUC1.CT and fluorescent beta-catenin were prepared. S2-013.MUC1
eGFP cells express eGFP at the C-terminus of MUC1.CT. These cells were transduced
with mCherry murine beta-catenin (Addgene plasmid #55001, a gift from Michael
Davidson). Murine beta-catenin differs by one amino acid residue in the C-terminus of
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the protein (P706A). The mCherry beta-catenin was inserted into pCW57-MCS1-2AMCS2, Addgene plasmid #71782, a gift from Adam Karpf. Stbl3 (Thermo Fisher
Scientific) E. coli was used to prepare pCW57-MCS1-2A-MCS2/mCherry beta-catenin
DNA to infect HEK 293T cells to package viruses, which were used to infect S2013.MUC1 eGFP cells.

The cells expressed mCherry beta-catenin upon 48 hours

doxycycline treatment (16 µg/mL).
Methods
Subcellular Fractionation
To each 15-cm dish, 250 µL cytoplasm/membrane lysis buffer was applied. The
lysate was passed through a 25G needle 10 times and then allowed to incubate on ice
for 20 minutes. The lysate was centrifuged at 700g for 5 minutes at 4°C. The
supernatant from this spin was centrifuged at 10,000g for 5 minutes. If not used directly,
the cytoplasm/membrane fraction was stored at -80°C. The pellet produced from the
first spin was washed once with 250 µL lysis buffer. The supernatant was then removed,
and the pellet (mostly nuclei) was lysed with 100 µL of the nuclear lysis buffer. After
sitting on ice for 10 minutes, the nuclear fraction was centrifuged at 10,000g for 5
minutes. Turbonuclease (1:1000 v/v) and DTT (1 mM) were added to the nuclear lysis
buffer at the time of nuclear lysis. The nuclear fraction was stored at -80°C. Before
freezing the lysates, 5 µL cytoplasm/membrane lysate and 10 µL nuclear lysate were
placed in microcentrifuge tubes with NuPAGE (Thermo Fisher Scientific) sample buffer
(5 µL per sample) in preparation for western blot. Membrane fractions were obtained
with the Mem-PERTM Plus Membrane Protein Extraction Kit (Thermo Fisher Scientific).
Coimmunoprecipitation
For large scale immunoprecipitation experiments a beta-catenin affinity column
was prepared by covalently binding 1 mg 15B8 antibody to 2 mL PierceTM NHS-activated
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agarose slurry (26200, Thermo Fisher Scientific). The isotype control column was made
in an identical fashion with 1 mg mouse IgG1 antibody (3877, Santa Cruz).
S2-013.MUC1F protein lysate (lysed in 1% NP40, 25 mM Tris-Cl, 150 mM NaCl, 1 mM
EDTA, pH 7.4) was incubated on the column overnight at 4°C. Equal portions of lysate
protein (same in volume and concentration) were applied to isotype control and betacatenin affinity columns (typically 10 to 15 mg in 2 mL). Halt protease and phosphatase
inhibitor cocktail (Thermo Fisher Scientific, 78440) was added to the lysis buffer prior to
lysing the cells. The column was rinsed with 1 mL lysis buffer five to six times and six 1
mL 0.2M glycine (pH 3.0) elution fractions were collected.
For small scale immunoprecipitation experiments, 10 µg 15B8 or CT2 or IgG
control antibody was applied to 50 μL Dynabeads (up to 200 µL Dynabeads for twodimensional gel electrophoresis) protein G (10003D, Thermo Fisher Scientific) for 2
hours at 4°C or 10 minutes at room temperature for two-dimensional gel electrophoresis
samples. Equal portions of lysate protein (same in volume and concentration) were
applied to isotype control and specific antibody preparations. The beads were allowed
to rotate overnight at 4°C or for 10 minutes at room temperature for two-dimensional gel
electrophoresis samples. Fifty μL 2D-Xtract (G-Bioscience) was used to elute the beads
for 30 minutes at 54°C. Two-hundred μL urea/thiourea buffer (described in Reagents
section) was used to elute beads for 10 minutes at 70°C for two-dimensional gel
electrophoresis samples.
Two-Dimensional Gel Electrophoresis
To each eluent (200 μL) from immunoprecipitation 1 μL strip ZOOMTM carrier
ampholyte pH 3-10 (Thermo Fisher Scientific, ZM0021) and 1 μL bromophenol blue
were added. The solution was added to a lane of the ZOOMTM IPG runner cassette
(Thermo Fisher Scientific, ZM0003) holding a gel strip (Thermo Fisher Scientific, pH 310 linear, ZM0018). The gels were rehydrated overnight at room temperature.
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For the first dimension the gel strips were electrophoresed at a constant 175V for
20 minutes, a gradient of 175 to 2000V for 50 minutes, and at a constant 2000V for 45
minutes. The gel strips were then equilibrated in 0.1 M DTT for 12 minutes and then 70
mM iodoacetamide solution for 12 minutes. For the second dimension the gel strips
were placed horizontally over a 4-12% Bis-Tris ZOOMTM protein gel (NP0330BOX,
Thermo Fisher Scientific). Agarose gel (0.5%) was used to merge the gel strip with the
protein gel. Then the proteins were electrophoresed for about 80 minutes at 150V.
Western Blot
Bis-tris gels were run for 60 minutes at 150V. Gels were transferred to
polyvinylidine fluoride (PVDF) for 80 minutes at 80V. The membranes were blocked in
5% BSA for 1 hour. The membranes were incubated with primary antibody in 2.5% BSA
in PBS with 0.1% Tween-20 overnight at 4°C with nutation. The beta-catenin antibody
(15B8) was diluted at 1 μg/mL. The MUC1.CT antibody (CT2) was diluted at 0.25
μg/mL. Anti-mouse secondary (diluted at 1:10,000) and anti-Armenian hamster (diluted
at 1:5,000) secondary antibodies were applied for 45 minutes at room temperature. The
fluorescence of the secondary antibodies was detected with an Odyssey Imager (LICOR, Bad Homburg, Germany) and quantified with Odyssey 3.0 software [135].
Confocal laser scanning microscopy
A Zeiss laser scanning microscope 800 with Airyscan (Thornwood, NY) with a
40x/1.3 oil immersion objective lens was used to produce all images of cells unless
otherwise specified. Unless otherwise indicated, the following excitation and emission
parameters apply to confocal microscopy images. For DAPI and Hoechst 33342 dyes
(detection of nuclei) the excitation wavelength was 405 nm and the emission spectrum
detected was 411 to 488 nm. Alexa Fluor 488 and MUC1 eGFP were excited with a
wavelength of 488 nm and the emission spectrum detected was 495 to 570 nm. The
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excitation wavelength for excitation of Alexa Fluor 568 antibodies was 561 nm and the
emission spectrum detected was 575 to 700 nm. The excitation wavelength for
excitation of Alexa Fluor 647 was 640 nm and the emission spectrum detected was 646
to 700 nm. All images were acquired using sequential scanning of individual
fluorophores with an image size of 1024x1024 pixels and a pixel scaling of 0.156 μm per
pixel. Images were additionally averaged 2 to 8 times and collected using bidirectional
scanning. All imaging parameters were universally applied across treatment groups of
each experiment.
If cells were to be treated with a growth factor, they were first serum starved for
about 24 hours. When used, Erlotinib (Selleckchem) was applied at 1 μM (or an equal
volume of DMSO as a vehicle control). Following fixation (4% PFA in PBS) and
permeabilization (0.15% Triton-X 100 and 1% BSA in PBS) cells were typically blocked
for 30 minutes with 5% BSA in PBS and then stained with primary antibody overnight at
4°C. Beta-catenin antibody 15B8 was applied at 1:200 μg/μL and MUC1.CT antibody
CT2 was applied at 1:250 μg/μL. For the confocal microscopy experiments in which
cells were probed for beta-catenin and MUC1.CT, the cells were blocked for 30 minutes
in 5% BSA and 5% goat serum in PBS. Secondary antibodies were applied at 1:3,000
(µg/µL) for one hour at room temperature. Antibody diluent was typically 1% BSA in
PBS. ProLong Gold Antifade mountant with DAPI (Thermo Fisher Scientific) was used
to stain the nuclei of fixed cells. Coverslips were stored at 4°C if not imaged
immediately.
For tissue staining of the PDAC sample formalin fixed paraffin embedded tissue
was rehydrated followed by antigen retrieval with citrate buffer. After permeabilization
(1.5% Triton X-100 in PBS) and blocking (5% BSA, 5% goat serum, 0.25% Triton X-100
in PBS) samples were stained with CT2 (1:100 v/v) and D10A8 (1:50 v/v) overnight at
4°C. Secondary antibodies Alexa Fluor 488 (1:100 v/v) and Alexa Fluor 647 (1:400 v/v)
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were applied for 1 hour at room temperature. The antibody diluent was 5% BSA, 1%
goat serum, and 0.10% Triton X-100 in PBS. Nuclei were stained with Duolink® In Situ
Mounting Medium with DAPI (82040, Sigma-Aldrich).
Live Cell Imaging
Cells were cultured on glass bottom microwell dishes (P35G-1.5-14-C, MatTek).
Cells were maintained at 37°C and 5% CO2 during image acquisition.
SU11274 Spectral Properties and Imaging
SU11274 (at 32 µM) was excited using 488 nm and spectrally profiled with a
Zeiss LSM 710 (Thornwood, NY). SU11274-associated fluorescence intensities were
acquired in bins of approximately 10 nm in size ranging from 482 to 725 nm. Given the
verified spectral properties of SU11274, SU11274-specific emission was collected using
a 495-570 nm filter set.
SU11274 Cellular Uptake Assay
S2-013.MUC1F cells were treated with 2 µM SU11274 and imaged (under the
aforementioned imaging parameters) for 15 minutes at 20 second intervals. To
characterize inhibitor uptake in individual cells, mean fluorescence intensities from
SU11274 were collected from discrete regions of interest (ROIs) representing individual
cells (n=5 per time point). The averaged cell-specific SU11274 fluorescence intensities
were normalized to the highest fluorescence intensity observed and plotted as a function
of time. The rate of uptake was calculated by dividing the change in fluorescence
intensity from consecutive intensity measurements by the increment of time elapsed
between measurements (20 seconds).
Subcellular SU11274 localization
SU11274 (Selleckchem) was applied at 2 µM for 30 minutes prior to fixing,
permeabilizing, and staining the cells with organelle-specific antibodies for 2 hours at
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4°C. A rabbit isotype control antibody (NI01, MilliporeSigma) was applied at the same
concentration as the specific primary antibodies. Anti-rabbit Alexa Fluor 647 was
applied to the cells in the case that the primary antibody was not conjugated to Alexa
Fluor 647.
Characterization of SU11274 concentration in the ER
SU11274 was applied to living cells at various concentrations (0, 0.1, 1, and 10
µM). ER colocalization was determined using ER-Tracker™ Red (10 nM, E34250,
Thermo Fisher Scientific). ER-TrackerTM Red was excited using a 561 nm laser line and
the resultant emission was collected using a 574-633 nm filter. Cells were imaged three
minutes after the application of SU11274 and ER TrackerTM Red (added to cells
simultaneously). Given that SU11274 emission could contaminate the ER-TrackerTM
Red fluorescence collection, cells were sequentially imaged. Briefly, 488 nm excitation
(used to excite SU11274) exhibits a 5% excitation efficiency for ER-TrackerTM Red, and
the resultant ER-Tracker Red emission was completely independent of the SU11274
fluorescence detection filter. In cells treated with SU11274 only, SU11274 emission into
the ER-TrackerTM Red specific channel was approximately 0.1% (0.10 ± 0.06%).
Areas of cells (n=9), cell medium (n=6), and the ER (n=9) were assigned as
individual ROIs and the mean fluorescence intensity values for SU11274 in the cell
medium, cells, and the ER were determined. Hoechst 33342 was used to stain the
nuclei (blue). The Iso Data method (ZEN Blue) was used to optimize the image
parameters to delimit the ER. SU11274-associated mean fluorescence intensities in
individual cell ROIs and in acellular ROIs were analyzed to determine the relationship
between SU11274 mean fluorescence intensity and SU11274 cell medium
concentration. The SU11274 concentration was plotted as a function of the SU11274
mean fluorescence intensity measured in the cell medium. The average fluorescence
intensity at 0 µM SU11274 of the cells and that of the ER was subtracted from cell and
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ER data sets, respectively. The equation relating fluorescence intensity to SU11274
concentration ([SU11274] = 8.0749 x SU11274 Mean Fluorescence Intensity - 1.365)
was used to estimate the SU11274 concentration in the cells and in the ER region of the
cells at given cell medium SU11274 concentrations.
Proximity Ligation Assay
Duolink® In Situ Probemaker PLUS (Sigma-Aldrich) kit was used to make the
CT2+ probe, which was applied to the cells at 1:100 v/v (1:100 μg/μL). The beta-catenin
antibody (15B8) probe was added at 1:50 v/v (or 1:250 μg/μL). For the isotype control,
the antibody was applied at 1:250 v/v (1:250 μg/μL). The total volume applied to each
coverslip was 100 μL. The Duolink® (Sigma-Aldrich) proximity ligation assay (PLA)
protocol was followed in order to quantify beta-catenin/MUC1.CT interactions in the
cells.
Mass Spectrometry
Mass spectrometry was performed by Dragana Lagundzin, Ph.D., at the
University of Nebraska Medical Center Mass Spectrometry and Proteomics Core
Facility. After electrophoretic protein separation, gels were stained with Coomassie blue
for 2h and left to destain overnight. Coomassie blue-stained gel pieces were manually
cut using a sterile scalpel and kept in sterile microcentrifuge tubes. Gel pieces were
washed with HPLC water and shrunk with acetonitrile (ACN) (100%). Proteins were
reduced with 2 mM tris(2-carboxyethyl)phosphine (TCEP)/50 mM ammonium
bicarbonate (AmBic) for 1h at 37°C. After incubation, ACN was added to TCEP to
destain gel pieces. After gel pieces were dried by adding additional portion of ACN, thiol
groups of proteins were alkylated with 55 mM iodoacetamide (IAA)/50 mM AmBic for 20
minutes in the dark, with rotation. Samples were dried with ACN, and 10 nM MS-grade
trypsin (Promega) was added for protein digestion. Samples were incubated with trypsin
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for 30 minutes on ice. After the excess trypsin was removed from the tubes, 25 mM
AmBic was added to the gel pieces. Tryptic digestion continued overnight at 37°C.
Digested peptides were then extracted from the gel with ACN (50%)/trifluoroacetic acid
(0.1%) solution. Samples were dried in a Speedvac, dissolved in 15 µL formic acid (FA)
(0.1%), and submitted for LC-MS/MS analysis.
In-gel digested peptide samples were analyzed using the high-resolution mass
spectrometry LC-MS/MS system (LTQ Orbitrap Elite Velos Pro, Thermo Scientific, West
Palm Beach, FL, USA), coupled with an Eksigent NanoLC-Ultra 1D plus (Eksigent,
Dublin, CA, US) and nanoFlex cHiPLC system (Eksigent), equipped with two alternating
peptide traps. Ten microliters of each sample were loaded onto the peptide trap using
0.1% FA solvent. The samples were eluted using a 1h linear gradient of 0-60% ACN in
0.1% FA. Resolution of the full scan in the Orbitrap was set to 120,000 m/z with a range
of 300 to 2000 Da. The collision energy was set at 35 kV.
The MS/MS spectra from the peptides were analyzed by assigning the fragments
to the candidate sequence using the MASCOT search engine (Matrix Science, London,
UK, version 2.5.1) with a Swissprot database (Taxonomy: Mammalia). Parameters on
MASCOT were set as follows: enzyme, trypsin; max missed cleavage, 2; peptide
charge, 1+, 2+, and 3+; peptide tolerance, ± 0.8 Da; fixed modifications,
carbamidomethyl (C); variable modifications, oxidation (M), phospho (ST) and phospho
(Y); MS/MS tolerance, ± 0.6 Da; instrument, ESI-TRAP. MASCOT results for different
gel cuts of the same sample were combined and analyzed using Scaffold (Proteome
Software, Inc., Portland, OR, version 4.4.5), which allows multiple search results to be
condensed into a single result file. Peptide identifications were accepted if they were
established at greater than 95.0% probability by the Peptide Prophet algorithm [136] with
Scaffold delta-mass correction. Protein identifications were accepted if they were
established at greater than 95.0%. Protein probabilities were assigned by the Protein
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Prophet algorithm [137]. Proteins that contained similar peptides and could not be
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of
parsimony. Proteins sharing significant peptide evidence were grouped into clusters.
Fluorescence Lifetime Imaging/Förster Resonance Energy Transfer
Fluorescence lifetime imaging (FLIM) of two-photon-excited eGFP was
performed using the 920-nm mode-locked femtosecond pulse train of a Spectra Physics
MaiTai Ti:S laser on a Leica TCS SP8 MP multiphoton laser scanning confocal
microscope (Leica Microsystems, Germany) using a Leica HC PL APO CS2 40X/1.3 NA
oil immersion objective at the Creighton University Integrated Biomedical Imaging
Facility (IBIF) with the assistance of Dr. Michael G. Nichols. Green and red nondescanned fluorescence was separated using a 565-nm long pass dichroic mirror,
isolated with an ET 525/50M and HQ 645/75M band-pass filters (Chroma Technology,
Bellows Falls, VT, USA), respectively, and detected with high-sensitivity Super HyD
detectors and a time-correlated single photon counting module (830 SPC, Becker and
Hickl, Berlin, Germany). Individual imaging windows (128x128 pixels) acquired using a
zoom of 2.5 represented an area of approximately 110 µm (0.87 µm per pixel). Photons
were accumulated for 120s (total acquisition time).
Isothermal Titration Calorimetry
All reactions were measured with an ITC200 isothermal titration calorimeter from
Microcal (Northampton, MA). The reaction cell was identical to the reference cell, which
was filled with distilled water. In a typical isothermal titration calorimetry (ITC)
experiment the ligand solution was placed in the syringe and injected by a computercontrolled step motor into the sample cell with the macromolecule solution. The heat
absorbed or released in each injection was measured by a thermoelectric device, which
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increased or reduced the power input of the sample to maintain the same temperature
between the sample and reference cells [138, 139].
A 40 μL syringe was used to inject the titrant, MUC1.CT peptide in this case.
The solution was mixed by stirring the syringe at 1000 rpm. Typically, 2 μL of MUC1.CT
peptide were injected into the sample cell containing beta-catenin. This was repeated
four additional times with about 5 minutes between injections. The peptide and protein
were both in 30 mM Tris and 150 mM NaCl at a pH of 8.0. The reaction heat of each
injection was measured by integration of the area of the injection curve, corrected for the
dilution heat of the titrant, and normalized by the moles of titrant added to yield the
reaction change in enthalpy, ΔHITC [138]. ITC experiments were designed to obtain the
heat, ΔHITC, for each reaction by averaging the reaction heat of the five injections under
unsaturated conditions. Typically, the solution of the MUC1.CT peptide in the titrating
syringe had a ten-fold higher molarity than the recombinant beta-catenin solution to
produce peaks under unsaturated conditions.
A PD Midi Trap G-10 column was used to remove excess TFA from MUC1.CT
peptides in which TFA was present. The peptides were dissolved in the same buffer
used to purify the beta-catenin in all ITC experiments.
OpenSPR
A Nicoya OpenSPR instrument and TraceDrawer software were used to
determine kinetics of interaction between beta-catenin and MUC1.CT peptides.
Freshly prepared His-tag beta-catenin (50 μg) was applied to a carboxyl sensor chip
(SEN-AU-100-12-COOH, Nicoya LifeSciences). All experiments were conducted in
PBS, pH 8.0. If TFA was present in the MUC1.CT peptide, it was removed by chloride
replacement (at least two rounds of dissolving the peptide in 10 mM HCl followed by
lyophilization to complete dryness). The peptides were dissolved in the same buffer
used to purify the beta-catenin in all OpenSPR experiments.
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Statistical analysis
Values were expressed as means ± standard error of the mean (SEM).
Differences between groups were evaluated by a one-way ANOVA followed by nonparametric Mann Whitney tests (performed by GraphPad Prism 7.0d) for comparison
between two groups. For Pearson correlation analysis in Chapter 4 the nonparametric
Mann-Whitney test with Bonferroni method accounting for multiple comparisons was
used to compare all non-control groups with the isotype antibody control. Differences
were considered significant at p<0.05. Significant differences are indicated by asterisks
only if confirmed with an experimental replicate unless otherwise noted in the text.
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CHAPTER 3. THE BETA-CATENIN/MUC1.CT INTERACTION IN PANCREATIC
CANCER
Introduction
The cytoplasmic tail of MUC1 and beta-catenin physically interact [95, 124].
Normally, MUC1 is restricted to the apical surface of epithelial cells. However, this
apical polarity is lost in cancer cells, and MUC1 is expressed over the entire surface of
the cell [47]. This expands the potential interactome of MUC1 to include proteins in the
lateral surface as well as the basal surface of the cell. One such lateral protein is betacatenin, which in cells normally associates with E-cadherin in the formation of adherens
junctions. The beta-catenin/MUC1.CT interaction prevents degradation of beta-catenin
in the cytoplasm, thereby permitting beta-catenin to translocate to the nucleus where it
acts as a transcriptional coactivator (through association with TCF/LEF transcription
factors) [95, 124]. Dysregulation of Wnt signaling correlates with increased expression
of proto-oncogenes such as c-Myc and cyclin D1 in various human cancers [140, 141],
including pancreatic cancer [142]. Additionally, some evidence suggests that aberrant
beta-catenin signaling is necessary for pancreatic carcinogenesis [13].
Just as MUC1 is no longer restricted to the apical surface of cancer cells,
receptor tyrosine kinases are no longer constrained to the basolateral surface [7]. This
means that stimulation of RTKs by growth factors could lead to MUC1.CT
phosphorylation, and, in fact, it has been reported that stimulation of certain RTKs not
only causes phosphorylation of MUC1.CT, but also an increase in interaction between
MUC1.CT and beta-catenin [67]. Serine/threonine kinases are also known to
phosphorylate MUC1.CT [93, 99], and in some cases such phosphorylation increases
interaction with beta-catenin [99].
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The phosphorylation state or states of MUC1.CT that are important for interaction
with beta-catenin are not fully characterized. Phosphorylation of tyrosine residues in
MUC1.CT are believed to be important for this interaction [143]. A specific sequence in
the C-terminus of MUC1, known as the serine-rich motif, has also been shown to be
important for interaction with beta-catenin [94]. Because phosphorylation of serine
residues in other beta-catenin binding serine-rich motif-containing proteins (i.e., Ecadherin and APC) increases binding affinity by two to three orders of magnitude [25,
144], one might easily conceive of a similar scenario between beta-catenin and
MUC1.CT. However, phosphorylation of MUC1.CT does not always have a positive
effect on its interaction with beta-catenin. GSK-3β has been shown to phosphorylate a
serine residue of MUC1.CT in a span of residues just N-terminal to the serine-rich motif,
and this phosphorylation actually has an inhibitory effect on its interaction with betacatenin [93]. Thus, phosphorylation of MUC1.CT may in some cases promote and in
others abolish interaction with beta-catenin. Because Wnt signaling results in cellular
proliferation and the beta-catenin/MUC1.CT interaction is known to occur in and promote
PDAC, understanding the nature of this interaction is of consequence.
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Results
In order to understand the nature of the beta-catenin/MUC1.CT association at
steady state in PDAC cells, S2-013.MUC1F cells were fractionated into
cytoplasm/membrane (Figure 2A) and nuclear (Figure 2B) fractions and subjected to
immunoprecipitation with a beta-catenin antibody as well as with a MUC1.CT antibody in
a reciprocal experiment. The lysate and immunoprecipitation samples were subjected to
western blot to determine the presence of beta-catenin and MUC1.CT.
A typical result of fractionation of S2-013.MUC1F cells into cytoplasm/membrane
(Figure 2C) and nuclear fractions (Figure 2D) is also shown.
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Figure 2. The beta-catenin/MUC1.CT association occurs both in the
cytoplasm/membrane and nuclear fractions of S2-013.MUC1F cells.
(A) S2-013.MUC1F cells were lysed and fractionated. The cytoplasm/membrane
fraction was subjected to immunoprecipitation with beta-catenin antibody 15B8 (and
mouse IgG isotype control) and MUC1.CT antibody CT2 (and hamster IgG isotype
control). Lys stands for lysate. (B) The nuclear fraction was also subjected to the
same immunoprecipitation regime as in A. Notice the especially dark band at the top
of the MUC1.CT band. This corresponds to the light chain of the mouse antibody
used for immunoprecipitation. (C) This blot is a typical result of fractionation of S2013.MUC1F cells into cytoplasm/membrane (presence of β-actin and no H2B) and
(D) nuclear (presence of H2B and no β-actin) fractions prior to immunoprecipitation.
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When we immunoprecipitated beta-catenin (15B8 antibody), we found that
MUC1.CT coimmunoprecipitated with it from the cytoplasm/membrane fraction of the
cells (Figure 2A). In the reciprocal experiment MUC1.CT was immunoprecipitated
(CT2), and beta-catenin coimmunoprecipitated with it from the cytoplasm/membrane
fraction. In Figure 2B we show that beta-catenin and MUC1.CT coimmunoprecipitated
from the nuclear fraction as well. The fractionation method was confirmed (Figure 2C
and D) by probing for β-actin (which was observed in the cytoplasm/membrane fraction
and only minimally in the nuclear fraction) and H2B (observed in the nuclear fraction and
not in the cytoplasm/membrane fraction). The results suggest that a subset of MUC1.CT
isoforms between 20-25 kDa coimmunoprecipitate with beta-catenin.
In order to study the importance of phosphorylation of MUC1.CT on its
association with beta-catenin, two-dimensional gel electrophoresis of beta-catenin
immunoprecipitates were performed (Figure 3). Two-dimensional gel electrophoresis
separates proteins by mass and charge, and any phosphorylation of MUC1.CT would
alter the charge of the protein and its position within the gel. The immunoprecipitation
samples are separated based on charge in the first dimension and then by molecular
weight in the second dimension. The cytoplasm/membrane fraction of S2-013.MUC1F
cells was used for this experiment. Because the beta-catenin antibody is a mouse
antibody, and remnants of the antibody used in immunoprecipitation were anticipated in
the gel, a mouse secondary antibody was used to manifest the presence of these
antibody fragments in the isotype control (Figure 3A) and in the beta-catenin
immunoprecipitate (Figure 3D). Then the membrane was probed for MUC1.CT (Figure
3B, isotype control; Figure 3E, beta-catenin immunoprecipitate) and finally for betacatenin (Figure 3C, isotype control; Figure 3F, immunoprecipitate). Mouse antibody
staining (Figure 3A and D) and MUC1.CT staining (Figure 3B and E) have been
greyscaled.
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Figure 3. MUC1.CT coimmunoprecipitates with beta-catenin from
S2-013.MUC1F cells.
Two-dimensional gel electrophoresis was used to resolve MUC1.CT by molecular
weight and isoelectric point from S2-013.MUC1F cell lysate. The
cytoplasm/membrane fraction of S2-013.MUC1F cells was subjected to
immunoprecipitation with an antibody that recognizes beta-catenin (15B8, mouse
antibody) or an isotype control. Two-dimensional gel electrophoresis was used to
resolve beta-catenin and MUC1.CT by molecular weight and isoelectric point. (A)
The isotype control sample was electrophoresed in two dimensions. The membrane
was then probed with secondary anti-mouse antibody to detect antibody fragments
(immunoprecipitation remnants) prior to (B) probing the membrane for MUC1.CT. (C)
The same membrane was then probed for beta-catenin. (D), (E), and (F) were
probed in the same sequence as (A), (B), and (C). (F) This is a two-dimensional gel
electrophoresis of the 15B8 immunoprecipitate from the cytoplasm/membrane
fraction of S2-013.MUC1F cells. Beta-catenin is the red band between 75 and 100
kDa.
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When we immunoprecipitated beta-catenin and then probed for MUC1.CT after
two-dimensional gel electrophoresis (Figure 3E), we found beta-catenin appeared as a
red band (Figure 3F) at about 75 kDa, predominantly with an isoelectric point of 5 to 8.
This suggests that beta-catenin has been charge modified in S2-013.MUC1F cells. We
also found that MUC1.CT coimmunoprecipitated with beta-catenin. MUC1.CT appears
as a dark blotchy smear between 20 and 25 kDa with an isoelectric point of 4 to 7. The
breadth of MUC1.CT forms at various isoelectric points suggests that MUC1.CT of
various charge-related post translational modifications interacts with beta-catenin.
Similar results were produced at least three times.
To study the beta-catenin/MUC1.CT association in a cell line with endogenous
MUC1 expression, the PDAC cell line CFPAC-1 was selected. This cell line produces
an easily detectable amount of both beta-catenin and MUC1.CT. The cytosol and
membrane fractions of the cells were subjected to immunoprecipitation with a MUC1.CT
antibody. Western blot of lysates and immunoprecipitation (IP) samples was performed.
The membrane was probed for beta-catenin and MUC1.CT (Figure 4).
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Figure 4. Beta-catenin associates with MUC1.CT in the membrane of CFPAC-1
cells.
CFPAC-1 cells were separated into cytosol and membrane fractions. Each fraction
was divided in two and applied to either Dynabeads Protein G bound to isotype
control hamster IgG antibody or Dynabeads Protein G bound to MUC1.CT (CT2)
antibody. Lys stands for lysate.
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We see in Figure 4 that the beta-catenin/MUC1.CT association occurs in a
pancreatic cancer cell line with endogenous beta-catenin and MUC1. We
immunoprecipitated MUC1.CT and probed for MUC1.CT (bands at 15 and 20 kDa) and
beta-catenin (90 kDa) and found the association in the membrane fraction of the cells,
but not in the cytosol fraction.
Proximity ligation assay (PLA) [145] was performed to detect the interaction
between beta-catenin and MUC1.CT in S2-013.MUC1F cells (Figure 5). PLA enables
one to detect molecular interactions that are no more than 40 nm apart [146]. A yellow
spot in the image indicates an interaction between beta-catenin and MUC1.CT.
MUC1.CT antibody only was applied to the negative control cells (132 cells in three
fields) (Figure 5A), and beta-catenin and MUC1.CT antibodies were applied to the test
samples (103 cells in three fields) (Figure 5B).
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Figure 5. Beta-catenin and MUC1.CT interact in S2-013.MUC1F cells as
determined by proximity ligation assay.
(A) The beta-catenin antibody was omitted for the negative control. (B) Each yellow
spot indicates that a beta-catenin molecule is within 40 nm of a MUC1.CT molecule in
the cell. (C) Three consecutive z stacks of the cells enable one to see that some of
the interactions are occurring within the nuclei of the cells. The arrows point to
nuclear interactions.
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In the negative control cells (in which no beta-catenin antibody was applied), 0.05
± 0.10 spots per cell were counted (Figure 5A). When beta-catenin and MUC1.CT
antibodies were applied to the S2-013.MUC1F cells (Figure 5B), 17.0 ± 1.7 spots per cell
were counted. The images in Figure 5C were produced by taking three sequential
confocal microscopy images along the z-axis (z stacks) with 1 µm separation between
images. The beta-catenin/MUC1.CT interactions can be found in the cytoplasm and/or
membrane as well as within the DAPI stained nuclei (arrows). In a repeat experiment
1.3 ± 0.8 spots per cell were observed in the negative control samples and 10.7 ± 2.2
spots per cell were observed in the test samples.
PLA was performed to detect the interaction between beta-catenin and MUC1.CT
in CFPAC-1 cells (Figure 6). Only MUC1.CT antibody was applied to the negative
control cells (111 cells in three fields) (Figure 6A), and beta-catenin and MUC1.CT
antibodies were applied to the test samples (70 cells in three fields) (Figure 6B).
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Figure 6. Beta-catenin and MUC1.CT interact in CFPAC-1 cells as determined
by proximity ligation assay.
(A) The beta-catenin antibody was omitted for the negative control. (B) Each yellow
spot indicates that a beta-catenin molecule is within 40 nm of a MUC1.CT molecule in
the cell. The nuclei are stained with DAPI (blue).
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In the negative control cells (to which no beta-catenin antibody was applied), 1.5
± 1.1 spots were detected per cell in 111 cells (Figure 6A). When beta-catenin and
MUC1.CT antibodies were applied to the CFPAC-1 cells, a mean of 15.0 ± 2.2
interactions per cell were detected in 70 cells (Figure 6B). Thus, we show by PLA that
beta-catenin/MUC1.CT interactions occur in the cytoplasm and/or membrane of
CFPAC-1 cells. We have now observed that the beta-catenin/MUC1.CT association
occurs in PDAC cells that overexpress MUC1 as well as those with endogenous
expression of MUC1 by immunoprecipitation and PLA.
In order to study the nature of the association between beta-catenin and
MUC1.CT in human tissue, a PDAC liver metastasis was stained for beta-catenin and
MUC1.CT (Figure 7). The emission spectrum detected for DAPI (nuclei) was 400 to 491
nm. The emission spectrum detected for Alexa Fluor 488 (MUC1.CT) was 488 to 591.
The emission spectrum detected for Alexa Fluor 647 (beta-catenin) was 645 to 700 nm.
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Figure 7. Beta-catenin and MUC1.CT colocalize in pancreatic cancer.
(A) Secondary only control. (B) In a serial section beta-catenin is displayed in purple
and MUC1.CT is displayed in green. DAPI was used to stain the nuclei (blue).
Colocalization is shown in white.
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In this PDAC liver metastasis sample beta-catenin staining is visible in the
membrane of about half of the cells in the field (Figure 7). MUC1.CT (green) stained the
lumen of ducts. Neither beta-catenin nor MUC1.CT was present in the nuclei of the
cells. It appears that the association between beta-catenin and MUC1.CT in the
pancreatic cancer sample occurs largely in the membrane of the cells, especially along
the lumen of ducts. In some cases, large areas of beta-catenin/MUC1.CT colocalization
occurred at points of contact between three or more cells.
To this point, we have observed examples of association of beta-catenin and
MUC1.CT in cells and tissue. It has been reported that the beta-catenin/MUC1.CT
interaction is enhanced by phosphorylation of MUC1.CT [55], so we completed several
experiments to elucidate the phosphorylation status of MUC1.CT that
coimmunoprecipitates with beta-catenin. To this end, we prepared a beta-catenin affinity
column. We incubated 13 mg of S2-013.MUC1F protein lysate (1% NP40 lysis) on a
beta-catenin affinity column overnight at 4°C. The column was rinsed, and glycine
elution fractions were collected. The lysate, a rinse fraction, and all elution fractions
were analyzed by western blot (Figure 8A), and elution fraction 2 (E2) was analyzed by
SDS-PAGE and Coomassie staining (Figure 8B).
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Figure 8. Beta-catenin affinity column elution fractions for MUC1.CT analysis.
S2-013.MUC1F cytoplasm/membrane fraction lysate incubated on a beta-catenin
antibody (15B8) agarose column. (A) Beta-catenin and MUC1.CT were detected in the
lysate (Lys), flow through (FT), rinses (R), and elution fractions (E) by western blot. (B)
Fraction E2 was analyzed by SDS-PAGE and Coomassie staining.
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Because elution fraction 2 had the highest amount of beta-catenin (Figure 8A),
we decided to pursue mass spectrometric analysis of this sample. The
coimmunoprecipitating MUC1.CT is barely detectable in the western blot. Elution
fraction 2 was subjected to SDS-PAGE and Coomassie staining (Figure 8B).
Following in-gel trypsin digestion, the sample was analyzed by tandem mass
spectrometry. MUC1.CT peptide ions were identified by matching the mass and charge
of the peptide ions detected to a Mascot database (Table 1). Ions score is -10log(P),
where P is the calculated probability that the observed match between the experimental
data and the Mascot database sequence is a random event. The expect score is the
number of equal or better matches expected to occur by chance alone. The highest ions
score and lowest expect score for each peptide are listed in Table 1.
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Span

Ion

Ions Score

P

Expect
Score

#1083-1093

QGGFLGLSNIK

65.3

3.0E-07

1.4E-02

#1190-1200

NYGQLDIFPAR

72.5

5.6E-08

2.6E-04

Table 1. S2-013.MUC1F cytoplasm/membrane beta-catenin
coimmunoprecipitated MUC1.CT peptides identified by mass spectrometry, initial
attempt.
Beta-catenin antibody immunoprecipitation elution fraction 2 (Figure 8) was subjected
to in-gel trypsin digestion followed by tandem mass spectrometry. The peptides
identified by mass spectrometry are listed here. Span indicates the region of MUC1
that the peptide spans (human MUC1, P15941, UniProtKB). Ion indicates the amino
acid sequence of the ion identified. Ions Score is -10log(P), where P is the calculated
probability that the observed match between the experimental data and the Mascot
database sequence is a random event. The Expect Score is the number of equal or
better matches expected to occur by chance alone.
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The QGGFLGLSNIK peptide (Table 1) was identified eight times in the first
replicate and two times in a second replicate. This stretch of amino acids of MUC1 is
believed to be normally situated in the extracellular space. The high ions score and low
expect score make it likely that MUC1 components that include this portion of MUC1
interact with beta-catenin. The NYGQLDIFPAR peptide was identified once in the first
replicate and three times in the second technical replicate. This stretch of amino acids is
within the cytoplasmic tail of MUC1. Again, the high ions score and low expect score
indicate that this is a valid identification, suggesting that the forms of MUC1 that interact
with beta-catenin include this sequence. In this experiment, no phosphorylated
MUC1.CT was detected in the beta-catenin coimmunoprecipitate, suggesting that
unphosphorylated MUC1.CT associates with beta-catenin.
Again, S2-013.MUC1F cells were lysed and the cytoplasm/membrane fraction
collected. In this case, phosphatase inhibitors were used in every step of preparation
prior to mass spectrometry to ensure no loss of phosphorylation of MUC1.CT peptides
and to increase the odds of identifying phosphorylated peptides. The lysate was
subjected to immunoprecipitation with beta-catenin antibody 15B8. The
immunoprecipitates were isolated after SDS-PAGE and Coomassie staining. Following
in-gel trypsin digestion, samples were analyzed by tandem mass spectrometry.
MUC1.CT peptide ions were identified by matching the mass and charge of the peptide
ions detected to a Mascot database (Table 2).
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Span

Ion

Ions

P

Score

Expect

#86-101

EpTpSApTQRSSVPSSpTEK

5

3.2E-01

2.5

#86-101

EpTSATQRSSVPSSpTEK

3

5.0E-01

1.6

2

6.3E-01

2

2

6.3E-01

2.5

2

6.3E-01

1.5

ApTpTTPASKSTPFSIPSHHSDTPp
#981-1011

TpTLApSHpSpTK
ATTTPASKSTPFSIPpSHHpSDpTP

#981-1011

pTpTLApSHpSTK
QGGFLGLSNIKFRPGpSVVVQLTL

#1083-1108

AFR

#1109-1125

EGTINVHDVETQFNQYK

67

2.0E-07

2.20E-06

#1190-1200

NYGQLDIFPAR

59

1.3E-06

4.60E-05

DpTpYHPMpSEYPpTYHTHGRYVP
#1201-1227

PSSpTDR

2

6.3E-01

1.8

#1218-1231

pYVPPpSpSpTDRpSPYEK

5

3.2E-01

1.8

#1218-1231

pYVPPSSTDRSPYEK

6

2.5E-01

2.1

6

2.5E-01

1.7

4

4.0E-01

0.92

3

5.0E-01

1.2

3

5.0E-01

1.2

pYVPPpSpSpTDRSPYEKVSAGNG
#1218-1255

GSSLSpYTNPAVAATpSANL
SPpYEKVSAGNGGpSpSLpSpYpT

#1227-1255

NPAVAApTSANL
VpSAGNGGSSLSpYTNPAVAATpS

#1232-1255

ANL
VSAGNGGSSLSYTNPAVAApTpSA

#1232-1255

NL
VSAGNGGSSLpSpYTNPAVAATSA

#1232-1255 NL
1
7.9E-01
Table 2. S2-013.MUC1F cytoplasm/membrane beta-catenin
coimmunoprecipitated MUC1.CT peptides identified by mass spectrometry.

1.1

Beta-catenin antibody immunoprecipitates were analyzed by tandem mass
spectrometry. The peptides identified are listed here. Span indicates the region of
MUC1 that the peptide spans (human MUC1, P15941, UniProtKB). Ion indicates the
amino acid sequence of the ion identified. Phosphorylated residues are indicated with
a lowercase p followed by the amino acid residue symbol (both in red font). Ions Score
is -10log(P), where P is the calculated probability that the observed match between the
experimental data and the Mascot database sequence is a random event. The Expect
Score is the number of equal or better matches expected to occur by chance alone.
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Though we had used phosphatase inhibitors in the buffers of all stages of
preparation of the mass spectrometry sample (lysis, rinse, and elution buffers) to
maintain phosphorylation of the fraction of MUC1.CT that coimmunoprecipitates with
beta-catenin, no phosphorylation was observed (Table 2). However, the
NYGQLDIFPAR peptide of MUC1.CT was observed again. The high ions score (59)
and low expect score (4.6E-5) indicate that this is a true identification. In addition, the
MUC1.CT peptide EGTINVHDVETQFNQYK was observed. The high ions score (67)
and low expect score (2.2E-6) signify the validity of this identification. This peptide is at
the N-terminus of the 158 amino acid C-terminal subunit of MUC1.
As a control for nonspecific interactions of MUC1.CT with the Dynabeads used
for immunoprecipitation, the following experiment was performed. S2-013.MUC1F cells
were lysed and the cytoplasm membrane fraction collected. Again, phosphatase
inhibitors were used in every step of preparation prior to mass spectrometry. The lysate
was subjected to immunoprecipitation with an isotype antibody. The immunoprecipitates
were isolated after SDS-PAGE and Coomassie staining. Following in-gel trypsin
digestion, samples were analyzed by tandem mass spectrometry. MUC1.CT peptide
ions were identified by matching the mass and charge of the peptide ions detected to a
Mascot database (Table 3).
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Span

Ion

Ions

P

Score

Expect

pTPGTQSPFFLLLLLTVLTVVTGSG
#2-35

HASSpTPGGEK

4

4.0E-01

0.92

5

3.2E-01

1.1

12

6.3E-02

1.2

5

3.2E-01

1.1

5

3.2E-01

1.2

ApTTTPASKSTPFSIPSHHSDTPTT
#981-1011

LASHSpTK
SPpYEKVpSAGNGGpSpSLSpYTN

#1227-1255

PAVAATSANL
SPpYEKVSAGNGGSpSLpSpYpTN

#1227-1255

PAVAATSANL
VSAGNGGSpSLpSpYpTNPAVAAp

#1232-1255

TSANL

Table 3. S2-013.MUC1F cytoplasm/membrane fraction MUC1.CT peptides
identified by mass spectrometry, isotype control.
Isotype control antibody immunoprecipitates were analyzed by tandem mass
spectrometry. The peptides identified are listed here. Span indicates the region of
MUC1 that the peptide spans (human MUC1, P15941, UniProtKB). Ion indicates the
amino acid sequence of the ion identified. Phosphorylated residues are indicated with
a lowercase p followed by the amino acid residue symbol (both in red font). Ions Score
is -10log(P), where P is the calculated probability that the observed match between the
experimental data and the Mascot database sequence is a random event. The Expect
Score is the number of equal or better matches expected to occur by chance alone.
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Neither unphosphorylated MUC1.CT peptide observed in the beta-catenin
immunoprecipitation sample was observed in the isotype control experiment (Table 3),
and only non-significant scores for the possible identifications indicate that no detectable
MUC1.CT eluted from the isotype control column. To summarize mass spectrometry
results to this point, MUC1.CT peptides were found in association with beta-catenin in
the cytoplasm/membrane fraction of PDAC cells. However, none of these MUC1.CT
peptides were phosphorylated. This result suggests that phosphorylation is not required
for beta-catenin/MUC1.CT association.
We then looked for MUC1.CT peptides coimmunoprecipitating with beta-catenin
from the nuclear fraction of cells. S2-013.MUC1F cells were lysed and the nuclear
fraction collected. Phosphatase inhibitors were used in every step of preparation prior to
mass spectrometry to ensure no loss of phosphorylation of MUC1.CT peptides and to
increase the odds of identifying phosphorylated peptides. The lysate was subjected to
immunoprecipitation with a beta-catenin antibody. The immunoprecipitates were
isolated after SDS-PAGE and Coomassie staining. Following in-gel trypsin digestion,
samples were analyzed by tandem mass spectrometry. MUC1.CT peptide ions were
identified by matching the mass and charge of the peptide ions detected to a Mascot
database (Table 4).
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Span

Ion

Ions

P

Score

Expect

MpTPGpTQSPFFLLLLLTVLTVVTG
#1-35

SGHASSpTPGGEK

2

6.3E-01

1.2

3

5.0E-01

1.2

3

5.0E-01

1.0

MpTPGpTQSPFFLLLLLTVLpTVVp
#1-35

TGpSGHApSpSpTPGGEK
TPGTQSPFFLLLLLTVLTVVTGSG

#2-35

HASpSpTPGGEK

#1109-1125

EGTINVHDVETQFNQYK

77

2.0E-08

6.9E-07

#1190-1200

NYGQLDIFPAR

34

4.0E-04

7.6E-02

DpTpYHPMpSEYPpTYTHTHGRYV
#1201-1227

PPSSpTDR

2

6.3E-01

1.2

#1218-1231

pYVPPpSpSpTDRpSPYEK

2

6.3E-01

1.5

7

2.0E-01

1.1

5

3.2E-01

1.1

2

6.3E-01

1.1

1

7.9E-01

1.3

SPYEKVSAGNGGSpSLSYTNPAV
#1227-1255

AATSANL
pSPYEKVSAGNGGSSLSpYTNPA

#1227-1255

VAATpSANL
VpSAGNGGpSpSLSpYTNPAVAAT

#1232-1255

pSANL
VpSAGNGGpSpSLSpYpTNPAVAA

#1232-1255

pTpSANL

Table 4. S2-013.MUC1F nuclear fraction beta-catenin coimmunoprecipitated
MUC1.CT peptides identified by mass spectrometry.
Nuclear beta-catenin immunoprecipitates were analyzed by tandem mass
spectrometry. The peptides identified are listed here. Span indicates the region of
MUC1 that the peptide spans (human MUC1, P15941, UniProtKB). Ion indicates the
amino acid sequence of the ion identified. Phosphorylated residues are indicated with
a p followed by the amino acid residue symbol (both in red font). Ions Score is 10log(P), where P is the calculated probability that the observed match between the
experimental data and the Mascot database sequence is a random event. The Expect
Score is the number of equal or better matches expected to occur by chance alone.
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The EGTINVHDVETQFNQYK and NYGQLDIFPAR MUC1.CT peptides were
observed in the nuclear fraction for the beta-catenin coimmunoprecipitates analyzed by
mass spectrometry (Table 4). The high ions score and low expect score for these
peptides indicate the validity of these identifications. The low ions scores and high
expect scores for the phosphorylated MUC1.CT peptides listed in Table 4 indicate that
phosphorylated MUC1.CT did not coimmunoprecipitate with beta-catenin from the
nuclear fraction of S2-013.MUC1F cells.
An experiment to control for nonspecific interactions of MUC1.CT with the
Dynabeads was performed with the nuclear fraction as well. S2-013.MUC1F cells were
lysed and the nuclear fraction collected. Phosphatase inhibitors were used in every step
of preparation prior to mass spectrometry. The lysate was subjected to
immunoprecipitation with an isotype antibody. The immunoprecipitates were isolated
after SDS-PAGE and Coomassie staining. Following in-gel trypsin digestion, samples
were analyzed by tandem mass spectrometry. MUC1.CT peptide ions were identified by
matching the mass and charge of the peptide ions detected to a Mascot database (Table
5).
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Span

Ion

Ions

P

Score

Expect

#1072-1082

DISEMFLQIpYK

6

2.5E-01

2.8

#1072-1082

DISEMFLQIpYK

6

2.5E-01

4.4

#1109-1125

EGTINVHDVETQFNQYK

16

2.5E-02

0.27

#1190-1200

NYGQLDIFPAR

54

4.0E-06

7.4E-04

Table 5. S2-013.MUC1F nuclear fraction MUC1.CT peptides identified by mass
spectrometry, isotype control.
Nuclear isotype control immunoprecipitates were analyzed by tandem mass
spectrometry. The peptides identified are listed here. Span indicates the region of
MUC1 that the peptide spans (human MUC1, P15941, UniProtKB). Ion indicates the
amino acid sequence of the ion identified. Phosphorylated residues are indicated with
a lowercase p followed by the amino acid residue symbol (both in red font). Ions Score
is -10log(P), where P is the calculated probability that the observed match between the
experimental data and the Mascot database sequence is a random event. The Expect
Score is the number of equal or better matches expected to occur by chance alone.
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In the isotype control sample a few MUC1 peptides were observed by mass
spectrometry in the nuclear fraction (Table 5), possibly due to non-specific sticking of low
levels of MUC1 to either isotype control antibodies or the beads used in purification. The
NYGQLDIFPAR peptide was detected with significant scores, but not the
EGTINVHDVETQFNQYK peptide. The mass spectrometry results indicate that
MUC1.CT associates with beta-catenin in both the cytoplasm/membrane and nuclear
fractions of PDAC cells. It also appears that MUC1.CT phosphorylation is not required
for this association.
We also wanted to probe the nature of the beta-catenin/MUC1.CT interaction
through biophysical methods. In order to conduct in vitro studies with beta-catenin, the
recombinant protein was produced in and purified from E. coli. The BL21 (DE3) [132]
strain was selected for synthesis of the murine recombinant His-tag [147] protein betacatenin (Figure 9). The human and murine proteins are both 781 amino acids in length.
The human protein differs from the murine protein by a single amino acid in the Cterminus (proline to alanine at 706) [148, 149]. Protein samples were analyzed by SDSPAGE and Coomassie Brilliant Blue [150] protein staining.

Size Exclusion
Elution Fraction

____________

Size Exclusion Input

Nickel Affinity
Elution Fractions

Input

MW, kDa
250

Pellet

64

150
100
75

50

37

25
20
Figure 9. Full-length beta-catenin purification strategy.
This Coomassie stained gel shows the recombinant protein at various stages of
purification. The protein is purified first by nickel affinity chromatography followed by
size exclusion chromatography.
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The protein is soluble (the pellet fraction has little beta-catenin), and nickel
affinity chromatography [151] (imidazole elution) successfully purifies the protein (Figure
9). The protein has an apparent molecular weight between 75 and 100 kDa. After size
exclusion chromatography [152] the protein was exceptionally pure.
It has been hypothesized that beta-catenin interacts with the serine-rich motif of
MUC1.CT (SXXXXXSSL). Therefore, isothermal titration calorimetry (ITC) was
performed to investigate this. Five different MUC1.CT serine-rich motif peptides were
injected into a recombinant beta-catenin solution (Table 6). A representative example of
an ITC trace (MUC1.CT peptide VSGNGGSSLSYTNPA) is shown in Figure 10. Dilution
heat, the heat released when the buffer (without peptide) is injected into the beta-catenin
protein solution, is subtracted from the heat released upon peptide injection in order to
determine the enthalpy resulting from protein/peptide interaction.
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µcal/second

0.02

Time, minutes
40

0.01
0.00
-0.01
-0.02

kCal/mole of injectant

-0.03
-0.04
Enthalpy change
-1.00

-2.00

0.016
0.024
Molar ratio
Figure 10. Isothermal titration calorimetry trace of beta-catenin and a
MUC1.CT peptide.
The peptide sequence is VSAGNGGSSLSYTNPA. The enthalpy change is derived
from the area under the curve of the trace.
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Each peak corresponds to a point at which MUC1.CT peptide was injected into
the beta-catenin protein solution (Figure 10). The area under the curve is used to
determine the enthalpy change, which is plotted in the lower half of the figure. Four
identical injections were used to estimate the enthalpy change for the interaction of betacatenin with this specific MUC1.CT peptide. The enthalpy change determined was very
low, suggesting a lack of interaction between beta-catenin and this serine-rich
motif-containing MUC1.CT peptide.
The enthalpies of interaction of five MUC1.CT peptides with beta-catenin were
determined by ITC. Two beta-catenin constructs were used to study the betacatenin/MUC1.CT interaction: full-length beta catenin and the armadillo repeat region
(residues 134-671) of beta-catenin (β59) [148]. In each case, at least four injections
were made, and the average enthalpy change is displayed in Table 6. One
phosphorylated MUC1.CT peptide and one phosphomimetic peptide (serine to glutamate
residue mutations) were selected to study the impact of phosphorylation on interaction
with beta-catenin.
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MUC1.CT Peptide Sequence

GRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPA
GRYVPPSSTDRSPYEKV
VSAGNGGSSLSYTNPA
GRpYVPPSSTDRSPpYEKVSAGNGGSSLSYTNPA
GRYVPPSSTDRSPYEKVSAGNGGEELEYTNPA

Enthalpy
change,
kCal/mol,
beta-catenin
-1.1
-1.4
-1.4
-3.7
1.2

Enthalpy
change,
kCal/mol,
β59
0.0
-1.3
-1.1
2.2
-0.6

Table 6. Beta-catenin and MUC1.CT peptide interaction enthalpy change as
determined by isothermal titration calorimetry.
The change in enthalpy was investigated with five MUC1.CT peptides, one of which
was phosphorylated at two tyrosine residues (pY), and one of which was a serine
residue to glutamate residue phosphomimetic (glutamate residues, E). The enthalpy
change was determined with full-length beta-catenin as well as with β59, the armadillo
repeat region (N- and C-termini omitted) of beta-catenin.
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The enthalpy change upon interaction of beta-catenin and the MUC1.CT
peptides tested was generally about -1 kcal/mol (Table 6). A hydrogen bond between
two peptides has an enthalpy change of -0.5 to -1.5 kcal/mol [153]. When ITC was
performed with beta-catenin and proteins that bind beta-catenin, the highest enthalpy
change measured (phosphorylated cytoplasmic tail of E. cadherin) was -53.5 kcal/mol,
and the weakest (third 20 amino-acid repeat of APC) was -4.5 kcal/mol [24]. The
MUC1.CT peptide GRpYVPPSSTDRSPpYEKVSAGNGGSSLSYTNPA produced a
similar result to the beta-catenin/APC interaction. However, this result was confounded
by the fact that the enthalpy change was actually endothermic (2.2 kcal/mol) when the
interaction between this MUC1.CT peptide and β59 (the armadillo repeat region of betacatenin) was tested. The armadillo repeat region of beta-catenin is thought to be
important in the beta-catenin/MUC1.CT interaction [95]. No ITC isotherms were
produced between MUC1.CT peptides and beta-catenin, so the thermodynamic profiles
of the reactions were not determined. It appears that none of these peptides, with or
without the serine-rich motif and with or without phosphorylation, interact strongly with
beta-catenin.
In order to study the interaction between beta-catenin and longer forms of
MUC1.CT in vitro, His-tag MUC1.CT was purified by cobalt-affinity chromatography.
After purification, the protein was concentrated. MUC1.CT is not stained by Coomassie
or silver. Therefore, a Coomassie stained gel and western blot were used to confirm
identity and to determine purity of the protein (Figure 11).
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Figure 11. MUC1.CT purification strategy.
(A) The His-tag MUC1.CT protein fractions eluted from the cobalt affinity column were
concentrated. A Coomassie stained gel indicates that the cobalt affinity purification
removed many contaminating proteins. (B) A western blot confirms the identity of
MUC1.CT.
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This recombinant protein has a ten-residue histidine tag at the N-terminus and 72
amino acids of the cytoplasmic tail of MUC1. After the protein was eluted with imidazole,
it was concentrated to about 0.2 mg/mL. The Coomassie staining was used to
determine that impurities were removed, and the western blot confirmed the identity of
the protein (Figure 11). With methods to produce and purify both proteins, we were now
ready to conduct in vitro experiments with beta-catenin and MUC1.CT.
One such method that we employed was OpenSPR [154]. In an OpenSPR
experiment, one of the proteins is covalently bound to a gold sensor chip by
dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) and N-hydroxy succinimide chemistry
[155]. In this way we tested the interaction between full-length beta-catenin and
MUC1.CT with beta-catenin bound to the sensor chip and MUC1.CT as the analyte. The
reciprocal experiment was also performed (Figure 12).
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Figure 12. OpenSPR traces of the interaction between recombinant betacatenin and recombinant MUC1.CT.
(A) Beta-catenin was applied to the sensor chip and MUC1.CT served as the analyte.
Duplicates of three concentrations of MUC1.CT (indicated to the right of each line)
were used to determine the kinetics of interaction and the binding affinity. (B) In the
reciprocal experiment MUC1.CT was applied to the sensor chip and beta-catenin
served as the analyte. Three concentrations of beta-catenin (indicated to the right of
each line) were tested to determine the kinetics of interaction and the binding affinity.
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The concave down curve between approximately 0 and 250 seconds represents
the association (binding) phase of interaction, and the concave up curve from 250 to 350
seconds represents the dissociation phase of the interaction (Figure 12). The computergenerated black line was used to determine the kinetics of interaction.
In addition to the experiments shown in Figure 12, OpenSPR was employed to
test the interaction between full-length beta-catenin and ten MUC1.CT peptides (and a
scrambled sequence control) (Table 7). Six of the MUC1.CT peptides tested were
phosphopeptides. Ecyto (the full cytoplasmic tail of murine E-cadherin) [24] served as a
positive control for interaction with beta-catenin. All experiments were performed in PBS
(pH 8.0). The equilibrium dissociation constants (KD), on rates (kon), off rates (koff),
maximum SPR signal (Bmax), and chi-squared (χ2) values are listed. Also, to control for
the fact that covalently binding beta-catenin to the sensor chip might alter its ability to
interact with MUC1.CT, the reciprocal experiment was performed, in which MUC1.CT
was covalently bound to the sensor chip and beta-catenin served as the analyte.
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Analyte

KD

kon (1/Ms)

(beta-catenin bound to chip)
Ecyto

koff

Bmax

χ2

(1/s)
110 ± 20 nM

650 ± 20

7E-5 ± 206

9.8

1E-5
His-tag MUC1.CT (full-length)

13.8 ± 0.3 µM

174 ± 4

2.41E-3 345

16

± 1E-5
NYGQLDIFPARDTYHPMSEYPTYHTH 15 ± 0.2 µM

340 ± 50

GRYVPPSSTDRSPYEKVSAGNGGSS

5.2E-3 155

19

± 1E-4

LSYTNPAVAATSANL
CQCRRKNYGQLDIFPARDTYHPMSE 2.3 ± 0.1 µM

1,020 ± 40 2.32E-3 1,981 1,278

YPTYH

± 1E-5

CQCRRKNYGQLDIFPARDTpYHPMS 2.3 ± 1 mM

10 ± 30

EYPTYH
KSVGSPNESTAYSGLNAGYP

± 1E-5
1.06 ± 0.01 mM 10 ± 5E3 1.09E-2 60

(Scrambled MUC1.CT sequence)
PYEKVSAGNGGSSLSYTNPA

2.47E-3 2,118 3,868
163

± 1E-4
270 ± 40 µM

30 ± 270

9.35E-3 176

129

± 1E-5
PYEKVpSAGNGGSSLSYTNPA

45 ± 1 µM

90 ± 6E2 3.96E-3 108

117

± 3E-5
PYEKVSAGNGGpSSLSYTNPA

160 ± 20 µM

50 ± 390

7.89E-3 194

177

± 1E-5
PYEKVSAGNGGSpSLSYTNPA

210 ± 20 µM

50 ± 490

1.03E-2 136

150

± 1E-4
PYEKVSAGNGGSSLpSYTNPA

130 ± 20 µM

80 ± 670

1.0E-3 131

132

± 1E-4
GRYVPPSSTDRSPYEKVSAGNGGSS 306 ± 9 µM
LSYTNPA

30 ± 100

9.18E-3 676
± 1E-5

GRYVPPpSpSpTDRSPYEKVSAGNG 6.49 ± 0.28 mM 10 ± 2E3 6.3E-2 360
GSSLSYTNPA

185
493

± 1E-3

Analyte (MUC1.CT bound to chip)
His-tag beta-catenin

2.69 ± 0.08 µM 1490 ± 40 4.03E-3 510

211

± 1E-5
Table 7. Beta-catenin and MUC1.CT binding affinity as determined by OpenSPR.
Beta-catenin/MUC1.CT binding affinities were determined by OpenSPR. The
experimentally determined values are displayed. Phosphorylation is indicated with red
font (e.g., pS: phosphorylated serine residue). The PYEKVSAGNGGSSLSYTNPA
sequence was scrambled to serve as a negative control for that sequence only.
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Ecyto served as a positive control for interaction with beta-catenin (Table 7). The
beta-catenin/Ecyto interaction was reported to have a 40 nM binding affinity by ITC [24].
The OpenSPR result reported here is 110 nM. However, the binding affinity (as
determined by ITC) was determined in a different buffer, so comparison is not direct.
The binding affinity determined with His-tag MUC1.CT was confirmed with the (nearly)
full-length MUC1.CT peptide. Notice also that in the reciprocal experiment (MUC1.CT
bound to the sensor chip, beta-catenin as the analyte) the binding affinity was within an
order of magnitude of that observed with beta-catenin bound to the sensor chip and
MUC1.CT serving as the analyte. According to these results the N-terminal half of
MUC1.CT binds about 20 times more tightly to beta-catenin than the C-terminal half of
MUC1.CT (which contains the serine-rich motif). It appears that the
beta-catenin/MUC1.CT interaction relies on the N-terminal portion of MUC1.CT rather
than on the serine-rich motif of MUC1.CT. The highest binding affinity of any
phosphorylated peptide was that of the sequence PYEKVpSAGNGGSSLSYTNPA,
though this binding affinity was about three times lower than that of full-length MUC1.CT.
The OpenSPR results corroborated the ITC results: the beta-catenin/MUC1.CT
interaction does not require MUC1.CT phosphorylation.
Several kinases are known to phosphorylate MUC1, and phosphorylation of
MUC1.CT may affect its interaction with other proteins, including an increase in nuclear
association of MUC1.CT with beta-catenin [47, 59]. Various growth factors were
selected to study the impact of growth factor-induced phosphorylation of MUC1.CT on
levels of beta-catenin and MUC1.CT in the cytoplasm/membrane and nuclear fractions
of pancreatic cancer cells. The beta-catenin and MUC1.CT levels in the
cytoplasm/membrane fraction and nuclear fraction were tested to determine whether or
not MUC1.CT translocated into the nucleus upon growth factor stimulation.
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S2-013.MUC1F cells were treated with 10 ng/mL EGF for 0, 5, 10, 30, and 60
minutes. Cells were then lysed and fractionated into cytoplasm/membrane and nuclear
fractions. The following western blots show beta-catenin and MUC1.CT levels at the
indicated time points (Figure 13). Actin was used to determine relative levels of betacatenin and MUC1.CT in the cytoplasm/membrane fraction, and HDAC2 was used to
determine relative levels of beta-catenin and MUC1.CT in the nuclear fraction. ImageJ
software was used to quantify protein levels.
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Figure 13. Impact of EGF on cytoplasm/membrane and nuclear beta-catenin
and MUC1.CT in S2-013.MUC1F cells.
(A) A representative western blot shows levels of beta-catenin and MUC1.CT in the
cytoplasm/membrane fraction of the cells at selected time points after 10 ng/mL EGF
stimulation. The number below each lane is the level of each protein relative to the
level of actin at each time point. The values are normalized to protein levels at time
point 0. (B) This is a representative western blot showing levels of beta-catenin and
MUC1.CT in the nuclear fraction of the cells at selected time points after 10 ng/mL
EGF stimulation. The number below each lane represents the level of each protein
relative to the level of HDAC2 at each time point. The values are then normalized to
the protein level at time point 0.
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This is a representative example of the experiments performed to study the
impact of growth factors on beta-catenin and MUC1.CT levels (Figure 13). These
experiments were performed at least three times, and bar graphs summarize the results
(Figure 14-Figure 16).
S2-013.MUC1F cells were treated with 100 ng/mL CTGF (Figure 14), 10 ng/mL
HGF (Figure 15), or 10 ng/mL PDGF (Figure 16) for 0, 5, 10, 30, and 60 minutes. Cells
were then lysed and fractionated into cytoplasm/membrane (A) and nuclear (B) fractions.
Each experiment was repeated in triplicate. Western blots were prepared for each trial.
Actin was used to determine relative levels of beta-catenin and MUC1.CT in the
cytoplasm/membrane fraction, and HDAC2 was used to determine relative levels of
beta-catenin and MUC1.CT in the nuclear fraction. The level of each protein was
expressed as a value normalized to the level of each protein at time point 0.
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No significant changes in beta-catenin or MUC1.CT were observed upon
treatment with CTGF (Figure 14). At times the substantial amount of variability made
interpretation difficult. However, it appears that MUC1.CT may be slightly decreased in
the nucleus at 10 minutes CTGF stimulation.
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Again, no significant changes in beta-catenin or MUC1.CT levels were observed
upon treatment with HGF (Figure 15). Again, variability made interpretation difficult. It
may be that MUC1.CT and beta-catenin levels in the cytoplasm/membrane fraction are
decreased with HGF stimulation.
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MUC1.CT levels.
(A) Levels of beta-catenin and MUC1.CT in the cytoplasm/membrane fraction of S2013.MUC1F cells at selected time points after 10 ng/mL PDGF stimulation. (B)
Levels of beta-catenin and MUC1.CT in the nuclear fraction of S2-013.MUC1F cells
at selected time points after 10 ng/mL PDGF stimulation.
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As with CTGF and HGF, no significant changes in beta-catenin or MUC1.CT
levels were observed upon treatment with PDGF (Figure 16). It may be that betacatenin in the nuclear fraction was decreased with PDGF stimulation.
S2-013.MUC1F cells were treated with 10 ng/mL EGF (Figure 17A and B) or 1
µM Erlotinib or DMSO vehicle control (Figure 17C and D) for the indicated amounts of
time. Cells were then lysed and fractionated into cytoplasm/membrane (Figure 17A and
C) and nuclear (Figure 17B and D) fractions. EGF experiments were repeated four
times, and Erlotinib experiments were repeated in triplicate. Western blots were
prepared for each trial. Actin was used to quantify levels of beta-catenin and MUC1.CT
in the cytoplasm/membrane fraction, and HDAC2 was used for quantification of betacatenin and MUC1.CT levels in the nuclear fraction. The level of each protein was
expressed as a value normalized to the level of each protein at time point 0.
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It appears that EGF affects MUC1.CT levels (Figure 17A and B). A decrease in
MUC1.CT was observed in the cytoplasm/membrane fraction (at 10 and 60 minutes) and
the nuclear fraction (at 5 and 10 minutes). Variability within the Erlotinib experiment
made those results difficult to interpret (Figure 17C and D).
Because EGF in particular appears to alter MUC1.CT levels, two-dimensional gel
electrophoresis was used to investigate the impact of EGF stimulation on MUC1.CT
phosphorylation. To evaluate this within different cell compartments, cells were
fractionated before two-dimensional gel electrophoresis.
CFPAC-1 cells (Figure 18A) and S2-013.MUC1F cells (Figure 18B) were
untreated or treated for 5 minutes with 10 ng/mL EGF. Then cells were fractionated into
cytosol, membrane, and nuclear fractions. Western blots indicate levels of beta-catenin
and MUC1.CT following EGF stimulation. EGFR served as a membrane marker, and
actin served as a cytosol marker. The blots were also probed for phosphotyrosine to
determine whether or not EGF caused changes in phosphorylation of the cytoplasmic tail
of MUC1.
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Figure 18. Subcellular fractionation of CFPAC-1 and S2-013.MUC1F prior to
two-dimensional gel electrophoresis.
The EGFR blot was used to verify membrane fraction isolation, and actin was used
to verify cytosol fraction isolation. (A) CFPAC-1 cells were untreated (-) or treated (+)
with 10 ng/mL EGF for 5 minutes and then fractionated into cytosol, membrane, and
nuclear fractions. (B) S2-013.MUC1F cells were untreated (-) or treated (+) with 10
ng/mL EGF for 5 minutes and then fractionated in the same way.
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We successfully separated the membrane fraction from other fractions as
evidenced by the presence of EGFR and absence of beta-actin in the membrane fraction
(Figure 18). We were therefore able to test the impact of EGF stimulation on MUC1.CT
specifically in the membrane fraction.
CFPAC-1 cells were untreated or treated for 5 minutes with 10 ng/mL EGF.
Following lysis, cells were fractionated into cytosol, membrane, and nuclear fractions.
The membrane fraction was selected to investigate potential changes in phosphorylation
of MUC1.CT. MUC1.CT was immunoprecipitated and then subjected to two-dimensional
gel electrophoresis [156] (Figure 19). The blots were probed for MUC1.CT. The same
blots were probed for phosphotyrosine also (Figure 19C and F). This experiment was
repeated to ensure reproducibility.

89
A

D
MW, kDa

MW, kDa

50
37
25
20
15
10

Secondary 50
⍺ hamster 37

Secondary
⍺ hamster

50
37

25
20
15
8 9 10 10 pH 3 4
E
MW, kDa
MUC1.CT 50
37

25
20
15
10

25
20
15
10

B

C

pH 3

4

5

6

7

MW, kDa

pH 3

4

5

6

7

8

9

10

F

MW, kDa

50
37

Phospho 50
tyrosine 37

25
20
15
10

25
20
15
10

pH 3

4

5

6

7

8

9

10

pH 3

4

5

6

7

8

9

10

MUC1.CT

5

6

7

8

9

10

MW, kDa
Phospho
tyrosine

pH 3

4

5

6

7

8

9

10

Figure 19. EGF causes phosphorylation of MUC1.CT in the membrane of
CFPAC-1 cells.
The membrane fraction of CFPAC-1 cells was subjected to immunoprecipitation with
an antibody that recognizes the cytoplasmic tail of MUC1 (CT2, Armenian hamster
antibody). Two-dimensional gel electrophoresis was used to resolve MUC1.CT by
molecular weight and isoelectric point. (A) Secondary anti-hamster antibody was
used to probe the membrane for antibody fragments prior to (B) blotting the
membrane for MUC1.CT. (C) The same membrane was then probed for
phosphotyrosine. (D), (E), and (F) are in the same sequence as (A), (B), and (C).
(D), (E), and (F) are blots produced by two-dimensional gel electrophoresis of the
CT2 immunoprecipitate from the membrane fraction of CFPAC-1 cells after 5 minutes
of 10 ng/mL EGF stimulation. The arrows in the figure are described in the text
below.
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Four major MUC1.CT forms (black arrows, Figure 19B) exist in the membrane
of CFPAC-1 cells spanning pH 5 to 7. After only 5 minutes of EGF stimulation
phosphorylation of MUC1.CT occurred in all of the forms. A fifth MUC1.CT form (at
about pH 6) appeared with EGF stimulation (yellow arrow, Figure 19E). The fraction of
MUC1.CT phosphorylated in CFPAC-1 cells was visible at the top of the MUC1.CT band
(25 kDa) (between red arrows, Figure 19F). This result supports the hypothesis that
EGF stimulation causes MUC1.CT phosphorylation. We investigated the impact of EGF
on the phosphorylation of membrane-fraction MUC1.CT in S2-013.MUC1F cells as well.
S2-013.MUC1F cells were untreated or treated for 5 minutes with 10 ng/mL EGF.
Following lysis, cells were fractionated into cytosol, membrane, and nuclear fractions.
The membrane fraction was selected to investigate potential changes in phosphorylation
of MUC1.CT. MUC1.CT was immunoprecipitated and then subjected to two-dimensional
gel electrophoresis (Figure 20). The blots were probed for MUC1.CT. The same blots
were probed for phosphotyrosine also (Figure 20C and F). This experiment was
repeated to ensure reproducibility.
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Figure 20. EGF causes phosphorylation of MUC1.CT in the membrane of
S2-013.MUC1F cells.
The membrane fraction of S2-013.MUC1F cells was subjected to immunoprecipitation
with an antibody that recognizes the cytoplasmic tail of MUC1 (CT2, Armenian
hamster antibody). Two-dimensional gel electrophoresis was used to resolve
MUC1.CT by molecular weight and isoelectric point. (A) Secondary anti-hamster
antibody was used to probe the membrane for antibody fragments prior to (B) blotting
the membrane for MUC1.CT. (C) The same membrane was then probed for
phosphotyrosine. (D), (E), and (F) are in the same sequence as (A), (B), and (C).
(D), (E), and (F) are blots produced by two-dimensional gel electrophoresis of the
CT2 immunoprecipitate from the membrane fraction of S2-013.MUC1F cells after 5
minutes of 10 ng/mL EGF stimulation. The arrows in the figure are described in the
text below.
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From this two-dimensional gel electrophoresis result, it appears that S2013.MUC1F cells had seven major forms (black arrows, Figure 20B) of MUC1.CT.
Notice also that some of these forms overlapped with those observed in Figure 3
(MUC1.CT coimmunoprecipitated with beta-catenin). The MUC1.CT form at pH 7 is
most affected by EGF stimulation (red arrow, Figure 20F). Again, a 25 kDa MUC1.CT
form becomes more visible with EGF stimulation, sitting just left of pH 7 (yellow arrow,
Figure 20F). From the results of Figure 19 and Figure 20 it appears that EGF
stimulation causes MUC1.CT phosphorylation of the membrane fraction of MUC1.CT.
EGF stimulation causes changes in levels of MUC1.CT (Figure 17) and in the
phosphorylation of MUC1.CT (Figure 19 and Figure 20) in PDAC cells. To determine
the impact of EGF stimulation on the association of beta-catenin and MUC1.CT, we
performed immunoprecipitation experiments. S2-013.MUC1F cells were lysed after
being untreated or treated with 10 ng/mL EGF for 5 minutes. The cytoplasm/membrane
fraction was subjected to immunoprecipitation with a beta-catenin antibody (15B8). The
lysates, isotype control immunoprecipitation samples, and beta-catenin specific
immunoprecipitation samples were analyzed by western blot (Figure 21A). The
experiment was repeated, except that in this case proteins extracted from the membrane
were used in the immunoprecipitation, and MUC1.CT was immunoprecipitated (CT2)
rather than beta-catenin (Figure 21B). Beta-catenin and MUC1.CT levels were
normalized to no EGF treatment and quantified with ImageJ.
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Figure 21. EGF causes loss of interaction between beta-catenin and MUC1.CT
in the membrane fraction of S2-013.MUC1F cells according to
coimmunoprecipitation data.
(A) When 10 ng/mL EGF was applied to S2-013.MUC1F cells for 5 minutes, the
amount of beta-catenin that immunoprecipitated decreased as was the amount of
coimmunoprecipitated MUC1.CT in the cytoplasm/membrane fraction. (B) In a similar
experiment, upon 5 minutes 10 ng/mL EGF stimulation, the amount of beta-catenin
that coimmunoprecipitated with MUC1.CT from the membrane fraction decreased.
Numbers under the western blot lanes represent the relative amount of protein in the
lane normalized to no EGF treatment.
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EGF caused decreased MUC1.CT coimmunoprecipitation with beta-catenin in
the cytoplasm/membrane fraction of S2-013.MUC1F cells (Figure 21). The reciprocal
experiment (MUC1.CT immunoprecipitation, beta-catenin blot) conducted specifically in
the membrane fraction of S2-013.MUC1F cells produced a corroborating result (Figure
21B).
To validate the result of diminished beta-catenin/MUC1.CT association observed
by coimmunoprecipitation, confocal microscopy was employed. S2-013.MUC1F cells
with mCherry beta-catenin and eGFP MUC1.CT were treated with 10 ng/mL EGF for 0,
20 minutes, or 4 hours and then fixed. Images were taken of cells expressing both
fluorescent proteins with a confocal laser scanning microscope (Figure 22). Red
indicates mCherry beta-catenin (Figure 22A-C), green indicates eGFP MUC1.CT (Figure
22D-F), and white indicates colocalization of the two fluorescent proteins (Figure 22G-I).
The nuclei are stained with DAPI (blue). S2-013.MUC1F cells that produce no
fluorescent proteins served as the negative control (Figure 22J-L). The thresholds for
analyzing colocalization of MUC1.CT eGFP and mCherry beta-catenin were set based
on the negative control S2-013.MUC1F cells that express neither fluorescent protein so
that colocalization was virtually absent in the negative control cells. The emission
spectrum detected for DAPI was 400 to 486 nm. The emission spectrum detected for
MUC1.CT eGFP was 494 to 562 nm. The emission spectrum detected for mCherry
beta-catenin was 574 to 637 nm.
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Figure 22. EGF stimulation decreases colocalization of fluorescently labeled
beta-catenin and MUC1.CT in S2-013 MUC1.CT eGFP/mCherry beta-catenin
cells in a fixed-cell experiment.
Beta-catenin is labeled with mCherry (displayed in red, A-C), and MUC1.CT is
labeled with eGFP (displayed in green, D-F). White indicates colocalization between
the two fluorescent proteins (G-I). DAPI was used to stain the nuclei (blue). S2013.MUC1F cells served as the negative control for both fluorescent protein level
and colocalization (J-L). Cells are shown at three time points of EGF treatment. A,
D, G, and J are time point 0. B, E, H, and K are time point 20 minutes. C, F, I, and L
are time point 4 hours. Cells that expressed both mCherry beta-catenin and eGFP
MUC1.CT were outlined in red for analysis.
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It appears that in S2-013.MUC1 eGFP/mCherry beta-catenin cells the betacatenin/MUC1.CT colocalization was most prevalent in the membrane of the cells
(Figure 22). Upon EGF stimulation, we noticed loss in fluorescent beta-catenin and
fluorescent MUC1.CT as well as an EGF-induced decrease in beta-catenin/MUC1.CT
colocalization after twenty minutes of stimulation. In these cells this loss of
colocalization appeared to persist for at least four hours.
To be certain that this observed loss of colocalization was not simply due to
variability from one group of cells to another the experiment was conducted in living
cells. S2-013.MUC1F cells with mCherry beta-catenin and eGFP MUC1.CT were
treated with 10 ng/mL EGF for 0, 5, or 20 minutes. A group of living cells expressing
both fluorescent proteins was imaged with a confocal laser scanning microscope at 0, 5,
and 20 minutes post EGF stimulation. Red indicates mCherry beta-catenin (Figure
23A), green indicates eGFP MUC1.CT (Figure 23B). Colocalization of mCherry betacatenin and eGFP MUC1.CT is indicated in white (Figure 23C). The emission spectrum
detected for the Hoechst 33342 was 400 to 486 nm. The emission spectrum detected
for MUC1.CT eGFP was 494 to 562 nm. The emission spectrum detected for mCherry
beta-catenin was 574 to 637 nm.
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Figure 23. EGF stimulation decreases colocalization of fluorescently labeled
beta-catenin and MUC1.CT in S2-013 MUC1.CT eGFP/mCherry beta-catenin
cells in a live-cell experiment.
A group of S2-013.MUC1 eGFP/mCherry beta-catenin cells were imaged at 0, 5, and
20 minutes after application of 10 ng/mL EGF (0, 5, and 20 minutes are arranged
from left to right in each panel). Beta-catenin is labeled with mCherry (displayed in
red, A), and MUC1.CT is labeled with eGFP (displayed in green, B). White indicates
colocalization between the two fluorescent proteins (C). S2-013.MUC1F cells served
as the negative control for both fluorescent protein levels and colocalization (D).
Hoechst 33342 (1 µM) was used to stain the nuclei (blue).
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As with the fixed-cell experiment it appears that EGF stimulation caused a loss in
beta-catenin and MUC1.CT as well as diminished colocalization of the two proteins
(Figure 23). This rapid EGF-induced loss in membrane colocalization was observed
repeatedly in this cell line. Therefore, we quantified these results.
From the experiment illustrated in Figure 22, mean fluorescence intensities were
collected from ROIs representing individual cells, and levels of mCherry beta-catenin
(Figure 24A) and eGFP MUC1.CT (Figure 24B) were determined by averaging the mean
fluorescence intensity of eGFP MUC1.CT and mCherry beta-catenin, respectively in
cells expressing both fluorescent proteins. The extent of colocalization in the cells is
expressed as relative area of colocalization, the percentage of pixels with co-occurrence
of mCherry beta-catenin and eGFP MUC1.CT fluorescence intensities in which the
fluorescence intensities of both channels exceed the thresholds established with the
negative control (Figure 24C).
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When ROIs representing individual cells were analyzed (Figure 24), it did not
appear that EGF stimulation impacted beta-catenin or MUC1.CT levels with the
exception of the rise in beta-catenin levels at 24h. Colocalization of beta-catenin and
MUC1.CT was not significantly changed with EGF treatment at the whole-cell level.
However, it may be that EGF prompts changes in the levels of beta-catenin and
MUC1.CT and their colocalization in specific compartments within the cells. We
therefore quantified changes within these compartments as well.
From the experiment illustrated in Figure 22 and Figure 24, ROIs representing
individual cell membranes were analyzed. Levels of mCherry beta-catenin (Figure 25A)
and eGFP MUC1.CT (Figure 25B) were determined by averaging the mean fluorescence
intensity values for eGFP and mCherry beta-catenin, respectively, in the membrane
ROIs of cells expressing both fluorescent proteins. The extent of membrane
colocalization of mCherry beta-catenin and eGFP MUC1.CT is expressed as relative
area of colocalization (Figure 25C).
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determined by confocal microscopy.
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When we quantified beta-catenin and MUC1.CT in the membrane of the cells, a
significant decrease in MUC1.CT was observed at an early time point (20 minutes) and a
later time point (4 hours) (Figure 25). We also noted a decline in beta-catenin/MUC1.CT
colocalization in the cell membrane of these PDAC cells at both time points tested.
In the same experiment, we probed the levels and colocalization of these
proteins in the cell nuclei. ROIs representing cell nuclei were analyzed. Levels of
mCherry beta-catenin (Figure 26A) and eGFP MUC1.CT (Figure 26B) were determined
by averaging the mean fluorescence intensities for MUC1.CT eGFP and mCherry betacatenin, respectively, in the nuclear ROIs of cells expressing both fluorescent proteins.
The extent of nuclear colocalization of mCherry beta-catenin and eGFP MUC1.CT is
expressed as relative area of colocalization (Figure 26C). In a similar experiment,
nuclear beta-catenin/MUC1.CT colocalization was determined at the 5-minute time point
(Figure 26D).
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Figure 26. EGF stimulation decreases colocalization of beta-catenin and
MUC1.CT in the nuclei of S2-013.MUC1F cells as determined by confocal
microscopy.
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(A) Beta-catenin levels in the nucleus upon 10 ng/mL EGF stimulation. (B) Levels of
MUC1.CT in the nucleus following 10 ng/mL EGF stimulation. (C) Colocalization of
beta-catenin and MUC1.CT in S2-013.MUC1F (negative control) and S2-013.MUC1F
cells with eGFP MUC1.CT and mCherry beta-catenin with 10 ng/mL EGF stimulation.
(D) In this graph, the effect of 10 ng/mL EGF stimulation on nuclear
beta-catenin/MUC1.CT colocalization at the 5-minute time point is illustrated.
*p<0.01, ***p<0.001
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EGF stimulation appears to decrease levels and colocalization of beta-catenin
and MUC1.CT through experiments with fluorescently labeled proteins (Figure 22-Figure
26). However, the nuclear analysis of beta-catenin and MUC1.CT levels and
colocalization was confounded by high 488 nm background signal (found in the negative
control S2-013.MUC1F cells). To avoid this problem and to verify that EGF stimulation
decreases beta-catenin/MUC1.CT colocalization, we used antibody labeling of betacatenin and MUC1.CT in S2-013.MUC1F cells.
S2-013.MUC1F cells were treated with 10 ng/mL EGF for 0 minutes (Figure 27
A), 5 minutes (Figure 27B), 20 minutes (Figure 27C), 4 hours (Figure 27D), and 24 hours
(Figure 27E). The cells were fixed, permeabilized, blocked, and then stained for betacatenin and MUC1.CT. The negative control cells received secondary antibody only
(Figure 27F).
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Figure 27. Effect of EGF on beta-catenin and MUC1.CT in S2-013.MUC1F cells,
beta-catenin and MUC1.CT probed with antibodies.
S2-013.MUC1F cells were treated with 10 ng/mL EGF for 0 minutes (A), 5 minutes
(B), 20 minutes (C), 4 hours (D), and 24 hours (E). The cells were stained for betacatenin (red) and MUC1.CT (green). DAPI (blue) indicates position of nuclei. The
negative control cells received secondary antibody only (F).
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The cells appeared to change quite dramatically upon EGF stimulation by 20
minutes (Figure 27). Changes in levels and localization of beta-catenin and MUC1.CT
were visible as well. Certain changes (such as an increase in nuclear beta-catenin)
were persistent over time.
Images of the S2-013.MUC1F cells of Figure 27 were split into individual
channels to evaluate the impact of EGF on beta-catenin (red) and MUC1.CT (green)
separately (Figure 28).
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Figure 28. Effect of EGF on beta-catenin and MUC1.CT in S2-013.MUC1F cells,
split channels.
Images of cells (Figure 27) were split into individual channels to show beta-catenin
(red), MUC1.CT (green), and nuclei (blue) at 0 minutes (A), 5 minutes (B), 20 minutes
(C), 4 hours (D), and 24 hours (E) after application of 10 ng/mL EGF.
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With the split-channel view it appears that EGF stimulation caused an increase in
beta-catenin and MUC1.CT in the nuclei of the cells by 20 minutes (Figure 28). Notice
also the punctate MUC1.CT structures in the nuclei at 20 minutes.
We next quantified the levels of beta-catenin and MUC1.CT in these cells (Figure
29). Mean fluorescence intensities were collected from ROIs representing individual
cells (n=15), cell membranes (n=15), and nuclei (n=15) with ZEN Blue software to
determine levels of beta-catenin and MUC1.CT.
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Figure 29. Impact of EGF on levels of beta-catenin and MUC1.CT in S2013.MUC1F cells, beta-catenin and MUC1.CT probed with antibodies.
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At the whole-cell level beta-catenin levels have risen by 20 minutes and remain
high (relative to the zero-minute time point) for four hours (Figure 29A and B). MUC1.CT
is also higher at the four-hour time point at the whole-cell level. This is different from the
result with fluorescently labeled proteins in which we observed no change in betacatenin levels and a decrease in MUC1.CT by the four-hour time point (Figure 24). As
opposed to what had been observed with the experiment with fluorescently labeled betacatenin and MUC1.CT (Figure 25), in which beta-catenin levels were unchanged and
MUC1.CT levels dropped by the four-hour time point, beta-catenin levels were
apparently higher in the membrane fraction at the four-hour time point of this experiment
(Figure 29C). The increase in beta-catenin and MUC1.CT in the nuclei of the cells after
20 minutes of EGF stimulation (Figure 29E and F) was striking. In fact, the MUC1.CT
nuclear levels increased by a factor of seven. This increase was persistent throughout
the time course. This stands in contrast to what was observed in the experiment with
fluorescently labeled proteins in which no significant change was detected in betacatenin levels and a decrease of MUC1.CT levels were observed in the nuclei of the
cells (Figure 26).
The S2-013.MUC1F cells from the immediately preceding experiment (Figure 27Figure 29) were analyzed in terms of colocalization of beta-catenin and MUC1.CT. Z
stacks spaced 0.54 µm apart were produced for a field of cells at each time point.
Consecutive z-stack images in sets of three (from the bottom towards the top of the
cells) are shown for each time point (Figure 30).
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Figure 30. Effect of EGF on colocalization of beta-catenin and MUC1.CT in S2013.MUC1F cells, beta-catenin and MUC1.CT probed with antibodies.
The colocalization of beta-catenin and MUC1.CT is shown in white after 0 minutes
(A), 5 minutes (B), 20 minutes (C), 4 hours (D), and 24 hours (E) EGF treatment (10
ng/mL). Beta-catenin is displayed in red, MUC1.CT is displayed in green, and nuclei
are stained with DAPI (blue).
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This view of the cells made it obvious that the location and amount of betacatenin/MUC1.CT colocalization was changed by EGF stimulation (Figure 30). For
example, the amount of colocalization diminished at the 5-minute time point, and by 20
minutes colocalization increased in the nuclei of the cells.
In the same experiment (Figure 27-Figure 30), colocalization of beta-catenin and
MUC1.CT was quantified in ROIs representing the membrane (Figure 31A) and nuclei
(Figure 31B) of the cells. The thresholds for MUC1.CT (Alexa Fluor 488) and betacatenin (Alexa Fluor 568) fluorescence intensities were set so that the negative control
cells (which received secondary antibody only) showed virtually no colocalization.
Colocalization was expressed with the Pearson correlation coefficient where 1 indicates
perfect linear correlation and -1 indicates the opposite. The Pearson correlation
coefficient was measured in ROIs representing the membrane of fifteen cells and fifteen
nuclei of S2-013.MUC1F cells (three from five independent fields).
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The loss in membrane beta-catenin/MUC1.CT colocalization was confirmed;
however, it was observed at the five-minute time point in one experiment and at the
twenty-minute time point in a repeat experiment (Figure 31A). In either case EGF
induced a decline in membrane beta-catenin/MUC1.CT interaction in S2-013.MUC1F
cells after a short amount of time. This loss in colocalization at the membrane with 20
minutes EGF stimulation was also observed in the experiment with fluorescently labeled
beta-catenin and MUC1.CT (Figure 25). It is important to note that the decrease in
colocalization in the membrane of the S2-013.MUC1F cells with EGF stimulation did not
coincide with changes in levels of beta-catenin and MUC1.CT. Beta-catenin and
MUC1.CT levels in the membrane were unchanged by EGF stimulation at the 20-minute
time point (Figure 29C and D), while a statistically significant drop in
beta-catenin/MUC1.CT membrane colocalization occurred at that point (Figure 31A).
While we observed a loss in nuclear colocalization of beta-catenin and MUC1.CT in the
experiment with fluorescently labeled proteins (Figure 26), no statistically significant
change occurred in nuclear colocalization in this experiment (Figure 31B).
Because EGF induced changes in levels and colocalization of beta-catenin and
MUC1.CT, we next tested the impact of an EGFR inhibitor on the levels and
colocalization of these proteins. S2-013.MUC1F cells were treated with 1 µM Erlotinib
for 0 minutes (Figure 32A), 20 minutes (Figure 32B), or 4 hours (Figure 32C). An equal
volume of DMSO (0.01% v/v) was applied to a set of cells as a vehicle control. The cells
were fixed, permeabilized, blocked, and then stained for beta-catenin and MUC1.CT.
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Figure 32. Effect of Erlotinib on levels of beta-catenin and MUC1.CT in S2013.MUC1F cells.
S2-013.MUC1F cells were treated with 1 µM Erlotinib for 0 minutes (A), 20 minutes
(B), or 4 hours (C). The cells were stained for beta-catenin (red) and MUC1.CT
(green). DAPI (blue) indicates position of nuclei. The negative control cells received
secondary antibody only (D).
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It appears from these images that Erlotinib increased levels of beta-catenin and
MUC1.CT, especially by the four-hour time point (Figure 32). These increases were
most obvious in the membrane of the cells.
Images of the S2-013.MUC1F cells of Figure 32 were split into individual
channels to evaluate the impact of Erlotinib on beta-catenin (red) and MUC1.CT (green)
separately Figure 33).
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Figure 33. Effect of Erlotinib on beta-catenin and MUC1.CT in S2-013.MUC1F
cells, split channels.
Images of cells (Figure 32) were split into individual channels to show beta-catenin
(red), MUC1.CT (green), and nuclei (blue) at 0 minutes (A), 20 minutes (B), and 4
hours (C) after application of 1 µM Erlotinib.
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Beta-catenin levels in the nuclei of the cells was higher by 4 hours Erlotinib
treatment (Figure 33). Like EGF treatment (Figure 29F), Erlotinib affected nuclear
MUC1.CT levels in S2-013.MUC1F cells, but at a later time point (four hours rather than
20 minutes).
With cells from this Erlotinib-treatment experiment, ROIs representing cell
membranes (n=15) and nuclei (n=15) were analyzed with ZEN Blue software to
determine levels of beta-catenin and MUC1.CT (Figure 34).

SM Erlotinib Whole Cell Red Secondary Left Primary Right Set 1, rotated
Legend
Beta-Catenin
DMSO

Legend
Secondary
Only Control B
Legend Control
DMSO
120
Data Set-A
Legend
Beta-Catenin
100
***

60

MUC1.CT Fl.
Intensity (A.U.)

40
20
0

0

20 min

4h

Legend

Data Set-A

20 min

4h

4h
4h

20

20

20

0

4h

20

***

60

***

10

10

0

0

0

20 min

4h
4h

20

Figure 34. Impact of Erlotinib on levels of beta-catenin and MUC1.CT in S2013.MUC1F cells.
4h

0

***

60

80

20

20

120
100

F
0

40

4h

80

0

60

120
100

E
80

20 min
20

***

4h

0

80

0

0

0

Legend
DMSO

D
4h
MUC1.CT
Fl.
Intensity (A.U.)

20

Data Set-A

80
60
SM Erlotinib
Nucleus Red Set 1, rotated [Data Set-A]
40
40
40
Legend
20
20
20
Legend
0
0
0
DMSO
20 min
4h
0
0

Beta-Catenin Fl.
Intensity (A.U.)

20

0

40

4h
Beta-Catenin
Fl.
Intensity (A.U.)

60

0

4h

50

Legend

Legend
DMSO
0

0

20 min

Legend
DMSO

***

0

100
0

C
80

MUC1.CT Fl.
Intensity (A.U.)

80
60
200
SM Erlotinib
Membrane Red Set 1, rotated [Data Set-A]
40
40
40
Legend
150
20
20
20

0

Data Set-A

Legend

Legend
Secondary
Only Control
Legend Control
DMSO
Legend
MUC1.CT

60

20

20

120
100

80

20

40

60

0

60

80

0

Data Set-A

80

Beta-Catenin Fl.
Intensity (A.U.)

A

119

Beta-catenin (A) and MUC1.CT (B) levels in whole cells upon 1 µM Erlotinib (or
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Quantification of the images confirmed that significant increases in nuclear betacatenin and nuclear MUC1.CT occurred with 4 hours Erlotinib treatment in S2013.MUC1F cells (Figure 34). Significant increases in the level of both proteins were
observed at the four-hour time point at the whole-cell level, in the membrane, and in the
nuclei of the cells. EGF and Erlotinib both caused an increase in beta-catenin and
MUC1.CT levels in the nuclei of the cells. However, while EGF stimulation caused
significant changes in both MUC1.CT and beta-catenin levels in the nuclei of the cells at
20 minutes (Figure 29E and F), Erlotinib required a longer period of action before
causing significant changes in levels of beta-catenin and MUC1.CT.
S2-013.MUC1F cells from the preceding experiment (Figure 32-Figure 34) were
analyzed in terms of beta-catenin/MUC1.CT colocalization. Consecutive z-stack images
in sets of three (from the bottom towards the top of the cells) are shown for each time
point (Figure 35).
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Figure 35. Effect of Erlotinib on colocalization of beta-catenin and MUC1.CT in
S2-013.MUC1F cells.
The colocalization of beta-catenin and MUC1.CT is shown in white after 0 minutes
(A), 20 minutes (B), and 4 hours Erlotinib treatment (1 µM). Beta-catenin is displayed
in red, MUC1.CT is displayed in green, and nuclei are stained with DAPI (blue).
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The Erlotinib-induced increase in colocalization of beta-catenin and MUC1.CT is
clear by the four-hour time point (Figure 35). This involved both the membrane and
nuclei of the cells.
In the same Erlotinib experiment (Figure 32-Figure 35), colocalization of betacatenin and MUC1.CT was quantified in ROIs representing individual cells (Figure 36A),
the membrane (Figure 36B), and nuclei (Figure 36C) of the cells. The Pearson
correlation coefficient was measured in fifteen membrane and fifteen nuclear regions of
the S2-013.MUC1F cells (three of each from five independent fields).
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whole cells, in the membrane, and in the nuclei of S2-013.MUC1F cells
following Erlotinib treatment.
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The increase in colocalization of beta-catenin and MUC1.CT was confirmed at
the whole-cell level and in the membrane of the Erlotinib-treated S2-013.MUC1F cells
(Figure 36). Thus, as one might expect due to their opposite impact on EGFR, EGF
stimulation decreased membrane beta-catenin/MUC1.CT colocalization (Figure 31A),
while Erlotinib increased it (Figure 36B). As with EGF stimulation (Figure 31B), Erlotinib
did not induce changes in nuclear beta-catenin/MUC1.CT colocalization (Figure 36C).
We also investigated the impact of EGF and Erlotinib on a PDAC cell line with
endogenous beta-catenin and MUC1.CT. CFPAC-1 cells were treated with 10 ng/mL
EGF for 0 minutes (Figure 37A), 5 minutes (Figure 37B), 20 minutes (Figure 37C), 4
hours (Figure 37D), and 24 hours (Figure 37E). The cells were fixed, permeabilized,
blocked, and then stained for beta-catenin and MUC1.CT.
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Figure 37. Effect of EGF on beta-catenin and MUC1.CT in CFPAC-1 cells, betacatenin and MUC1.CT probed with antibodies.
CFPAC-1 cells were treated with 10 ng/mL EGF for 0 minutes (A), 5 minutes (B), 20
minutes (C), 4 hours (D), and 24 hours (E). The cells were stained for beta-catenin
(red) and MUC1.CT (green). DAPI (blue) indicates the nuclei. The negative control
cells received secondary antibody only (F).
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The changes induced by EGF in CFPAC-1 cells were clearly different from the
changes induced in S2-013.MUC1F cells (compare Figure 27 to Figure 37). For
example, membrane beta-catenin levels rose dramatically after 20 minutes of EGF
stimulation in CFPAC-1 cells, whereas a rise in membrane beta-catenin was observed at
the four-hour time point in S2-013.MUC1F cells (Figure 29C).
Images of the CFPAC-1 cells of Figure 37 were split into individual channels to
evaluate the impact of EGF on beta-catenin (red) and MUC1.CT (green) separately
(Figure 38).
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Figure 38. Effect of EGF on beta-catenin and MUC1.CT in CFPAC-1 cells, split
channels.
Images of cells (Figure 37) were split into individual channels to show beta-catenin
(red), MUC1.CT (green), and nuclei (blue) at 0 minutes (A), 5 minutes (B), 20 minutes
(C), 4 hours (D), and 24 hours (E) after application of 10 ng/mL EGF.
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As with S2-013.MUC1F cells, EGF stimulation caused nuclear accumulation of
MUC1.CT in CFPAC-1 cells at the twenty-minute time point (compare Figure 28C to
Figure 38C). However, the dramatic increase in membrane beta-catenin at 20 minutes
in the CFPAC-1 cells was not observed in the S2-013.MUC1F cells (compare Figure
28C to Figure 38C).
In the same CFPAC-1 experiment (EGF stimulation), the mean fluorescence
intensities of ROIs representing individual cells (n=15), cell membrane regions (n=10),
and nuclei (n=15) were analyzed with ZEN Blue software to determine levels of betacatenin and MUC1.CT (Figure 39).
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Figure 39. Impact of EGF on levels of beta-catenin and MUC1.CT in CFPAC-1
cells, beta-catenin and MUC1.CT probed with antibodies.
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The increase in levels of beta-catenin and MUC1.CT was significant at the
whole-cell level, in the membrane, and in the nuclei of cells at 20 minutes EGF
stimulation (Figure 39). However, while this increase persisted in the nuclei of S2013.MUC1F cells (Figure 29E and F), the EGF-induced nuclear increase of beta-catenin
and MUC1.CT was not seen at the four-hour time point in CFPAC-1 cells.
CFPAC-1 cells from the preceding experiment (Figure 37-Figure 39) were
analyzed in terms of beta-catenin/MUC1.CT colocalization. Z stacks (serial crosssection images) spaced 0.54 µm apart were produced for a field of cells at each time
point (Figure 40). Consecutive z-stack images in sets of three (from the bottom towards
the top of the cells) are shown for each time point. Beta-catenin is displayed in red,
MUC1.CT in green, nuclei (DAPI) in blue, and colocalization of beta-catenin and
MUC1.CT is shown in white.
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Figure 40. Effect of EGF on colocalization of beta-catenin and MUC1.CT in
CFPAC-1 cells, beta-catenin and MUC1.CT probed with antibodies.
The colocalization of beta-catenin and MUC1.CT is shown in white after 0 minutes
(A), 5 minutes (B), 20 minutes (C), 4 hours (D), and 24 hours (E) EGF treatment (10
ng/mL). Beta-catenin is displayed in red, MUC1.CT is displayed in green, and nuclei
are stained with DAPI (blue).
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Because the EGF-induced increase in levels of beta-catenin and MUC1.CT
occurred at the 20-minute time point, it is not surprising that the colocalization of the
proteins was so striking at that time (Figure 40C). Colocalization of beta-catenin and
MUC1.CT returned to the original level by 24 hours EGF stimulation.
In the same EGF-treated CFPAC-1 cell experiment, colocalization of
beta-catenin and MUC1.CT was analyzed in ROIs representing the membrane (Figure
41A) and nuclei (Figure 41B) of the cells. The Pearson correlation coefficient was
measured in ten membrane and fifteen nuclear regions of CFPAC-1 cells (two
membrane regions and three nuclei from five independent fields).
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Figure 41. Quantification of colocalization of beta-catenin and MUC1.CT in the
membrane and nuclei of CFPAC-1 cells following EGF stimulation, beta-catenin
and MUC1.CT probed with antibodies.
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determined in the cell membrane (A) and the nuclei (B) at each time point following
EGF treatment. Colocalization in cells to which only secondary antibody was applied
is displayed alongside beta-catenin/MUC1.CT colocalization values.
***p<0.001
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Analysis of the CFPAC-1 cells confirmed what appeared to be an increase in
beta-catenin/MUC1.CT colocalization at 20 minutes EGF stimulation (Figure 41A and B).
Concerning membrane colocalization of the proteins, this result was opposite to that
observed in S2-013.MUC1F cells (Figure 31A). Also, while no statistically significant
change occurred in nuclear beta-catenin/MUC1.CT colocalization in S2-013.MUC1F
cells (Figure 31B), a rise in beta-catenin/MUC1.CT colocalization was observed in
CFPAC-1 nuclei at 20 minutes EGF stimulation (Figure 41B).
Because EGF caused dramatic changes in beta-catenin and MUC1.CT levels
and colocalization in CFPAC-1 cells, we next investigated their response to EGFR
inhibition. CFPAC-1 cells were treated with 1 µM Erlotinib for 0 minutes (Figure 42 A),
20 minutes (Figure 42 B), or 4 hours (Figure 42 C). The cells were fixed, permeabilized,
blocked, and then stained for beta-catenin and MUC1.CT.
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Figure 42. Effect of Erlotinib on levels of beta-catenin and MUC1.CT in
CFPAC-1 cells.
CFPAC-1 cells were treated with 1 µM Erlotinib for 0 minutes (A), 20 minutes (B), or 4
hours (C). The cells were stained for beta-catenin (red) and MUC1.CT (green). DAPI
(blue) indicates the nuclei of the cells. The negative control cells received secondary
antibody only (D).
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Erlotinib impacts neither beta-catenin nor MUC1.CT in CFPAC-1 cells at the 20minute time point. However, the cells were visibly perturbed by the drug by four hours
(Figure 42). This clumped-cell phenotype occurred in both replicates of this experiment.
MUC1.CT was universally increased in the cells by four hours.
Images of the CFPAC-1 cells of Figure 42 were split into individual channels to
evaluate the impact of Erlotinib on beta-catenin (red) and MUC1.CT (green) separately
(Figure 43).
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Figure 43. Effect of Erlotinib on beta-catenin and MUC1.CT in CFPAC-1 cells,
split channels.
Images of cells (Figure 42) were split into individual channels to show beta-catenin
(red), MUC1.CT (green), and nuclei (blue) at 0 minutes (A), 20 minutes (B), and 4
hours (C) after application of 1 µM Erlotinib.
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The level of beta-catenin in the membrane of CFPAC-1 cells has dramatically
increased by four hours of Erlotinib treatment (Figure 43C). This increase was actually
visible at the 20-minute time point (Figure 43B).
In the same CFPAC-1 experiment (Figure 42), ROIs representing the cell
membrane (n=10) and nuclei (n=15) were analyzed with ZEN Blue software to determine
levels of beta-catenin and MUC1.CT (Figure 44).
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Figure 44. Impact of Erlotinib on levels of beta-catenin and MUC1.CT in
CFPAC-1 cells as determined by confocal microscopy.
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After quantifying levels of both beta-catenin and MUC1.CT in the CFPAC-1 cells,
it was clear that Erlotinib caused increases in both proteins at the whole-cell level, in the
membrane, and in the nuclei of the cells (Figure 44). This change started at the 20minute time point, and beta-catenin and MUC1.CT levels were two to four times higher
by the 4-hour time point. A similar result was observed with Erlotinib-treated
S2-013.MUC1F cells, except in that case the rise in levels of beta-catenin and MUC1.CT
required a longer period of treatment (Figure 34).
The CFPAC-1 cells from the preceding experiment (Figure 42-Figure 44) were
analyzed in terms of beta-catenin/MUC1.CT colocalization. Z stacks (serial crosssection images) spaced 0.54 µm apart were produced for a field of cells at each time
point (Figure 45). Consecutive z-stack images in sets of three (from the bottom towards
the top of the cells) are shown for each time point.
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Figure 45. Effect of Erlotinib on colocalization of beta-catenin and MUC1.CT in
CFPAC-1 cells.
The colocalization of beta-catenin and MUC1.CT is shown in white after 0 minutes
(A), 20 minutes (B), and 4 hours Erlotinib treatment (1 µM). Beta-catenin is displayed
in red, MUC1.CT is displayed in green, and nuclei are stained with DAPI (blue).
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As with S2-013.MUC1F cells (Figure 35) it appears that Erlotinib causes
increased beta-catenin/MUC1.CT colocalization in the membrane of CFPAC-1 cells
(Figure 45). This increase continued until at least four hours after treatment.
With cells from the CFPAC-1 Erlotinib experiment, the Pearson correlation
coefficient was measured in ten ROIs representing the membrane compartment (Figure
46A) and in fifteen nuclei (Figure 46B) (two membrane regions and three nuclei from five
independent fields).
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Figure 46. Quantification of colocalization of beta-catenin and MUC1.CT in the
membrane and nuclei of CFPAC-1 cells following Erlotinib treatment.
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Quantification of the colocalization confirmed that an increase in membrane betacatenin/MUC1.CT colocalization occurred in Erlotinib-treated CFPAC-1 cells by 20
minutes (Figure 46A). In the membrane compartment colocalization tripled by four
hours. A similar trend was also observed in the nuclei of the cells (Figure 46B). With
S2-013.MUC1F cells, increased beta-catenin/MUC1.CT colocalization was observed in
the membrane of the cells also, but this required four hours of Erlotinib treatment (Figure
36B). However, as opposed to what was observed in CFPAC-1 cells, no betacatenin/MUC1.CT colocalization change was measured in the nuclei of S2-013.MUC1F
cells with Erlotinib treatment (Figure 36C).
We also employed PLA to determine how EGF changes the interaction between
beta-catenin and MUC1.CT in S2-013.MUC1F cells (Figure 47). Cells were untreated or
treated with 10 ng/mL EGF for 5 minutes. Cells were fixed and then analyzed by PLA.
A yellow spot in the image indicates that a beta-catenin molecule was within 40 nm of a
MUC1.CT molecule. Images of cells were taken with a confocal laser scanning
microscope. A representative image of EGF-untreated cells (Figure 47A) and a
representative image of EGF-treated cells (Figure 47B) are shown.
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Figure 47. EGF stimulation decreases the interaction between beta-catenin
and MUC1.CT as determined by proximity ligation assay.
(A) Each yellow spot indicates that a beta-catenin molecule is within 40 nm of a
MUC1.CT molecule. (B) A representative PLA image of the cells 5 minutes after 10
ng/mL EGF stimulation. (C) The negative control sample for the 0-minute time point
and (D) for the 5-minute time point.
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A drop in the average number of beta-catenin/MUC1.CT interactions occurred
with only 5 minutes EGF stimulation (Figure 47). This supports what was observed by
coimmunoprecipitation and confocal microscopy experiments with S2-013.MUC1F cells.
PLA was also performed with EGF-untreated and EGF-treated CFPAC-1 cells to
determine how EGF impacted the interaction between beta-catenin and MUC1.CT in this
PDAC cell line. The results of experiments with both S2-013.MUC1F (Figure 48A) and
CFPAC-1 (Figure 48B) cells were quantified and graphed. Cells were untreated or
treated with 10 ng/mL EGF for the indicated periods of time. Cells were fixed and then
analyzed by PLA. Negative control cells were probed with a MUC1.CT antibody and an
isotype control antibody, and the test samples were probed with a MUC1.CT antibody
and a beta-catenin antibody. Images of cells were produced by confocal scanning laser
microscopy and analyzed with ImageJ software. Three fields of cells were analyzed at
all time points for both cell lines, and the experiment was conducted at least twice with
both cell lines.
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The number of interactions between beta-catenin and MUC1.CT tended to
decrease (mean of 2.4 vs. 0.8 interactions per cell) upon stimulation of cells with EGF,
though no statistically significant difference was determined (Figure 48A). Though
CFPAC-1 cells did not follow the same trend as S2-013.MUC1F cells, the interaction
between beta-catenin and MUC1.CT was similar to that which was observed in the
CFPAC-1 cells in the confocal microscopy experiment (initial rise followed by a return to
previous levels). As with the S2-013.MUC1F cells, the CFPAC-1 PLA results were not
statistically significant (Figure 48B).
To summarize the confocal microscopy experimental results to this point, we saw
that both EGF and Erlotinib affected the beta-catenin/MUC1.CT association in PDAC
cells, suggesting that EGFR regulates the beta-catenin/MUC1.CT association. Typically,
the responses of S2-013.MUC1F and CFPAC-1 cells to the treatments were
incongruous. However, with both S2-013.MUC1F and CFPAC-1 cell lines, an increase
in beta-catenin/MUC1.CT colocalization occurred in the membrane compartment with
Erlotinib treatment. One should also note that changes in beta-catenin/MUC1.CT
colocalization in S2-013.MUC1F cells (Figure 31, Figure 36) did not correspond to
changes in beta-catenin and MUC1.CT levels (Figure 29, Figure 34), while changes in
beta-catenin/MUC1CT colocalization in CFPAC-1 cells (Figure 41, Figure 46) always
followed the trend in levels of beta-catenin and MUC1.CT (Figure 39, Figure 44). It
appears that the mechanism by which the beta-catenin/MUC1.CT association is
regulated differs in these cell lines.
While coimmunoprecipitation does not require that proteins physically interact
(proteins can coimmunoprecipitate if they are merely in associating protein complexes),
and confocal microscopy can only resolve distances of about 250 nm [157], Förster
resonance energy transfer (FRET) only occurs if interacting proteins are within 10 nm of
one another [158], which is on the order of the size of an individual protein molecule.
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This allows one to study the physical interaction of proteins. In addition, when FRET is
coupled with fluorescence lifetime imaging (FLIM), one can detect protein-protein
interaction events that occur within cells even at low levels because FLIM is independent
of the concentrations of the donor and acceptor fluorophore molecules [159]. For these
reasons, we employed FRET FLIM to assess the nature of the beta-catenin/MUC1.CT
interaction. To that end, we conducted FRET FLIM studies with nonfluorescent S2013.MUC1F cells, S2-013 cells with eGFP MUC1.CT, and S2-013 cells with eGFP
MUC1.CT and mCherry beta-catenin [159-161]. Fixed cells were excited with 517 nm
light, and the lifetimes of emitted light were collected. All observed lifetimes are shown
for each cell type in Figure 49.
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Figure 49. The interaction between beta-catenin and MUC1.CT as determined
by FRET FLIM.
All fluorescence lifetimes of light emitted by cells excited by 488 nm laser light in S2013 cells with no fluorescent protein expression, in S2-013 cells expressing eGFP
labeled MUC1.CT, and in S2-013 cells expressing both eGFP labeled MUC1.CT and
mCherry beta-catenin are displayed in this histogram.

151
After taking scores of images of S2-013.MUC1F, S2-013.MUC1 eGFP, and S2013.MUC1 eGFP/mCherry beta-catenin cells and making hundreds of measurements of
lifetimes of photons we produced a histogram to summarize all lifetimes observed
(Figure 49). The lifetimes fell into four major groups: one at 0.3 ns, one at 0.4 ns, one at
2.25 ns, and a fourth at 2.4 ns. The nonfluorescent cells produced autofluorescent
lifetimes at about 0.4 ns and at 2.6 ns. The 0.4 ns lifetimes of the nonfluorescent cells
aligns with a lifetime commonly observed in S2-013.MUC1 eGFP/mCherry beta-catenin
cells. However, the number of counts for the nonfluorescent cells at 0.4 ns was much
lower than that observed in the fluorescent cells (consider the area under the curve).
The 0.3 ns lifetime was only observed in the S2-013.MUC1 eGFP cells. Though it is not
certain, it is possible that this lifetime was due to homo-FRET (FRET between two
MUC1.CT eGFP molecules). Homo-FRET is not typically detected with FRET FLIM
[162], though it has been reported [163]. The second shortest lifetime (about 0.4 ns)
was not observed in S2-013.MUC eGFP cells, but it occurred when mCherry betacatenin was present. Perhaps this lifetime relates to an interaction between an mCherry
beta-catenin molecule and a MUC1.CT eGFP dimer (or multimer). Because the 2.25 ns
lifetime pool only occurred in the S2-013.MUC1 eGFP/mCherry beta-catenin cells, it
likely resulted from low-efficiency FRET between individual molecules of MUC1.CT
eGFP and mCherry beta-catenin. The highest lifetime (2.4 ns) most likely corresponds
to unbound (free) MUC1.CT eGFP [164].
The impact of EGF stimulation on beta-catenin/MUC1.CT interaction was studied
by FRET FLIM. Nonfluorescent S2-013.MUC1F cells, S2-013 cells with eGFP
MUC1.CT, and S2-013.MUC1 eGFP and mCherry beta-catenin cells were untreated or
treated with 10 ng/mL EGF for 5 minutes. Fixed cells were excited with 488 nm light.
ROIs representing individual cells and cell compartments were analyzed to determine
the impact of mCherry beta-catenin on MUC1.CT eGFP fluorescence lifetimes as well as
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to determine the impact of EGF on the beta-catenin/MUC1.CT interaction. An example
of compartmental analysis of a cell is shown in Figure 50.
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Figure 50. FRET FLIM compartmental analysis of an S2-013.MUC1
eGFP/mCherry beta-catenin cell.
A group of cells was excited by 488 nm laser light. The emitted photons were
counted and their lifetimes determined. Regions of interest (green border) were
drawn around whole cells (A), the membrane (B), the cytoplasm (C), the synthetic
machinery (D), or the nucleus (E) of each cell analyzed.
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After imaging cells, mean fluorescence intensities were collected from ROIs
representing individual cells and various cell compartments (membranes, cytoplasm,
synthetic machinery, and nuclei) in order to analyze the impact of EGF stimulation at a
subcellular level. The synthetic machinery of the cell is the perinuclear area of the cell
with visibly high levels of eGFP. This region appears white in Figure 50.
Membrane, cytoplasm, synthetic machinery, and nuclear compartments were
individually analyzed in nonfluorescent S2-013.MUC1F cells, S2-013 cells with eGFP
MUC1.CT, and S2-013.MUC1 eGFP and mCherry beta-catenin cells with or without
EGF stimulation. The measured fluorescence lifetimes were pooled into five groups: 0
to 0.35 ns, 0.35 to 0.70 ns, 0.70 to 2.00 ns, 2.00 to 2.30 ns, and 2.30 to 3.00 ns. The
following pie graphs (Figure 51 to Figure 55) summarize the results of this eGFP lifetime
pool analysis. Approximately fifty measurements were made for each group analyzed.
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Figure 51. The effect of EGF on MUC1.CT and the impact of EGF on the
MUC1.CT/beta-catenin interaction in whole S2-013.MUC1 eGFP and S2013.MUC1 eGFP/mCherry beta-catenin cells as determined by FRET FLIM.
The pie charts display the lifetime distributions for photons emitted by 488 nm laserexcited S2-013.MUC1 eGFP cells untreated (A) and treated with 10 ng/mL EGF (B),
and S2-013.MUC1 eGFP/mCherry beta-catenin cells untreated (C) and treated with
10 ng/mL EGF (D).
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At the whole-cell level (Figure 51) EGF stimulation caused the percentage of
lifetimes in pool 1 to decrease by about 3.4% in S2-013.MUC1 eGFP cells. This means
that homo-FRET (MUC1 eGFP dimerization) has decreased. At the same time, an
increase of about 2.7% in the percentage of lifetimes in pool 5 occurred. This means
that a higher percentage of MUC1.CT eGFP molecules have entered an unbound state
with EGF treatment. Concerning the S2-013.MUC1 eGFP/Cherry beta-catenin cells a
decrease of 0.9% in pool 4 and an increase of 1.2% in pool 5 indicate that a lower
percentage of interactions is taking place between mCherry beta-catenin and MUC1.CT
eGFP molecules, and a higher percentage of MUC1.CT eGFP molecules are in the free
state.
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Figure 52. The effect of EGF on MUC1.CT and the impact of EGF on the
MUC1.CT/beta-catenin interaction in the membrane of S2-013.MUC1 eGFP and
S2-013.MUC1 eGFP/mCherry beta-catenin cells as determined by FRET FLIM.
The pie charts display the lifetime distributions for photons emitted by the
membranes of 488 nm laser-excited S2-013.MUC1 eGFP cells untreated (A) and
treated with 10 ng/mL EGF (B), and S2-013.MUC1 eGFP/mCherry beta-catenin cells
untreated (C) and treated with 10 ng/mL EGF (D).
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In the membrane of cells (Figure 52) EGF stimulation caused the percentage of
lifetimes in pool 1 to decrease by about 2.5% in S2-013.MUC1 eGFP cells. This means
that homo-FRET (MUC1 eGFP dimerization) has decreased. At the same time, an
increase of about 5.8% in the percentage of lifetimes in pool 5 occurred. This means
that a higher percentage of MUC1.CT eGFP molecules have entered an unbound state
with EGF treatment. Concerning the membrane compartment of S2-013.MUC1
eGFP/Cherry beta-catenin cells, an increase of 4.6% in pool 2 indicates that a higher
percentage of MUC1.CT eGFP dimers are interacting with mCherry beta-catenin
molecules. A decrease of 7.3% in pool 4 indicates that a lower percentage of MUC1.CT
eGFP/mCherry beta-catenin heterodimer interactions are taking place. An increase of
4% in pool 5 indicates that a higher percentage of MUC1.CT eGFP molecules are in the
free state. This corresponds well with coimmunoprecipitation and confocal microscopy
data for S2-013.MUC1F cells.
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Figure 53. The effect of EGF on MUC1.CT and the impact of EGF on the
MUC1.CT/beta-catenin interaction in the cytoplasm of S2-013.MUC1 eGFP and
S2-013.MUC1 eGFP/mCherry beta-catenin cells as determined by FRET FLIM.
The pie charts display the lifetime distributions for photons emitted by the cytoplasm
of 488 nm laser-excited S2-013.MUC1 eGFP cells untreated (A) and treated with 10
ng/mL EGF (B), and S2-013.MUC1 eGFP/mCherry beta-catenin cells untreated (C)
and treated with 10 ng/mL EGF (D).
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In the cytoplasm of cells (Figure 53) EGF stimulation caused the percentage of
lifetimes in pool 1 to decrease by about 1% in S2-013.MUC1 eGFP cells. This means
that homo-FRET (MUC1 eGFP dimerization) has slightly decreased. No change has
occurred in lifetime pool 5, or the MUC1.CT eGFP unbound state. Concerning the
cytoplasm compartment of S2-013.MUC1 eGFP/Cherry beta-catenin cells, a decrease in
pool 2 of about 2.4% indicates that a lower percentage of MUC1.CT eGFP dimers are
interacting with mCherry beta-catenin molecules. A decrease of 7.6% in pool 4 indicates
that a lower percentage of MUC1.CT eGFP/mCherry beta-catenin heterodimer
interactions are taking place. An increase of 9.8% in pool 5 indicates that a higher
percentage of MUC1.CT eGFP molecules are in the free state. This interpretation
corresponds well with immunoprecipitation and confocal microscopy data for S2013.MUC1F cells.
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Figure 54. The effect of EGF on MUC1.CT and the impact of EGF on the
MUC1.CT/beta-catenin interaction in the synthetic machinery of S2-013.MUC1
eGFP and S2-013.MUC1 eGFP/mCherry beta-catenin cells as determined by
FRET FLIM.
The pie charts display the lifetime distributions for photons emitted by the synthetic
machinery (perinuclear region of particularly high MUC1.CT eGFP concentration) of
488 nm laser-excited S2-013.MUC1 eGFP cells untreated (A) and treated with 10
ng/mL EGF (B), and S2-013.MUC1 eGFP/mCherry beta-catenin cells untreated (C)
and treated with 10 ng/mL EGF (D).
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In the synthetic machinery (Figure 54) a different trend was observed. EGF
stimulation caused the percentage of lifetimes in pool 1 to decrease by about 9.8% in
S2-013.MUC1 eGFP cells. This means that homo-FRET (MUC1 eGFP dimerization)
has decreased. A decrease in lifetime pool 5 of about 1.3% indicates that a higher
percentage of MUC1.CT eGFP molecules are in a bound state. Concerning the
synthetic machinery compartment of S2-013.MUC1 eGFP/Cherry beta-catenin cells, an
increase in pool 1 of about 1.5% indicates the presence of a higher percentage of
MUC1.CT eGFP homo-FRET pairs. A decrease of 5.4% in pool 2 indicates that less
MUC1.CT eGFP dimers are interacting with mCherry beta-catenin molecules. An
increase of 16.3% in pool 4 indicates that a higher percentage of MUC1.CT
eGFP/mCherry beta-catenin heterodimer interactions are taking place. A decrease of
12.4% in pool 5 indicates that a lower percentage of MUC1.CT eGFP molecules are in
the free state. This result was unlike that of the membrane and cytoplasm
compartments where an increase in MUC1.CT eGFP in the free state was observed with
EGF stimulation (Figure 52 and Figure 53).
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Figure 55. The effect of EGF on MUC1.CT and the impact of EGF on the
MUC1.CT/beta-catenin interaction in the nuclei of S2-013.MUC1 eGFP and S2013.MUC1 eGFP/mCherry beta-catenin cells as determined by FRET FLIM.
The pie charts display the lifetime distributions for photons emitted by the nuclear
region of 488 nm laser-excited S2-013.MUC1 eGFP cells untreated (A) and treated
with 10 ng/mL EGF (B), and S2-013.MUC1 eGFP/mCherry beta-catenin cells
untreated (C) and treated with 10 ng/mL EGF (D).
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Concerning the nuclei (Figure 55) EGF stimulation caused very little change to
occur in either cell type. The percentage of lifetime pools in S2-013.MUC1 eGFP cells
remained virtually unchanged. Concerning the nuclear compartment of S2-013.MUC1
eGFP/Cherry beta-catenin cells, a decrease in pool 1 of about 1.5% indicates the
presence of a lower percentage of MUC1.CT eGFP homo-FRET pairs. An increase of
1.3% in pool 4 indicates that a higher percentage of MUC1.CT eGFP/mCherry betacatenin heterodimer interactions are taking place.
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Discussion
The steady state coimmunoprecipitation data show that beta-catenin and
MUC1.CT interact in the cytoplasm and/or membrane as well as in the nucleus of PDAC
cells (Figure 2-Figure 6). The Rapid Autopsy sample stained for beta-catenin and
MUC1.CT (Figure 7) indicates that the beta-catenin/MUC1.CT interaction occurs in
pancreas cancer tissue as well, particularly in the membrane of the cells. The mass
spectrometry data provide support that the beta-catenin/MUC1 interaction occurs both in
the cytoplasm/membrane and nuclear fractions (Table 1). According to mass
spectrometry data this interaction includes MUC1 forms with a portion of MUC1 that
normally sits just above the plasma membrane in the extracellular space. The N- and Cterminal subunits of MUC1 interact noncovalently and the C-terminal subunit (that
crosses the cell membrane and includes the cytoplasmic tail) is only 158 amino acids in
size [78]. It is easy to imagine that the entire C-terminal subunit of MUC1 enters the cell
and interacts with beta-catenin.
In the first attempt to identify beta-catenin-coimmunoprecipitating MUC1.CT
peptides by mass spectrometry, two MUC1 peptides were observed in the
cytoplasm/membrane fraction (Table 1-Table 5). For example, the QGGFLGLSNIK
peptide was identified eight times in the first sample and two times in a technical
replicate. This peptide is just five residues N-terminal to the C-terminal subunit of
MUC1. The ions score and expect score make it likely that forms of MUC1 including this
portion interacted with beta-catenin for those experiments. However, this peptide was
not again seen in biological replicates. The NYGQLDIFPAR peptide was identified once
in the first sample and three times in a technical replicate. The ions score of 72.5 and
expect score of 2.6E-4 suggest that this is not a random match nor a false positive. On
the second attempt to observe MUC1.CT peptides in a beta-catenin
coimmunoprecipitate, special attention was paid to maintaining phosphorylation. Again,
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the NYGQLDIFPAR peptide was observed in the cytoplasm/membrane fraction. The
ions score (59) and expect score (4.6E-5) indicate that this is a true identification. In
addition, the MUC1.CT peptide EGTINVHDVETQFNQYK was observed. This peptide is
at the N-terminus of the 158 amino acid C-terminal subunit of MUC1. The ions score
(67) and expect score (2.2E-6) are again indicative that this is a valid identification
(Table 2). This raises the possibility that the entire small MUC1 subunit associates with
beta-catenin. Neither of these peptides were observed in the isotype control sample,
lending credibility to the possibility that beta-catenin and MUC1 interact through this
region of MUC1 (Table 3).
The EGTINVHDVETQFNQYK and NYGQLDIFPAR peptides were also observed
in the nuclear fraction for the beta-catenin coimmunoprecipitates analyzed by mass
spectrometry (Table 4). The ions score and expect score for the
EGTINVHDVETQFNQYK peptide were 77 and 6.9E-7, respectively. The same peptide
was observed in the nuclear isotype control sample, but in that case the ions score and
expect score were very low, only 16 and 0.27, respectively. The identification of
EGTINVHDVETQFNQYK in nuclear isotype control immunoprecipitation is much more
likely to be a random match occurring by chance alone than that of the nuclear betacatenin coimmunoprecipitate sample.
Concerning the OpenSPR results, large chi-squared (χ2) values of some of the
OpenSPR results mean that the experimental curves did not fit well to the
mathematically modelled curves in those cases. Also, in some cases the kon value error
is larger than the value itself, making these results difficult to interpret. The OpenSPR
results still provide valuable information about the beta-catenin/MUC1.CT interaction.
Interestingly, when the CQCRRKNYGQLDIFPARDTYHPMSEYPTYH peptide
(which contains the MUC1.CT peptide detected by mass spectrometry) was analyzed by
OpenSPR for interaction with beta-catenin, the highest binding affinity was observed (2.3
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± 0.1 µM, Table 7). However, the chi-squared was high, at 1,278. Fortunately, another
longer peptide encompassing nearly the entire stretch of MUC1.CT
(NYGQLDIFPARDTYHPMSEYPTYHTHGRYVPPSSTDRSPYEKVSAGNG
GSSLSYTNPAVAATSANL) had a much lower chi-squared value of 19, though its
binding affinity, 15 ± 0.2 µM, was six times lower than that of the
CQCRRKNYGQLDIFPARDTYHPMSEYPTYH peptide. The beta-catenin binding affinity
for full-length recombinant His-tag MUC1.CT was 13.8 ± 0.3 µM, with a fairly low chisquared value of 16. Interestingly, ITC and SPR data indicate that beta-catenin does not
interact strongly with the latter C-terminal half of MUC1.CT
(GRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPA). This peptide had a very low
exothermic enthalpy change with beta-catenin as determined by ITC (-1.1 kcal
/mol) and a binding affinity of 306 ± 9 µM by OpenSPR (Table 7), though the chisquared value is fairly high, at 185. The binding affinity of the phosphorylated version of
this peptide (pYHPM) was over seven times lower (2.3 ± 1 mM) with an even higher chisquared value of 3,868. The highest binding affinity observed with a phosphorylated
MUC1.CT peptide was that of PYEKVpSAGNGGSSLSYTNPA, with a binding affinity of
45 ± 1 µM (six times higher binding affinity than the unphosphorylated form). Still, the
highest beta-catenin/MUC1.CT binding affinities observed involved unphosphorylated
MUC1.CT.
The ITC data (Table 1) provide evidence that the interaction between betacatenin and MUC1.CT does not involve the C-terminal half of MUC1.CT
(GRYVPPSSTDRSPYEKVSAGNGGSSLSYTNPA), which includes the previously
hypothesized SAGNGGSSL binding site. This is in contrast to the report that this
serine-rich motif of MUC1.CT is responsible for beta-catenin binding [94]. OpenSPR
data confirmed the lack of interaction of beta-catenin with this stretch of amino acids in
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the cytoplasmic tail of MUC1. In addition, the phosphomimetic form of the serine-rich
motif peptide GRYVPPSSTDRSPYEKVSAGNGGEELEYTNPA
actually produced an endothermic enthalpy change, which means that the interaction
was energetically unfavorable.
Mass spectrometry, ITC, and OpenSPR data taken together paint a picture that
beta-catenin and MUC1.CT interact in the low micromolar range, and this interaction is
through the N-terminal half of the cytoplasmic tail, the portion of the molecule that would
be closest to the cell membrane.
Several kinases are known to phosphorylate MUC1, and phosphorylation of
various MUC1.CT residues have been implicated in its interaction with various
transcription factors [47]. However, it is not clear from the results presented here how
CTGF, PDGF, or HGF impact MUC1.CT and beta-catenin levels and colocalization.
Only trends were observed. These trends include decreased MUC1.CT in the nucleus
at 10 minutes CTGF stimulation (Figure 14), decreased MUC1.CT and beta-catenin in
the cytoplasm/membrane fraction after 60 minutes of HGF stimulation (Figure 15), and
decreased MUC1.CT in the nucleus of PDGF-treated cells at 60 minutes (Figure 16).
EGF seems to have an effect on both MUC1 and beta-catenin. This is not a
surprise given that EGFR has been reported to regulate both proteins [55, 165]. What
had not been previously explored was the impact of EGF stimulation on the interaction
between beta-catenin and MUC1. Western blot data show that EGF stimulation reduces
MUC1.CT in the cytoplasm/membrane fraction within 5 minutes of stimulation and in the
nucleus after 10 minutes but does not significantly change beta-catenin levels (Figure
17). The impact of Erlotinib was determined at the one-hour and four-hour time point to
produce this western blot data (Figure 17). According to the western blot data, Erlotinib
does not seem to significantly impact cytoplasm/membrane or nuclear beta-catenin or
MUC1.CT at these longer time points.
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Subcellular fractionation successfully separated the membrane fraction from
other fractions as evidenced by the presence of EGFR and absence of beta-actin in the
membrane fraction (Figure 18). This set the stage for determining the impact of EGF
stimulation on MUC1.CT specifically in the membrane fraction. It appears that four
major MUC1.CT forms exist in the membrane of CFPAC-1 cells, and that EGF
stimulation, even at five minutes, causes phosphorylation of MUC1.CT (Figure 19). It
appears that the fraction of MUC1.CT phosphorylated in CFPAC-1 cells situates itself at
the top of the MUC1.CT band (at about 25 kDa). In addition, it appears that a fifth
MUC1.CT form becomes visible by two-dimensional gel electrophoresis upon EGF
stimulation. This band is at a pH of about 6.
S2-013.MUC1F cells have seven major forms of MUC1.CT (Figure 20). The
MUC1.CT form farthest to the right in Figure 20 seems to be the most affected by EGF
stimulation, as it is very pronounced in the phosphotyrosine blot. As in the case of
CFPAC-1 cells, a MUC1.CT form becomes more visible with EGF stimulation. This
band sits just left of pH 7 at about 25 kDa. It is unknown if in this case EGFR is directly
phosphorylating MUC1.CT or a kinase downstream of EGFR signaling. Both
possibilities have been reported to occur at the YEKV motif of MUC1.CT [55, 67].
Based on coimmunoprecipitation data, EGF stimulation appears to decrease the
interaction of beta-catenin and MUC1.CT (Figure 21). Beta-catenin immunoprecipitates
from the cytoplasm/membrane fraction of S2-013.MUC1F cells had diminished levels of
coimmunoprecipitating MUC1.CT. The reciprocal experiment conducted in the
membrane fraction of S2-013.MUC1F cells produced a similar result in which
immunoprecipitated MUC1.CT had decreased coimmunoprecipitating beta-catenin.
When this phenomenon was studied in S2-013.MUC1 eGFP/mCherry betacatenin cells, the decrease in beta-catenin/MUC1.CT colocalization was observed
specifically in the membrane in both a fixed-cell (Figure 22) and in a live-cell (Figure 23)
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experiment. This loss in colocalization is visible at only five minutes of stimulation. At
the whole-cell level (Figure 24) EGF stimulation does not appear to greatly impact betacatenin or MUC1.CT levels, except that beta-catenin levels have significantly risen at the
24-hour time point.
In the membrane of the cells treated with EGF one can observe a trend of
decreased beta-catenin and MUC1.CT (Figure 25). At the four-hour time point,
membrane MUC1.CT is significantly diminished. The result of EGF stimulation is a
seven-fold drop in membrane colocalization at the 20-minute mark that persists for at
least four hours.
The impact of EGF stimulation on nuclear beta-catenin/MUC1.CT colocalization
is not clear based on the confocal microscopy data in Figure 26. The background 488
nm signal is high in the nucleus, making it difficult to tell whether or not the apparent
drop in MUC1.CT levels in the nucleus is accurate or not. The impact of the EGFR axis
on beta-catenin and MUC1.CT in cancer cells is made clearer in Figure 27 through
Figure 46. It appears that EGF causes a slight increase in beta-catenin at the whole-cell
level that persists for four hours as well as a moderate rise in MUC1.CT by the four-hour
time point. In the membrane it appears that beta-catenin levels rise by the four-hour
time point, but no significant change in MUC1.CT were observed in the membrane of
S2-013.MUC1F cells over the course of the 24-hour experiment. However, a significant
decrease in colocalization of beta-catenin and MUC1.CT occurred in the membrane at 5
minutes in one experiment and 20 minutes in a replicate. In the nuclei a nearly two-fold
increase in beta-catenin was observed with EGF treatment that persisted throughout the
time course. An even greater increase in MUC1.CT was observed in the nuclei of these
cells, also starting at the 20-minute time point and enduring throughout the 24-hour time
course. However, no significant increase in beta-catenin/MUC1.CT interaction in the
nucleus accompanied this rise in protein levels. It seems that the nuclear beta-
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catenin/MUC1.CT interaction remains totally unperturbed by EGF stimulation in these
cells. When EGFR was inhibited in S2-013.MUC1F cells, an increase in betacatenin/MUC1.CT interaction was observed at the whole-cell level and in the membrane.
Again, the beta-catenin/MUC1.CT interaction in the nucleus was unchanged by the
treatment (Figure 36).
In CFPAC-1 cells, EGF treatment also caused a rise in beta-catenin at the
whole-cell level at 20 minutes, but this returned to pre-treatment levels by four hours as
opposed to that of S2-013.MUC1F cells, which persisted for at least four hours. In
addition, MUC1.CT levels rose by the twenty-minute time point, which did not occur until
the later four-hour time point in the case of S2-013.MUC1F cells. However, the
MUC1.CT level dropped by the four-hour time point. While beta-catenin sluggishly
increased after four hours of EGF stimulation in S2-013.MUC1F cells, beta-catenin
levels rose nearly two-fold by the twenty-minute mark in CFPAC-1 cells but did not
persist. Membrane and nuclear beta-catenin and MUC1.CT followed the same trend of
a transient increase at the twenty-minute time point in CFPAC-1 cells, as did the betacatenin/MUC1.CT interaction in both the membrane and nuclei of these cells (Figure 41).
Whereas EGF treatment affected the CFPAC-1 cells and S2-013.MUC1F cells
differently, EGFR inhibition had a similar effect in that it caused levels of beta-catenin
and MUC1.CT to rise and persist in the cells, as did beta-catenin/MUC1.CT
colocalization, particularly in the membrane of the cells. However, unlike S2013.MUC1F cells, CFPAC-1 cells showed a significant increase in betacatenin/MUC1.CT colocalization in the nuclei (Figure 46).
The loss in beta-catenin/MUC1.CT interaction in S2-013.MUC1F cells is visible at
the five-minute time point by PLA also (Figure 47). It does appear that upon EGF
stimulation, the beta-catenin/MUC1.CT interaction is reduced in S2-013.MUC1F cells at
five minutes. However, in neither S2-013.MUC1F nor CFPAC-1 cells was the EGF-
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induced change in beta-catenin/MUC1.CT interaction determined to be significant by
PLA (Figure 48).
The FRET FLIM data (Figure 49) shows two short (0.3 and 0.4 ns) and two long
lifetimes (2.25 and 2.4 ns). The published lifetime of eGFP in living cells is 2.4 ns [164],
however this is very much dependent on the cellular environment of the fluorophore
[166]. In the case of the S2-013.MUC1 eGFP and S2-013.MUC1 eGFP/mCherry betacatenin cells the unbound lifetime of eGFP was concordant with the published value of
2.4 ns. The 2.25 ns lifetime pool is found only in the S2-013.MUC1 eGFP/mCherry betacatenin cells. Though 2.25 ns is not very different from 2.4 ns, the two lifetimes are
distinct. Thus, it appears that low efficiency FRET is occurring between mCherry betacatenin and MUC1.CT eGFP. For this to occur, the molecules must be within 10 nm of
one another [158], providing more evidence that beta-catenin and MUC1.CT physically
interact.
The FRET FLIM data brings another interesting aspect of MUC1.CT biology to
light. The very short 0.30 ns lifetime in MUC1 eGFP cells may indicate that MUC1 eGFP
molecules are quenching energy from one another, a phenomenon called homo-FRET
[167]. This could result from MUC1.CT associating with itself, or it could be an artefact
due to the presence of eGFP at the C-terminus of the molecule. However, it has been
reported that MUC1.CT does dimerize through its CQC motif [48]. In accordance with
the idea that MUC1.CT and beta-catenin interact, mCherry beta-catenin increases the
very short lifetime (0.3 ns) observed in MUC1 eGFP cells to a slightly longer lifetime (0.4
ns). This may be an occurrence of more efficient FRET between mCherry beta-catenin
and MUC1 eGFP, or it may be that an mCherry beta-catenin molecule is interacting with
a dimer of eGFP MUC1 molecules, modulating the homo-FRET lifetime.
Concerning the impact of EGF stimulation on the beta-catenin/MUC1.CT
interaction in S2-013.MUC1 eGFP/mCherry beta-catenin cells, the FRET FLIM data
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corresponds well with what has been shown by coimmunoprecipitation, PLA, and
confocal microscopy data. The percentage of lifetimes above 2.3 ns at the whole-cell
level (Figure 51), in the membrane (Figure 52), and in the cytoplasm (Figure 53)
fractions increased with EGF treatment. The longer lifetime indicates that eGFP
molecules are released into an unbound state upon EGF stimulation. In addition, the 2.0
to 2.3 ns pool decreases by 7 to 8% in the membrane and cytoplasm fractions of S2013.MUC1 eGFP/mCherry beta-catenin cells, suggesting that interactions between
mCherry-beta-catenin and MUC1 eGFP are lost upon EGF stimulation. In addition, it
appears that homo-FRET (the very short lifetime pool) is decreased upon EGF
stimulation in S2-013.MUC1 eGFP cells by about 3% at the whole-cell level and in the
membrane fraction of S2-013.MUC1 eGFP cells. It seems that MUC1.CT loses
association with itself and beta-catenin with EGF stimulation. It is interesting that the
opposite trend was observed in the synthetic machinery of the cells, where about 16%
more MUC1.CT enters a beta-catenin bound state upon EGF stimulation (Figure 54).
Perhaps this is related to EGF-induced endocytosis of MUC1 [168] and trafficking
through the perinuclear region of the cell. Also, the FRET FLIM data indicate that no
change occurs in the nuclei of the cells with EGF stimulation in five minutes. Perhaps a
longer period of EGF stimulation is required to see changes there.
Immunoprecipitation, PLA, confocal microscopy, and FRET FLIM data suggest
that EGF stimulation decreases MUC1.CT interaction with beta-catenin in S2013.MUC1F cells. Because EGF stimulation causes tyrosine residue phosphorylation of
MUC1.CT in the membrane fraction of S2-013.MUC1F, and this stimulation decreases
membrane beta-catenin/MUC1.CT colocalization in S2-013.MUC1F cells in 5 minutes, it
seems reasonable to hypothesize that tyrosine residue phosphorylation of MUC1.CT
diminishes the beta-catenin/MUC1.CT interaction. This is certainly in line with mass
spectrometry analysis of beta-catenin coimmunoprecipitates in which MUC1.CT
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phosphorylation was not observed, and with ITC and OpenSPR data, in which
phosphorylation (of either tyrosine or serine residues) tended to decrease the betacatenin/MUC1.CT binding affinity.
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CHAPTER 4. MET INHIBITOR SU11274 LOCALIZES AT THE ENDOPLASMIC
RETICULUM
Introduction
In the course of examining activities of Met, a receptor tyrosine kinase that
transduces signals from the extracellular space to the cell interior when its ligand,
hepatocyte growth factor (HGF) binds to its extracellular domain [169], we noted that
one small molecule inhibitor SU11274, a pyrrole indolinone compound, first described in
2003 [170] showed unexpected properties of fluorescence and cellular uptake into
specific organelles. This compound is reported to inhibit the Met receptor activation with
an IC50 of 10 nM as determined in a cell-free assay [171], due to the ability of SU11274
to bind tightly to the ATP pocket of the Met receptor [170].
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Results
SU11274 fluoresces when excited by a laser at 488 nm. Figure 56A is the
emission spectrum of SU11274. In order to produce the emission spectrum SU11274
was applied to S2-013.MUC1F cells at 32 µM.
SU11274 is a pyrrole indolinone compound that also contains a sulfonamide
group. Its structure is shown in (B). The compound readily enters cells. (C) S2013.MUC1F cells were treated with 2 µM SU11274 and imaged every 20 seconds for 10
minutes with a 488 nm laser. ROIs were drawn around five individual cells. The five
SU11274 mean fluorescence intensity measurements were averaged, and the emitted
light produced upon excitation was measured and plotted as a function of time. All
values were normalized to the highest fluorescence intensity measurement observed. In
the same experiment the rate of absorption of SU11274 by S2-013.MUC1F cells was
determined by dividing the change in mean fluorescence intensity between successive
measurements by the increment of time elapsed between measurements (20 seconds)
(D). All values were normalized to the highest rate measurement observed.
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Figure 56. SU11274 emission spectrum and uptake into cells.
After applying 32 µM SU11274 to S2-013.MUC1F cells, the cells were excited with
488 nm laser light. The emission spectrum (A) was produced by taking SU11274
mean fluorescence intensity measurements in approximately 10 nm bandpass
increments from 482 to 725 nm. The structure of SU11274 (chemical
formula: C28H30CIN5O4S) is shown in (B). (C) S2-013.MUC1F cells were treated with
2 µM SU11274 and imaged every 20 seconds for 10 minutes. Regions of interest
were drawn around five individual cells. The five intensity measurements were
averaged, and the emitted light produced upon excitation was measured and plotted
as a function of time. The highest intensity measurement was set at 1, and all other
values are relative to it. (D) The rate of absorption of SU11274 by S2-013.MUC1F
cells was determined by dividing the change in SU11274 mean fluorescence intensity
from consecutive intensity measurements by the increment of time elapsed between
measurements. The largest rate measurement was set at 1, and all other values are
relative to it.

SU11274 mainly localizes at the endoplasmic reticulum (Fig. 2).
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We were able to determine the emission spectrum of SU11274, which peaks at
515 nm (Figure 56A). Ostensibly, the structure of the compound facilitates both its
fluorescence properties as well as its ability to concentrate in cells (Figure 56B). The
rapid rate of cellular uptake of SU11274 slowly levels off after about 2 minutes (Figure
56C and D), probably because the cells reach a point of saturation.
SU11274 was applied at 2 µM for 30 minutes prior to fixing, permeabilizing, and
staining the cells with antibodies for specific subcellular compartments. A confocal
image split into individual channels shows SU11274 localization in green (Figure 57A)
and the ER (calreticulin staining) of the cells in purple (Figure 57B). The combined
image is shown in Figure 57C. Relative area colocalization of SU11274 with subcellular
compartments is shown in Figure 57D. The isotype antibody control was used to
establish the threshold for the SU11274 fluorescence intensity and the Alexa Fluor 647
fluorescence intensity in order to make colocalization measurements. Relative area
colocalization is the percentage of pixels with co-occurrence of SU11274 and Alexa
Fluor 647 fluorescence intensities in which the fluorescence intensities of both channels
exceed the threshold established with the isotype antibody negative control.
Colocalization measurements were made with ten cells (five cells in two fields). The
Pearson correlation coefficient is a measure of the linear correlation between the
SU11274 fluorescence intensity and the Alexa Fluor 647 fluorescence intensity (Figure
57E).
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Figure 57. SU11274 localization.
S2-013.MUC1F cells were treated with 2 µM SU11274 for 30 minutes. The cells
were stained with antibodies for various cell compartments. A confocal image split
into individual channels shows SU11274 localization (A) and the ER (calreticulin
staining) of the cells (B). The combined image is shown in (C). DAPI (blue) indicates
the location of the nuclei, and differential interference contrast is shown in
white. Relative area colocalizaton for the negative control and the cell compartments
is shown in (D). The Pearson correlation coefficient between SU11274 fluorescence
intensity and Alexa Fluor 647 (cell compartment) fluorescence intensity is shown in
(E).
***p<0.001 (endoplasmic reticulum compared to all other groups), **p<0.01.
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It is clear that SU11274 colocalizes with the ER in terms of the area of overlap of
SU11274 and the ER marker calreticulin (Figure 57A-D). In addition, the linear
correlation of SU11274 and the ER marker calreticulin or that of the early endosome
marker EEA1 significantly exceed that of the isotype control and all other cell
compartment markers tested (Figure 57E). This indicates that SU11274 preferentially
localizes in the ER region of cells as well as early endosomes. Because the ER volume
is so much larger than that of the early endosomes, it appears to predominantly localize
in the ER region of the cells.
In an effort to quantify the concentration of SU11274 in cells and in the ER, we
performed the following experiment. SU11274 was applied to living cells at 0, 0.1, 1,
and 10 µM. At the same time ER-Tracker™ Red was applied to cells at 10 nM in order
to define the ER. Cells were imaged three minutes after SU11274 and ER-Tracker™
Red were applied (Figure 58). The SU11274 mean fluorescence intensity in ROIs
representing cells, acellular areas, and ER regions was measured. Figure 58A and B
contain representative images from cells treated with 10 µM SU11274. The SU11274
mean fluorescence intensity of ROIs representing acellular areas at various cell medium
concentrations of SU11274 was quantified to determine the relationship between
SU11274 mean fluorescence intensity and SU11274 concentration. The SU11274
concentration in the cell medium is plotted as a function of the SU11274 mean
fluorescence intensity measured in the ROIs representing acellular areas (Figure
58C). The equation relating SU11274 mean fluorescence intensity to SU11274
concentration was used to determine the SU11274 concentration in the cells and in the
ER region of the cells at given cell medium SU11274 concentrations (Figure 58D).
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We found that the relationship between the applied SU11274 cell medium
concentration and the SU11274 mean fluorescence intensity (of the areas without cells,
circled in white, Figure 58A) was linear (Figure 58C). The equation that defines the
relationship is SU11274 concentration = 8.0749 x SU11274 mean fluorescence intensity
- 1.365. With this equation we determined the concentration of SU11274 in
S2-013.MUC1F cells (Figure 58D) and in the ER region (shown in yellow in Figure 58B)
of the cells. For example, the concentration of SU11274 in the cells is about 300 µM,
and in the ER it is nearly 600 µM when that of the cell medium is only 10 µM. SU11274
accumulates rapidly in the ER of cells. This property may be of therapeutic utility.
SU11274 (Figure 59A) has a certain moiety that is similar to the phenyl
sulfonylurea group found in the compound glibenclamide (Figure 59B) and glimepiride
(Figure 59C). Figure 59D shows a cryo-electron microscopy derived-structure of a
sulfonylurea receptor of ATP sensitive-potassium channel composed of four SUR1
subunits and four Kir6.2 subunits [172]. Glibenclamide (which is the sulfonylurea portion
of ER-Tracker™ Red) and glimepiride are known to bind sulfonylurea receptors of ATP
sensitive-potassium channels (Figure 59D) [173, 174]. The cryo-electron microscopy
image of the sulfonylurea receptor of ATP sensitive-potassium channel has been used
with the authors’ permission. Because sulfonylurea receptors of ATP sensitivepotassium channels are known to populate the ER [175], and because SU11274 shares
structural similarity with two compounds that bind to such channels, perhaps SU11274
rapidly accumulates in the ER by way of a sulfonylurea receptor of ATP sensitivepotassium channel.
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Figure 59. Sulfonylurea receptors of ATP-sensitive potassium channels and
drugs that bind them.
(A) Structure of SU11274, glibenclamide (B), and glimepiride (C) with the common
motif boxed. (D) Cryo-electron microscopy derived-structure of a sulfonylurea
receptor of ATP sensitive-potassium channel composed of four SUR1 subunits and
four Kir6.2 subunits. Four molecules of ATP bound to the channel are shown in
green bound to Kir6.2 subunits. Four glibenclamide molecules shown in red are
bound to SUR1 subunits. Cryo-electron microscopy structure used with permission.
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Discussion
The endoplasmic reticulum is involved in biosynthesis of lipids, folding and
assembly of proteins, and regulation of calcium signaling [176]. Loss of function of the
endoplasmic reticulum is related to several diseases, including cystic fibrosis, diabetes
mellitus, Alzheimer’s, and Parkinson’s [176]. SU11274 accumulates rapidly in cells
(Figure 56), specifically in the ER region (Figure 57). In fact, after treating cells with 100
nM SU11274 for only three minutes, we found that the cellular SU11274 concentration
was nearly 100 times that of the cell medium, and the concentration in the ER region
was over 350 times that of the cell medium (Figure 58). It is noteworthy that the
Pearson correlation coefficients indicate that SU11274 preferentially localizes with both
the ER and early endosomes (Figure 57E).
SU11274 shares a structural feature, a phenyl sulfonamide group, with
glibenclamide (the ER-targeting moiety of ER-Tracker™ Red) and glimepiride. These
drugs are known to bind sulfonylurea receptors of ATP sensitive-potassium channels
(Figure 59) [173, 174]. It may be that SU11274 interacts with the ER by way of this
channel.
Discovered in 1942, sulfonylureas are the most common drug used in the
treatment of diabetes mellitus [177]. Glibenclamide and glimepiride, second generation
sulfonylureas, act on β-pancreatic cells by binding and inhibiting the sulfonylurea
receptor of ATP sensitive-potassium channel, which stops the inflow of potassium ions
into the cells. This causes depolarization of the cell membrane and results in an influx of
calcium ions, which leads to a release of insulin [177]. Interestingly, SU11274 has been
shown to directly impact β-cells. SU11274 caused β-cell death and loss of β-cell mass
in rats after two weeks of treatment [178]. However, this stands in contrast to the impact
of glimepiride on β-cells. In a six-month clinical study, glimepiride was found to enhance
β-cell secretory capacity after six months of treatment [179].
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Though sulfonylureas and SU11274 affect cells differently, the moiety that they
share may be a useful tool to target drugs specifically to the ER. Cancer patients would
possibly benefit from ER-targeted therapy. In most types of cancer, the tumor
microenvironment is limited in oxygen and glucose, so oxidative ER protein folding and
glycosylation-assisted ER protein folding are impaired. This leads to activation of the
unfolded protein response (UPR). In fact, cancer cells often rely on UPR for growth and
survival [176]. Targeting the endoplasmic reticulum in B cell malignancies may be
especially advantageous. B-chronic lymphocytic leukemia (B-CLL) and multiple
myeloma (MM) cells have more developed ER networks than normal lymphocytes [180].
In addition, these cells rely on the unfolded protein response (UPR) for plasma cell
differentiation [180].
Some proteins crucial to UPR activity, such as X-box binding protein 1 (XBP1),
glucose-regulator protein 78 kDa (GRP78), and inositol-requiring enzyme 1 (IRE1) have
been targeted for the treatment of breast cancer, myeloma, melanoma, and
atherosclerosis [181-183]. It may be that modifying such a drug with a phenyl
sulfonamide group would cause it to accumulate in the ER region resulting in greater
efficacy. Such targeted therapy would allow decreased dosage and decreased toxicity.
Perhaps locked within the fluorescent molecule SU11274 is a key to ER-targeting drugs
of the future.
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CHAPTER 5. DISCUSSION AND FUTURE STUDIES
Concerning future SU11274 studies, the fact that SU11274 is fluorescent is of
itself perhaps something that may be clinically useful. Finding a way to chemically
target a drug to the ER, perhaps with a phenyl sulfonamide group, may also prove to be
useful. Inducing ER stress seems to be a particularly effective way to treat certain types
of cancers, such as leukemia and lymphoma. In the case that targeting a drug to the
endoplasmic reticulum would be helpful, causing such a drug to concentrate at the
endoplasmic reticulum would mean that less of the drug could be used, reducing toxicity.
Presently, it is not clear if SU11274 accumulates inside of the ER or at the
surface of the ER. Does SU11274 bind to sulfonylurea receptors of ATP sensitivepotassium channels or pass into the lumen of the ER? It will be important to answer
such questions to know how useful this phenyl sulfonylurea group will be in targeting the
ER of cells.
MUC1 and beta-catenin are important players in many cellular processes. MUC1
plays a role in the housekeeping function of lubricating and protecting luminal surfaces
of respiratory, gastrointestinal, and reproductive tracts. However, it also plays an
important role in signal transduction, that is communicating the current state of the cell
exterior to the nucleus so that the cell can reprogram transcription to adapt to various
stresses. Beta-catenin does not communicate information about the extracellular
environment with the nucleus. Rather, it provides cues to the nucleus that it is time for
division, the accumulative effect of which is the proliferation of cells.
Cancer is something like a wound that does not heal, which sets the stage for an
inflammatory microenvironment [184] swarming with growth factors and cytokines [185].
Such signaling molecules act by binding to specific receptors. However, the signal must
then be transduced into the cell interior in order to have the proper effect on the cell. In
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the case of cells that overexpress MUC1, many have hypothesized that phosphorylation
of the cytoplasmic tail of MUC1 would allow for interaction with various protein partners,
such as beta-catenin, which would allow the signal to reach the nucleus.
The purpose of this project was to understand how extracellular cues impact
signaling through the cytoplasmic tail of MUC1 by way of beta-catenin. Because cancer
cells have lost polarity, the normally apical MUC1 and basolateral receptor tyrosine
kinases are able to interact [7]. It is thought that in cancer cells growth factor stimulation
of receptor tyrosine kinases, such as EGFR, causes phosphorylation of MUC1.CT
resulting in its association with various transcription factors, such as beta-catenin [55].
The hypothesis is that increased interaction between beta-catenin and MUC1.CT
stabilizes beta-catenin and leads to nuclear localization of beta-catenin [124], which
results in increased expression of proto-oncogenes such as cyclin D1, c-Myc, and matrix
metalloproteinase-7 (MMP7) [96, 142].
The fact that EGF stimulation decreases colocalization and Erlotinib treatment
tends toward increased colocalization between the molecules supports the idea that
EGFR-mediated phosphorylation of MUC1.CT regulates the interaction between betacatenin and MUC1.CT, but the nature of this regulation may be different than previously
thought. Two-dimensional gel electrophoresis of MUC1.CT immunoprecipitates
indicates that EGF stimulation causes increased phosphorylation of tyrosine residues of
MUC1.CT. However, counter to a previous report [55], it seems that EGF stimulation
results in a decreased association between beta-catenin and MUC1.CT.
With EGF stimulation a trend of decreased beta-catenin in the membrane was
observed in S2-013.MUC1 eGFP/mCherry beta-catenin cells, as others have reported
[121, 165, 186]. A significant decrease was also observed in the levels of MUC1.CT in
the membrane of these cells. In the case of S2-013.MUC1F cells stained with betacatenin and MUC1.CT antibodies, this loss in membrane beta-catenin and MUC1.CT
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was not recapitulated. However, in both cases, a loss in membrane colocalization of the
two proteins was observed.
It is not clear if this loss in colocalization is due entirely to decreased levels of the
interacting partners or loss of beta-catenin/MUC1.CT binding affinity upon MUC1.CT
phosphorylation. However, beta-catenin and MUC1.CT levels appear to remain steady
or only moderately decrease in the minutes that follow EGF stimulation. The rapid drop
in colocalization at the membrane suggests that the loss in association is not simply due
to a loss in beta-catenin and MUC1.CT concentration. EGF-induced phosphorylation
seems to physically deter the interaction between beta-catenin and MUC1.CT.
The physiological implications of the loss of the beta-catenin/MUC1.CT
association with EGF stimulation are not known, and conflicting reports make
speculation difficult. Some have proposed that MUC1.CT binding to beta-catenin
stabilizes beta-catenin allowing for its increased presence in the nucleus [124]. Beyond
simply changing the quantity of Wnt target gene expression, one group reported that
MUC1.CT binding to beta-catenin stabilizes beta-catenin and also modifies the genes
that beta-catenin targets [74]. Contrarily, one group found that MUC1.CT actually
decreased Wnt signaling [97], and a second group showed that MUC1 levels are
inversely related to beta-catenin levels [98].
It seems clear how the beta-catenin/MUC1.CT interaction provides a survival
advantage to cancer cells. As discussed previously, beta-catenin is a transcription
coactivator. In cancer the transcription program beta-catenin activates is not only one of
proliferation but also of invasion and metastasis [187, 188]. Epithelial to mesenchymal
transition is important for cancer progression [189]. Because all three proteins associate
with the membrane, perhaps MUC1 competes with E-cadherin for beta-catenin binding,
and this beta-catenin/MUC1 interaction at the membrane helps cancer cells maintain
their mesenchymal phenotype by reducing the pool of beta-catenin at adherens
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junctions. In addition, as has been proposed, the beta-catenin/MUC1.CT interaction
stabilizes beta-catenin in the cytoplasm and allows for beta-catenin nuclear
accumulation and its cancer-driving transcriptional activity [95, 124].
So what survival benefit does EGF-stimulated abolition of the betacatenin/MUC1.CT interaction provide the cancer cell? In cancer cells MUC1 and betacatenin are able to interact due to loss in cell polarity [47]. When EGFR is activated by
EGF, membrane-bound MUC1.CT and beta-catenin [186, 190] have both been reported
to be phosphorylated. EGFR activation results in EGFR endocytosis [191]. Perhaps
when EGFR endocytosis occurs, the membrane-bound MUC1 is taken inside the cell
along with EGFR. It may be that MUC1 maintains a pool of E-cadherin-free beta-catenin
that can be internalized along with EGFR and MUC1. No longer bound to MUC1 but
now in an endosome, beta-catenin escapes the degradation complex. EGFR is known
to enter the nucleus. Conceivably this pool of beta-catenin enters the nucleus with
EGFR by way of nuclear envelope-associated endosomes [192]. Here it is then able to
activate transcription of genes involved in driving proliferation and invasion. In fact,
MUC1 has been proposed to play a role in nuclear accumulation of EGFR, and
MUC1/EGFR nuclear association has been shown to be important in upregulation of
cyclin D1, a transcriptional target of Wnt signaling [193]. Could it be that EGF
stimulation provides a pathway for beta-catenin to enter the nuclei of MUC1
overexpressing cancer cells?
It is surprising that EGF stimulation of pancreatic cancer cells actually reduces
interaction between beta-catenin and MUC1.CT. It is unclear if this is a transient effect
or is maintained chronically. In the context of cancer, the cells are bathed in growth
factors constantly [184, 185]. It will be important to more fully elucidate the long-term
aspects of EGF-stimulated changes in the interaction between beta-catenin and
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MUC1.CT in order to better understand cancer, especially that which involves high levels
and/or aberrantly localized MUC1 and beta-catenin.
Fluorescent MUC1.CT and fluorescent beta-catenin molecules have made it
possible to see inside of the cells in order to understand the interaction between the two
molecules. However, the particular genetics of the S2-013 cell line align with only an
undefined subgroup of pancreatic ductal adenocarcinomas. It seems advisable to
repeat these experiments in other pancreatic cancer cell lines in order to look for
overarching themes so that a broader understanding of the interaction between these
molecules in pancreatic cancer can be obtained.
EGF stimulation causes a rise in beta-catenin levels in the membrane of CFPAC1 cells, whereas it tends to cause nuclear beta-catenin to rise in S2-013.MUC1F cells.
Confocal microscopy and PLA data of CFPAC-1 cells indicate that a transient rise in
beta-catenin/MUC1.CT interaction occurs with EGF stimulation, whereas S2-013.MUC1
cells tend to lose beta-catenin/MUC1.CT interaction with EGF stimulation. CFPAC-1 cell
behavior stands in contrast to reports that EGF diminishes membrane beta-catenin [121,
165, 186]. It may be of use to determine the underlying cause for this discrepancy.
The OpenSPR data support the idea that beta-catenin and MUC1.CT interact, at
least in vitro. The ITC data coupled with the OpenSPR data suggest that the betacatenin/MUC1.CT interaction involves the N-terminal half of the cytoplasmic tail of
MUC1.CT. This would mean that the serine-rich motif of MUC1.CT is not involved in the
interaction as has been postulated [94]. Limited data in this dissertation suggest that the
interaction relies on the residues of MUC1.CT that lie closest to the membrane (of
membrane-bound MUC1). Interestingly, the immunoprecipitation data, confocal
microscopy data, and PDAC tissue sample point to the fact that the highest proportion of
beta-catenin/MUC1.CT interaction is taking place in the membrane of the cells. This
would not be surprising, however, given that MUC1 is a transmembrane protein and that
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beta-catenin is an important player in adherens junctions at the membrane of cells. In
order to more fully characterize the beta-catenin/MUC1.CT interaction, it will be
necessary to define the portion of MUC1.CT that physically associates with beta-catenin.
The clinical relevance of this dissertation would be enhanced by studies
conducted in human tissue samples comparing normal pancreas to pancreatic ductal
adenocarcinoma. This would show whether or not increased interaction of beta-catenin
and MUC1.CT occurs with cancer progression and whether or not this interaction is
occurring in the nuclei of cells, to determine the extent to which MUC1.CT impinges on
Wnt signaling in PDAC. Studies conducted with the University of Nebraska’s Rapid
Autopsy Program (RAP) suggest, as in the cell culture data, that the interaction between
beta-catenin and MUC1.CT occurs largely in the membrane of PDAC cells. To date, no
colocalization of beta-catenin and MUC1.CT has been observed in the nuclei of these
RAP samples. However, it is not difficult to imagine that only a very small subset of
MUC1.CT would interact with beta-catenin, and even a small amount of MUC1.CT
interacting with beta-catenin could be amplified to produce a large impact on the
transcriptional program of the cells. It may be that this small pool of betacatenin/MUC1.CT complexes is simply below the current means of detection. Others
have reported cytoplasm/membrane compartment beta-catenin/MUC1 colocalization in
gastric cancer [194] and colorectal cancer [195]. Both noted a trend of strong nuclear
beta-catenin staining in the invasive front of the tumor. Interestingly, in colorectal cancer
the areas of strongest beta-catenin/MUC1 colocalization are near the invasive front of
the tumor. Neither group reported nuclear MUC1 localization, though the groups probed
for full-length MUC1 rather than the cytoplasmic tail of MUC1.
It remains to be determined how other growth factors alter the interaction
between MUC1 and beta-catenin. CTGF, which binds to the receptor tyrosine kinase
Tropomyosin receptor kinase A (TrkA) [196], was studied (Figure 14) because this
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matricellular protein promotes fibrosis and cancer progression in multiple types of cancer
[197], including pancreatic cancer [198]. In addition, MUC1.CT has been observed at
the promoter of the gene [74]. PDGF has been reported to impact the betacatenin/MUC1.CT interaction. In this study, it was reported that PDGFR catalyzed the
phosphorylation of the tyrosine residues in the HGRYVPP and RDTYHPM motifs of
MUC1.CT resulting in greater nuclear colocalization of MUC1.CT and beta-catenin. This
in turn increased cancer cell invasion and metastasis in an animal model [60].
The impact of HGF on colocalization of MUC1 with various protein partners may
be of interest as Met is able to bind MUC1.CT [199], and one report indicates that Met
transactivates Wnt signaling in glioblastoma [200]. Furthermore, in a rat hepatoma cells
line HGF stimulation disrupted beta-catenin/E-cadherin association and caused
transactivation of beta-catenin through phosphorylation of tyrosine residues 654 and 670
[201]. Perhaps Met phosphorylation of MUC1.CT changes its cadre of interacting
partners and the downstream results.
It may be of use to determine how growth factors and growth factor receptor
inhibitors impact the interaction between MUC1 and other transcription factors such as
p53 and ERα. The impact of Met-mediated MUC1.CT phosphorylation on its interaction
with p53 has already been partially characterized [199].
In addition to questions about interactions of MUC1.CT with signaling molecules,
many questions about MUC1 biology remain unanswered. For example, how does the
plasma-membrane-bound MUC1 move into the cytosol? And how does it re-enter
membranes, such as the outer membrane of mitochondria [50, 81]? What is the
metabolic fate of MUC1.CT? Does MUC1.CT play any role in signaling in normal cell
physiology? Answers to such questions will help to unravel the mystery of pancreatic
cancer.
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In conclusion, the beta-catenin/MUC1.CT interaction has been reported by
multiple groups [91, 94, 124, 202]. The work presented here shows that a betacatenin/MUC1.CT interaction occurs in cells and in vitro. However, only a certain
fraction of MUC1.CT coimmunoprecipitates with beta-catenin and vice versa. This may
be the result of a weak or transient interaction. Yet compared to other noncovalent
interactions in biology such as the millimolar ubiquitin/ubiquitin binding domain
interaction and the femtomolar biotin-streptavidin interaction [203, 204], the betacatenin/MUC1.CT interaction is of moderate strength. Perhaps the interaction requires
that one or both partners fit specific post-translational modification parameters. Indeed,
if EGF-stimulated tyrosine residue phosphorylation of MUC1.CT decreases its
interaction with beta-catenin and phosphorylation generally weakens the betacatenin/MUC1.CT interaction, it seems that the beta-catenin/MUC1.CT interaction
requires that the proteins have a specific phosphorylation pattern. Perhaps the specific
population of MUC1.CT molecules that interacts most with beta-catenin is that which is
least phosphorylated.
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